clvs_Current_Folio

0001558370-18-008187.txt : 20181101 0001558370-18-008187.hdr.sgml : 20181101 20181031182156 ACCESSION NUMBER: 0001558370-18-008187 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 71 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181101 DATE AS OF CHANGE: 20181031 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Clovis Oncology, Inc. CENTRAL INDEX KEY: 0001466301 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900475355 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35347 FILM NUMBER: 181151352 BUSINESS ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (303) 625-5000 MAIL ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 10-Q 1 clvs-20180930x10q.htm 10-Q clvs_Current_Folio_10Q

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended September 30, 2018.

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the transition period from to .

Commission file number: 001-35347

Clovis Oncology, Inc.

(Exact name of Registrant as specified in its charter)


Delaware	90-0475355
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

5500 Flatiron Parkway, Suite 100
Boulder, Colorado	80301
(Address of principal executive offices)	(Zip Code)

(303) 625-5000

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, as of October 26, 2018 was 52,711,827.

Table of Contents

CLOVIS ONCOLOGY, INC.

FORM 10-Q

TABLE OF CONTENTS



PART I. Financial Information		3

ITEM 1.	Financial Statements (unaudited)	3

	Consolidated Statements of Operations and Comprehensive Loss — for the three and nine months ended September 30, 2018 and September 30, 2017	3

	Consolidated Balance Sheets — as of September 30, 2018 and December 31, 2017	4

	Consolidated Statements of Cash Flows — for the nine months ended September 30, 2018 and 2017	5

	Notes to Unaudited Consolidated Financial Statements	6

ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	23

ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk	36

ITEM 4.	Controls and Procedures	37

PART II. Other Information		38

ITEM 1.	Legal Proceedings	38

ITEM 1A.	Risk Factors	39

ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	40

ITEM 3.	Defaults Upon Senior Securities	40

ITEM 4.	Mine Safety Disclosures	40

ITEM 5.	Other Information	40

ITEM 6.	Exhibits	40

SIGNATURES		44

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1.FINANCIAL STATEMENTS

CLOVIS ONCOLOGY, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(In thousands, except per share amounts)


	Three months ended September 30,				Nine months ended September 30,
	2018		2017		2018		2017
	(in thousands, except per share amounts)				(in thousands, except per share amounts)
Revenues:
Product revenue	$	22,757	$	16,806	$	65,037	$	38,471
Operating expenses:
Cost of sales - product		4,766		3,026		13,262		6,920
Cost of sales - intangible asset amortization		771		372		1,851		1,115
Research and development		63,887		38,924		160,138		104,479
Selling, general and administrative		42,495		35,011		126,634		100,384
Total expenses		111,919		77,333		301,885		212,898
Operating loss		(89,162)		(60,527)		(236,848)		(174,427)
Other income (expense):
Interest expense		(3,376)		(2,618)		(9,592)		(7,796)
Foreign currency gain (loss)		151		(44)		(34)		(127)
Legal settlement loss		—		—		(7,975)		(117,000)
SEC settlement costs		—		—		(20,000)		—
Other income		2,536		1,291		5,419		2,237
Other expense, net		(689)		(1,371)		(32,182)		(122,686)
Loss before income taxes		(89,851)		(61,898)		(269,030)		(297,113)
Income tax (expense) benefit		(13)		1,234		280		2,599
Net loss	$	(89,864)	$	(60,664)	$	(268,750)	$	(294,514)
Other comprehensive income (loss):
Foreign currency translation adjustments, net of tax		(495)		1,595		(2,448)		4,874
Net unrealized (loss) gain on available-for-sale securities, net of tax		(10)		10		71		5
Other comprehensive (loss) income:		(505)		1,605		(2,377)		4,879
Comprehensive loss	$	(90,369)	$	(59,059)	$	(271,127)	$	(289,635)

Loss per basic and diluted common share:
Basic and diluted net loss per common share	$	(1.71)	$	(1.24)	$	(5.18)	$	(6.39)
Basic and diluted weighted average common shares outstanding		52,669		48,917		51,844		46,062

See accompanying Notes to Unaudited Consolidated Financial Statements.

Table of Contents

CLOVIS ONCOLOGY, INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except for share amounts)


	September 30,		December 31,
	2018		2017

ASSETS
Current assets:
Cash and cash equivalents	$	290,853	$	464,198
Accounts receivable, net		14,495		6,181
Inventories		43,682		27,508
Available-for-sale securities		313,525		99,533
Prepaid research and development expenses		2,907		1,559
Deposit on inventory		13,514		20,461
Other current assets		11,780		7,500
Total current assets		690,756		626,940
Inventories		20,005		—
Deposit on inventory		31,119		—
Property and equipment, net		11,035		4,007
Intangible assets, net		52,709		19,561
Goodwill		63,074		65,217
Other assets		22,766		19,505
Total assets	$	891,464	$	735,230
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	30,501	$	15,147
Accrued research and development expenses		21,259		18,465
Milestone liability		—		22,022
Other accrued expenses		24,732		25,883
Total current liabilities		76,492		81,517
Convertible senior notes		574,828		282,406
Deferred rent, long-term		6,478		3,671
Total liabilities		657,798		367,594
Commitments and contingencies (Note 14)
Stockholders' equity:
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized, no shares issued and outstanding at September 30, 2018 and December 31, 2017		—		—
Common stock, $0.001 par value per share, 100,000,000 shares authorized at September 30, 2018 and December 31, 2017; 52,708,767 and 50,565,119 shares issued and outstanding at September 30, 2018 and December 31, 2017 respectively		53		51
Additional paid-in capital		2,021,997		1,887,198
Accumulated other comprehensive loss		(44,550)		(42,173)
Accumulated deficit		(1,743,834)		(1,477,440)
Total stockholders' equity		233,666		367,636
Total liabilities and stockholders' equity	$	891,464	$	735,230

See accompanying Notes to Unaudited Consolidated Financial Statements.

Table of Contents

CLOVIS ONCOLOGY, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)


	Nine months ended September 30,
	2018		2017

Operating activities
Net loss	$	(268,750)	$	(294,514)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense		37,715		32,201
Depreciation and amortization		2,497		1,911
Amortization of premiums and discounts on available-for-sale securities		1,079		6
Amortization of debt issuance costs		1,536		956
Legal settlement loss		—		117,000
Deferred income taxes		—		(2,403)
Changes in operating assets and liabilities:
Accounts receivable		(4,978)		121
Inventory		(25,540)		(5,345)
Prepaid and accrued research and development expenses		1,390		(16,284)
Deposit on inventory		(24,173)		(31,818)
Other operating assets		(7,507)		(4,156)
Accounts payable		4,765		5,050
Other accrued expenses		(1,304)		1,949
Net cash used in operating activities		(283,270)		(195,326)
Investing activities
Purchases of property and equipment		(7,763)		(416)
Deposits for purchases of property and equipment		—		(2,515)
Purchases of available-for-sale securities		(320,000)		(180,000)
Sales of available-for-sale securities		105,000		213,500
Acquired in-process research and development - milestone payment		(55,000)		(1,100)
Net cash used in investing activities		(277,763)		29,469
Financing activities
Proceeds from the sale of common stock, net of issuance costs		93,890		545,838
Proceeds from the issuance of convertible senior notes, net of issuance costs		290,887		—
Proceeds from the exercise of stock options and employee stock purchases		3,197		14,419
Net cash provided by financing activities		387,974		560,257
Effect of exchange rate changes on cash and cash equivalents		(286)		886
(Decrease) increase in cash and cash equivalents		(173,345)		395,286
Cash and cash equivalents at beginning of period		464,198		216,186
Cash and cash equivalents at end of period	$	290,853	$	611,472
Supplemental disclosure of cash flow information:
Cash paid for interest	$	9,188	$	7,188
Non-cash investing and financing activities:
Vesting of restricted stock units	$	10,130	$	9,449

See accompanying Notes to Unaudited Consolidated Financial Statements.

Table of Contents

CLOVIS ONCOLOGY, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

1. Nature of Business and Basis of Presentation

Clovis Oncology, Inc. (together with its consolidated subsidiaries, the “Company”, “Clovis”, “we”, “our”, “us”) is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. We target our development programs for the treatment of specific subsets of cancer populations, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. We have and intend to continue to license or acquire rights to oncology compounds in all stages of clinical development. In exchange for the right to develop and commercialize these compounds, we generally expect to provide the licensor with a combination of upfront payments, milestone payments and royalties on future sales. In addition, we generally expect to assume the responsibility for future drug development and commercialization costs. We currently operate in one segment. Since inception, our operations have consisted primarily of developing in-licensed compounds, evaluating new product acquisition candidates and general corporate activities and since 2016 we have also marketed and sold products.

Our marketed product Rubraca® (rucaparib) is approved in the United States by the Food and Drug Administration (“FDA”) for two indications, encompassing two settings for the treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The initial treatment indication received in December 2016 covers the treatment of adult patients with deleterious BRCA (human genes associated with the repair of damaged DNA) mutation (germline and/or somatic) epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. In April 2018, the FDA also approved Rubraca for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. The FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Diagnostic testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

In May 2018, the European Commission granted a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. As this is a conditional approval, it will be necessary to complete confirmatory post marketing commitments, including ensuring that sufficient partially platinum sensitive patients are enrolled in our ARIEL4 confirmatory trial to support the indication. This may require enrollment of additional patients into the study, increasing its overall size and extending the time for enrollment. In June 2018, we submitted to the European Union’s European Medicines Agency (“EMA”) a variation to the marketing authorization for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy, for which we received EMA validation for this application in July 2018. We anticipate an opinion on this application from the Committee for Medicinal Products for Human Use (“CHMP”) of the EMA by the end of 2018, with a potential formal European Commission approval in early 2019.

Beyond our initial labeled indication, we have a robust Rubraca clinical development program underway in a variety of solid tumor types, also including prostate and bladder cancers, and in July 2017, we entered into a broad clinical collaboration with Bristol-Myers Squibb Company to evaluate the combination of their immunotherapy OPDIVO® (nivolumab) with Rubraca in several tumor types. We hold worldwide rights for Rubraca.

In October 2018, the FDA granted breakthrough therapy designation for Rubraca as a monotherapy treatment of adult patients with BRCA1/2-mutated metastatic castration resistant prostate cancer (mCRPC) who have received at least one prior androgen receptor (AR)-directed therapy and taxane-based chemotherapy.

In addition to Rubraca, we have two other product candidates.

Table of Contents

factor receptors 1 through 3 (FGFR1-3). Lucitanib was originally developed by Clovis and Servier with the hypothesis of activity in FGFR driven tumors; however, data in breast and lung cancer were insufficient to move that program forward. We received notice from Servier of termination of their rights to lucitanib, resulting in the return of global rights (excluding China) for lucitanib to us during October 2018. We believe that recent data for a drug similar to lucitanib that inhibits these same pathways – when combined with a PD-1 inhibitor – provide support for development of lucitanib in combination with a PD-(L)1 inhibitor, and we intend to initiate a study of the combination. We also intend to initiate a study of lucitanib in combination with Rubraca, based on encouraging data of VEGF and PARP inhibitors in combination. Each of these studies is expected to initiate in the first quarter of 2019. We maintain certain development and commercialization rights for lucitanib. Because of termination of the Servier license agreement, we have global development and commercialization rights (except for China) for lucitanib.

Rociletinib is an oral mutant-selective inhibitor of epidermal growth factor receptor (“EGFR”). While we have stopped enrollment in ongoing trials for rociletinib, we continue to provide drug to patients whose clinicians recommend continuing therapy. We have global development and commercialization rights for rociletinib.

Basis of Presentation

All financial information presented includes the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments that, in the opinion of management, are necessary to fairly state our financial position, results of operations and cash flows for the periods presented herein. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, 2017 (“2017 Form 10-K”) for a broader discussion of our business and the opportunities and risks inherent in such business.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and revenue and related disclosures. On an ongoing basis, we evaluate our estimates, including estimates related to revenue deductions, intangible asset impairment, clinical trial accruals and share-based compensation expense. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.

Liquidity

We have incurred significant net losses since inception and have relied on our ability to fund our operations through debt and equity financings. We expect operating losses and negative cash flows to continue for the foreseeable future. As we continue to incur losses, transition to profitability is dependent upon achieving a level of revenues from Rubraca adequate to support our cost structure. We may never achieve profitability, and unless or until we do, we will continue to need to raise additional cash.

In April 2018, we sold 1,837,898 shares of our common stock in a public offering at $54.41 per share. The net proceeds from the offering were $93.9 million, after deducting underwriting discounts and commissions and offering expenses. Concurrently, we completed the public offering of $300.0 million aggregate principal amount of 1.25% convertible senior notes due 2025. The net proceeds from this offering were $290.9 million, after deducting underwriting discounts and commissions and offering expenses. We intend to use the net proceeds of the offerings for general corporate purposes, including sales and marketing expenses associated with Rubraca in the United States and Europe, funding of our development programs, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. Based on current estimates, we believe that our existing cash, cash equivalents and available-for-sale securities will allow us to fund our operating plan through at least the next 12 months.

Table of Contents

2. Summary of Significant Accounting Policies

Recently Adopted Accounting Standards

In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, “Revenue from Contracts with Customers”, and has subsequently issued several supplemental and/or clarifying ASUs (collectively, “ASC 606”). ASC 606 prescribes a single common revenue standard that replaces most existing U.S. GAAP revenue recognition guidance. ASC 606 is intended to provide a more consistent interpretation and application of the principles outlined in the standard across filers in multiple industries and within the same industries compared to current practices, which should improve comparability. We adopted the new standard using the modified retrospective method on January 1, 2018 for contracts that are not completed as of the adoption date.

Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 also impacts certain other areas, such as the accounting for costs to obtain or fulfill a contract. The standard also requires disclosure of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.

We examined our revenue recognition policy specific to revenue streams from contracts governing product sales from Rubraca and have come to conclusions on the impact of the new standard using the 5-step process prescribed by ASC 606. We reviewed all of our contracts, including our collaboration agreements with Servier and Bristol-Myers Squibb, and determined the potential impact to our accounting policies, financial controls and operations. Our conclusions include recognizing revenue on product sales once the product is sold to the specialty distributor and specialty pharmacy providers.

As noted above, we used the modified retrospective method to adopt the new standard. This means that we did not restate previously issued financial statements, but we recorded a one-time adjustment to retained earnings of $2.4 million. This adjustment represents the sales of our product to our customers prior to January 1, 2018, that had not been sold to patients or healthcare providers, offset by related gross-to-net adjustments and other direct costs, including royalties and sales incentive compensation.

The cumulative effect of the changes made to our consolidated January 1, 2018 balance sheet for the adoption of ASC 606 was as follows (in thousands):


	Balance at		Adjustments due to		Balance at
	December 31, 2017		Adoption of ASC 606		January 1, 2018
ASSETS
Accounts receivable, net	$	6,181	$	3,336	$	9,517
Inventories	$	27,508		(62)	$	27,446
Total assets	$	735,230	$	3,274	$	738,504

LIABILITIES AND STOCKHOLDERS' EQUITY
Other accrued expenses	$	25,883	$	918	$	26,801
Accumulated deficit	$	(1,477,440)		2,356	$	(1,475,084)
Total liabilities and stockholders' equity	$	735,230	$	3,274	$	738,504

Previously, we recognized revenue on product sales once the product was sold to the patient or healthcare provider by the specialty distributor or specialty pharmacy provider, i.e. when product is sold through the channel. Effective January 1, 2018, we began recognizing revenue when our customers, the specialty distributors and specialty pharmacy providers, take control of our product or when product is sold into the channel. This will have the impact of us recognizing revenue approximately two to four weeks earlier than before adopting the new standard and will also

Table of Contents

increase the significance of estimating variable consideration. The following financial statement line items for the three and nine months ended September 30, 2018 were affected as a result of the adoption.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except for per share amounts)


	Three months ended September 30, 2018
			Balances without		Effect of Change
	As reported		Adoption of ASC 606		Higher/(Lower)
Product revenue	$	22,757	$	25,213	$	(2,456)
Cost of sales - product	$	4,766	$	5,158	$	392
Selling, general and administrative	$	42,495	$	42,689	$	194
Net loss	$	(89,864)	$	(87,994)	$	(1,870)

Loss per basic and diluted common share:
Basic and diluted net loss per common share	$	(1.71)	$	(1.67)	$	(0.04)


	Nine months ended September 30, 2018
			Balances without		Effect of Change
	As reported		Adoption of ASC 606		Higher/(Lower)
Product revenue	$	65,037	$	63,541	$	1,496
Cost of sales - product	$	13,262	$	12,697	$	(565)
Selling, general and administrative	$	126,634	$	126,602	$	(32)
Net loss	$	(268,750)	$	(269,648)	$	898

Loss per basic and diluted common share:
Basic and diluted net loss per common share	$	(5.18)	$	(5.20)	$	0.02

CONSOLIDATED BALANCE SHEET

(In thousands)


	September 30, 2018
			Balances without		Effect of Change
	As reported		Adoption of ASC 606		Higher/(Lower)
ASSETS
Accounts receivable, net	$	14,495	$	12,907	$	1,588
Inventories	$	63,687	$	63,992	$	(305)

LIABILITIES AND STOCKHOLDERS' EQUITY
Other accrued expenses	$	24,732	$	24,347	$	385
Accumulated deficit	$	(1,743,834)	$	(1,744,732)	$	898

ASC 606 did not have an aggregate impact on our net cash provided by operating activities but resulted in offsetting changes in certain assets and liabilities presented within net cash used in operating activities in our consolidated statement of cash flows, as reflected in the above tables.

Recently Issued Accounting Standards

From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification (“ASC”) are communicated through issuance of an ASU.

Table of Contents

2016-02 requires modified retrospective adoption for all leases existing at, or entered after, the date of initial application, with an option to use certain transition relief. We will adopt ASU 2016-02 as of January 1, 2019 using the effective date method which leaves the comparative period reporting unchanged. Comparative reporting periods are presented in accordance with Topic 840, while periods subsequent to the effective date are presented in accordance with Topic 842. We expect to recognize substantially all our leases on the balance sheet by recording a right-of-use asset and corresponding lease liability. We are currently evaluating the impact the standard may have on our consolidated financial statements and related disclosures.

In February 2018, the FASB issued ASU 2018-02, “Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income”, which allow a reclassification from accumulated other comprehensive income (loss) (“AOCI”) to retained earnings for stranded tax effects resulting from the change in the U.S. federal corporate income tax rate on the gross deferred tax amounts at the date of enactment of the Tax Cuts and Jobs Act of 2017 (the “2017 Tax Act”). The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We will adopt ASU 2018-02 as of January 1, 2019. We are currently evaluating the impact the standard may have on our consolidated financial statements and related disclosures.

In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting”, simplifies the accounting for share-based payment granted to nonemployees for goods and services. Under the standard, most of the guidance on such payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We will adopt ASU 2018-07 as of January 1, 2019. We do not expect significant impact on our consolidated financial statements and related disclosures since our accounting for share-based payments to employees and nonemployees is similar.

In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement”. The guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. We will adopt ASU 2018-02 as of January 1, 2020. We will evaluate the impact the standard may have on our consolidated financial statements and related disclosures as the adoption date approaches.

Revenue Recognition

We are currently approved to sell Rubraca in the United States market. We distribute our product principally through a limited number of specialty distributor and specialty pharmacy providers, collectively, our customers. Our customers subsequently sell our products to patients and health care providers. Separately, we have arrangements with certain payors and other third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts.

Product Revenue

Revenue from product sales are recognized when the performance obligation is satisfied, which is when customers obtain control of our product at a point in time, typically upon delivery. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less.

Reserves for Variable Consideration

Table of Contents

patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known.

Rebates. Rebates include mandated discounts under the Medicaid Drug Rebate Program and the Medicare coverage gap program. Rebates are amounts owed after the final dispensing of products to a benefit plan participant and are based upon contractual agreements or legal requirements with the public-sector benefit providers. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the consolidated balance sheet. We estimate our Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. The accrual for rebates is based on statutory discount rates and known sales to specialty pharmacy patients or expected utilization for specialty distributor sales to healthcare providers. As we gain more historical experience, the accrual will be based solely on the expected utilization from historical data we have accumulated since the Rubraca product launch. Rebates are generally invoiced and paid quarterly in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter’s activity, plus an accrual balance for known or estimated prior quarters’ unpaid rebates.

Chargebacks. Chargebacks are discounts that occur when contracted customers, which currently consist primarily of group purchasing organizations, Public Health Service organizations and federal government entities purchasing via the Federal Supply Schedule, purchase directly from our specialty distributors at a discounted price. The specialty distributor, in turn, charges back the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the healthcare provider. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. The accrual for specialty distributor chargebacks is estimated based on known chargeback rates and known sales to specialty distributors adjusted for the estimated utilization by healthcare providers.

Discounts and Fees. Our payment terms are generally 30 days. Specialty distributors and specialty pharmacies are offered various forms of consideration, including service fees and prompt pay discounts for payment within a specified period. We expect these customers will earn prompt pay discounts and therefore, we deduct the full amount of these discounts and service fees from product sales when revenue is recognized.

Co-pay assistance. Patients who have commercial insurance and meet certain eligibility requirements may receive co-pay assistance. The intent of this program is to reduce the patient’s out of pocket costs. Liabilities for co-pay assistance are based on actual program participation provided by third-party administrators at month end.

Returns. Consistent with industry practice, we generally offer customers a right of return limited only to product that will expire in six months or product that is six months beyond the expiration date. To date, we have had minimal product returns and we currently do not have an accrual for product returns. We will continue to assess our estimate for product returns as we gain additional historical experience.

Cost of Sales – Product

Product cost of sales consists primarily of materials, third-party manufacturing costs as well as freight and royalties owed to our licensing partners for Rubraca sales.

Cost of Sales – Intangible Asset Amortization

Cost of sales for intangible asset amortization consists of the amortization of capitalized milestone payments made to our licensing partners upon FDA approval of Rubraca. Milestone payments are amortized on a straight-line basis over the estimated remaining patent life of Rubraca.

Table of Contents

Inventory

Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out (“FIFO”) basis. We began capitalizing incurred inventory related costs upon the regulatory approval of Rubraca. Prior to the regulatory approval of Rubraca, we incurred costs for the manufacture of the drug that could potentially be available to support the commercial launch of Rubraca and all such costs were recognized as research and development expense. We periodically analyze our inventory levels, and write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and/or inventory in excess of expected sales requirements as cost of product revenues. Expired inventory would be disposed of and the related costs would be written off as cost of product revenues.

The active pharmaceutical ingredient (“API”) in Rubraca is currently produced by a single supplier. As the API has undergone significant manufacturing specific to its intended purpose at the point it is purchased by us, we classify the API as work-in-process inventory. Inventory used in clinical trials is expensed as research and development expense when it has been identified for such use.

Our other significant accounting policies are described in Note 2, Summary of Significant Accounting Policies of the Notes to the Consolidated Financial Statements included in our 2017 Form 10-K.

3. Financial Instruments and Fair Value Measurements

Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

The three levels of inputs that may be used to measure fair value include:

Level 1:	Quoted prices in active markets for identical assets or liabilities. Our Level 1 assets consist of money market investments. We do not have Level 1 liabilities.

Level 2:	Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Our Level 2 assets consist of U.S. treasury securities. We do not have Level 2 liabilities.

Level 3:	Unobservable inputs that are supported by little or no market activity. We do not have Level 3 assets or liabilities that are measured at fair value on a recurring basis.

The following table identifies our assets and liabilities that were measured at fair value on a recurring basis (in thousands):


	Balance		Level 1		Level 2		Level 3
September 30, 2018
Assets:
Money market	$	255,143	$	255,143	$	—	$	—
U.S. treasury securities		313,525		—		313,525		—
Total assets at fair value	$	568,668	$	255,143	$	313,525	$	—
December 31, 2017
Assets:
Money market	$	433,136	$	433,136	$	—	$	—
U.S. treasury securities		99,533		—		99,533		—
Total assets at fair value	$	532,669	$	433,136	$	99,533	$	—

There were no transfers between the Level 1 and Level 2 categories or into or out of the Level 3 category during the three and nine months ended September 30, 2018.

Table of Contents

Financial instruments not recorded at fair value include our convertible senior notes. At September 30 2018, the carrying amount of the 2021 Notes was $283.4 million, which represents the aggregate principal amount net of remaining debt issuance costs, and the fair value was $268.2 million. At September 30 2018, the carrying amount of the 2025 Notes was $291.4 million, which represents the aggregate principal amount net of remaining debt issuance costs, and the fair value was $232.8 million. The fair value was determined using Level 2 inputs based on the indicative pricing published by certain investment banks or trading levels of these notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system. See Note 9, Convertible Senior Notes for discussion of the convertible senior notes.

4. Available-for-Sale Securities

As of September 30, 2018, available-for-sale securities consisted of the following (in thousands):


			Gross		Gross		Aggregate
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
U.S. treasury securities	$	313,570	$	—	$	(45)	$	313,525

As of December 31, 2017, available-for-sale securities consisted of the following (in thousands):


			Gross		Gross		Aggregate
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
U.S. treasury securities	$	99,650	$	—	$	(117)	$	99,533

As of September 30, 2018, our available-for-sale securities have been in a continuous loss position for less than 12 months. We have concluded that decline in the market value of the available-for-sale securities is temporary. A decline in the market value of a security below its cost that is deemed to be other than temporary is charged to earnings and results in the establishment of a new cost basis for the security. Factors evaluated to determine if an investment is other-than-temporarily impaired include significant deterioration in earnings performance, credit rating, asset quality or business prospects of the issuer; adverse changes in the general market conditions in which the issuer operates; and our intent and ability to hold the security until an anticipated recovery in value occurs.

As of September 30, 2018, the amortized cost and fair value of available-for-sale securities by contractual maturity were (in thousands):


	Amortized		Fair
	Cost		Value
Due in one year or less	$	313,570	$	313,525
Due in one year to two years		—		—
Total	$	313,570	$	313,525

5. Inventories

The following table presents current and long-term inventories as of September 30, 2018 and December 31, 2017:


	September 30,		December 31,
	2018		2017
Work-in-process	$	51,707	$	24,721
Finished goods		11,980		2,787
Total inventories	$	63,687	$	27,508

Some of the costs related to our finished goods on-hand as of September 30, 2018 were expensed as incurred prior to the commercialization of Rubraca on December 19, 2016.

At September 30, 2018, deposit on inventory on the Consolidated Balance Sheets is a cash deposit of $44.6 million made to a manufacturer for the purchase of work-in-process inventory which we expect to be converted to finished goods during the next twelve months and beyond.

Table of Contents

6. Other Current Assets

Other current assets were comprised of the following (in thousands):


	September 30,		December 31,
	2018		2017
Prepaid insurance	$	752	$	1,926
Prepaid expenses - other		7,031		3,355
Receivable - other		3,741		2,023
Other		256		196
Total	$	11,780	$	7,500

7. Intangible Assets and Goodwill

Intangible assets related to capitalized milestones under license agreements consisted of the following (in thousands):


	September 30,		December 31,
	2018		2017
Intangible asset - milestones	$	56,100	$	21,100
Accumulated amortization		(3,391)		(1,539)
Total intangible asset, net	$	52,709	$	19,561

The increase in our intangible asset – milestones since December 31, 2017 is due to a $15.0 million milestone payment to Pfizer related to the April 6, 2018 FDA approval of our sNDA for Rubraca as maintenance treatment and a $20.0 million milestone payment to Pfizer related to the European Commission approval of Rubraca in May 2018. See Note 12, License Agreements for further discussion of these approvals.

The estimated useful lives of these intangible assets are based on the estimated remaining patent life of Rubraca and extend through 2035.

We recorded amortization expense of $0.8 million and $1.9 million related to capitalized milestone payments during the three and nine months ended September 30, 2018, respectively. We recorded amortization expense of $0.4 million and $1.2 million related to capitalized milestone payments during the three and nine months ended September 30, 2017, respectively. Amortization expense is included in cost of sales – intangible asset amortization on the Consolidated Statements of Operations and Comprehensive Loss.

Estimated future amortization expense associated with intangibles is expected to be as follows (in thousands):


2018	$	779
2019		3,116
2020		3,116
2021		3,116
2022		3,116
Thereafter		39,466
	$	52,709

The change in goodwill established as part of the purchase accounting of EOS in November 2013 consisted of the following (in thousands):


Balance at December 31, 2017	$	65,217
Change in foreign currency gains and losses		(2,143)
Balance at September 30, 2018	$	63,074

Table of Contents

8. Other Accrued Expenses

Other accrued expenses were comprised of the following (in thousands):


	September 30,		December 31,
	2018		2017
Accrued personnel costs	$	14,217	$	13,889
Accrued interest payable		—		2,096
Income tax payable		186		—
Accrued corporate legal fees and professional services		731		415
Accrued royalties		4,187		2,984
Accrued variable considerations		2,407		1,008
Payable to third party logistics provider		14		2,661
Accrued expenses - other		2,990		2,830
Total	$	24,732	$	25,883

9. Convertible Senior Notes

2021 Notes

On September 9, 2014, we completed a private placement of $287.5 million aggregate principal amount of 2.5% convertible senior notes due 2021 (the “2021 Notes”) resulting in net proceeds of $278.3 million after deducting offering expenses. In accordance with the accounting guidance, the conversion feature did not meet the criteria for bifurcation, and the entire principal amount was recorded as a long-term liability on the Consolidated Balance Sheets.

The 2021 Notes are governed by the terms of the indenture between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee. The 2021 Notes are senior unsecured obligations and bear interest at a rate of 2.5% per year, payable semi-annually in arrears on March 15 and September 15 of each year. The 2021 Notes will mature on September 15, 2021, unless earlier converted, redeemed or repurchased.

Holders may convert all or any portion of the 2021 Notes at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the holders will receive shares of our common stock at an initial conversion rate of 16.1616 shares per $1,000 in principal amount of 2021 Notes, equivalent to a conversion price of approximately $61.88 per share. The conversion rate is subject to adjustment upon the occurrence of certain events described in the indenture. In addition, following certain corporate events that occur prior to the maturity date or upon our issuance of a notice of redemption, we will increase the conversion rate for holders who elect to convert the 2021 Notes in connection with such a corporate event or during the related redemption period in certain circumstances.

On or after September 15, 2018, we may redeem the 2021 Notes, at our option, in whole or in part, if the last reported sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending not more than two trading days preceding the date on which we provide written notice of redemption at a redemption price equal to 100% of the principal amount of the 2021 Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2021 Notes.

If we undergo a fundamental change, as defined in the indenture, prior to the maturity date of the 2021 Notes, holders may require us to repurchase for cash all or any portion of the 2021 Notes at a fundamental change repurchase price equal to 100% of the principal amount of the 2021 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

The 2021 Notes rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the 2021 Notes; equal in right of payment to all of our liabilities that are not so subordinated; effectively junior in right of payment to any secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries.

Table of Contents

amortized as interest expense over the expected life of the 2021 Notes using the effective interest method. We determined the expected life of the debt was equal to the seven-year term of the 2021 Notes.

2025 Notes

On April 19, 2018, we completed an underwritten public offering of $300.0 million aggregate principal amount of 1.25% convertible senior notes due 2025 (the “2025 Notes”) resulting in net proceeds of $290.9 million, after deducting underwriting discounts and commissions and offering expenses. In accordance with the accounting guidance, the conversion feature did not meet the criteria for bifurcation, and the entire principal amount was recorded as a long-term liability on the Consolidated Balance Sheets.

The 2025 Notes are governed by the terms of the indenture between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee, as supplemented by the terms of that certain first supplemental indenture thereto. The 2025 Notes are senior unsecured obligations and bear interest at a rate of 1.25% per year, payable semi-annually in arrears on May 1 and November 1 of each year. The 2025 Notes will mature on May 1, 2025, unless earlier converted, redeemed or repurchased.

Holders may convert all or any portion of the 2025 Notes at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the holders will receive shares of our common stock at an initial conversion rate of 13.1278 shares per $1,000 in principal amount of 2025 Notes, equivalent to a conversion price of approximately $76.17 per share. The conversion rate is subject to adjustment upon the occurrence of certain events described in the indenture. In addition, following certain corporate events that occur prior to the maturity date or upon our issuance of a notice of redemption, we will increase the conversion rate for holders who elect to convert the 2025 Notes in connection with such a corporate event or during the related redemption period in certain circumstances.

On or after May 2, 2022, we may redeem the 2025 Notes, at our option, in whole or in part, if the last reported sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending not more than two trading days preceding the date on which we provide written notice of redemption at a redemption price equal to 100% of the principal amount of the 2025 Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2025 Notes.

If we undergo a fundamental change, as defined in the indenture, prior to the maturity date of the 2025 Notes, holders may require us to repurchase for cash all or any portion of the 2025 Notes at a fundamental change repurchase price equal to 100% of the principal amount of the 2025 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

The 2025 Notes rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the 2025 Notes; equal in right of payment to all of our liabilities that are not so subordinated, including the 2021 Notes; effectively junior in right of payment to any secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries.

In connection with the issuance of the 2025 Notes, we incurred $9.1 million of debt issuance costs. The debt issuance costs are presented as a deduction from the convertible senior notes on the Consolidated Balance Sheets and are amortized as interest expense over the expected life of the 2025 Notes using the effective interest method. We determined the expected life of the debt was equal to the seven-year term of the 2025 Notes.

As of September 30, 2018 and December 31, 2017, the balance of unamortized debt issuance costs was $12.7 million and $5.1 million, respectively.

Table of Contents

The following table sets forth total interest expense recognized during the three and nine months ended September 30, 2018 and 2017 (in thousands):


	Three months ended September 30,				Nine months ended September 30,
	2018		2017		2018		2017
Contractual interest expense	$	2,735	$	1,797	$	7,078	$	5,391
Accretion of interest on milestone liability		—		500		978		1,449
Amortization of debt issuance costs		641		321		1,536		956
Total interest expense	$	3,376	$	2,618	$	9,592	$	7,796

10. Stockholders’ Equity

Common Stock

The holders of common stock are entitled to one vote per share on all matters to be voted upon by our stockholders. Subject to the preferences that may be applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by our Board of Directors.

Accumulated Other Comprehensive Loss

Accumulated other comprehensive loss consists of changes in foreign currency translation adjustments, which includes changes in a subsidiary’s functional currency, and unrealized gains and losses on available-for-sale securities.

The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the three months ended September 30, 2018 and 2017, as follows (in thousands):


	Foreign Currency				Unrealized				Total Accumulated
	Translation Adjustments				(Losses) Gains				Other Comprehensive Loss
	2018		2017		2018		2017		2018		2017
Balance at July 1,	$	(43,870)	$	(44,155)	$	(175)	$	(151)	$	(44,045)	$	(44,306)
Other comprehensive income (loss)		(495)		2,510		(10)		15		(505)		2,525
Total before tax		(44,365)		(41,645)		(185)		(136)		(44,550)		(41,781)
Tax effect		—		(915)		—		(5)		—		(920)
Balance at September 30,	$	(44,365)	$	(42,560)	$	(185)	$	(141)	$	(44,550)	$	(42,701)

The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the nine months ended September 30, 2018 and 2017, as follows (in thousands):


	Foreign Currency				Unrealized				Total Accumulated
	Translation Adjustments				(Losses) Gains				Other Comprehensive Loss
	2018		2017		2018		2017		2018		2017
Balance at January 1,	$	(41,917)	$	(47,434)	$	(256)	$	(146)	$	(42,173)	$	(47,580)
Other comprehensive income (loss)		(2,448)		7,695		71		8		(2,377)		7,703
Total before tax		(44,365)		(39,739)		(185)		(138)		(44,550)		(39,877)
Tax effect		—		(2,821)		—		(3)		—		(2,824)
Balance at September 30,	$	(44,365)	$	(42,560)	$	(185)	$	(141)	$	(44,550)	$	(42,701)

The period change in each of the periods was primarily due to the currency translation of the goodwill and deferred income taxes associated with the acquisition of EOS in November 2013. There were no reclassifications out of accumulated other comprehensive loss in each of the three and nine months ended September 30, 2018 and 2017.

Table of Contents

11. Share-Based Compensation

Share-based compensation expense for all equity based programs, including stock options, restricted stock units and the employee stock purchase plan, for the three and nine months ended September 30, 2018 and 2017 was recognized in the accompanying Consolidated Statements of Operations as follows (in thousands):


	Three months ended September 30,				Nine months ended September 30,
	2018		2017		2018		2017
Research and development	$	5,038	$	5,636	$	15,380	$	14,628
Selling, general and administrative		5,909		7,001		22,335		17,573
Total share-based compensation expense	$	10,947	$	12,637	$	37,715	$	32,201

We did not recognize a tax benefit related to share-based compensation expense during the three and nine months ended September 30, 2018 and 2017, respectively, as we maintain net operating loss carryforwards and have established a valuation allowance against the entire net deferred tax asset as of September 30, 2018.

Stock Options

The following table summarizes the activity relating to our options to purchase common stock for the nine months ended September 30, 2018:


				Weighted
		Weighted		Average	Aggregate
		Average		Remaining	Intrinsic
	Number of	Exercise		Contractual	Value
	Options	Price		Term (Years)	(Thousands)
Outstanding at December 31, 2017	5,789,735	$	46.77
Granted	639,793		52.33
Exercised	(70,480)		25.82
Forfeited	(217,007)		60.47
Outstanding at September 30, 2018	6,142,041	$	47.11	6.6	$	24,884
Vested and expected to vest at September 30, 2018	5,919,341	$	47.00	6.5	$	24,555
Vested and exercisable at September 30, 2018	4,284,706	$	45.70	5.8	$	21,421

The aggregate intrinsic value in the table above represents the pretax intrinsic value, based on our closing stock price of $29.37 as of September 28, 2018, which would have been received by the option holders had all option holders with in-the-money options exercised their options as of that date.

The following table summarizes information about our stock options as of and for the three and nine months ended September 30, 2018 and 2017 (in thousands, except per share amounts):


	Three months ended September 30,				Nine months ended September 30,
	2018		2017		2018		2017
Weighted-average grant date fair value per share	$	28.97	$	60.81	$	38.52	$	48.39
Intrinsic value of options exercised	$	325	$	3,400	$	1,697	$	17,684
Cash received from stock option exercises	$	604	$	2,149	$	1,820	$	13,262

As of September 30, 2018, the unrecognized share-based compensation expense related to unvested options, adjusted for expected forfeitures, was $60.4 million and the estimated weighted-average remaining vesting period was 2.46 years.

Table of Contents

Restricted Stock

The following table summarizes the activity relating to our unvested restricted stock units (“RSUs”) for the nine months ended September 30, 2018:



		Weighted
		Average
	Number of	Grant Date
	Units	Fair Value
Unvested at December 31, 2017	589,529	$	41.67
Granted	479,255		55.05
Vested	(199,602)		40.43
Forfeited	(44,686)		46.65
Unvested as of September 30, 2018	824,496	$	49.48
Expected to vest after September 30, 2018	706,795	$	49.25

As of September 30, 2018, the unrecognized share-based compensation expense related to unvested RSUs, adjusted for expected forfeitures, was $31.2 million and the estimated weighted-average remaining vesting period was 3.0 years.

12. License Agreements

Rucaparib

In June 2011, we entered into a worldwide license agreement with Pfizer, Inc. to obtain exclusive global rights to develop and commercialize rucaparib, a small molecule inhibitor of poly (ADP-ribose) polymerase (“PARP”), used for the treatment of selected solid tumors. The exclusive rights are exclusive even as to Pfizer and include the right to grant sublicenses. Pursuant to the terms of the license agreement, we made a $7.0 million upfront payment to Pfizer and are required to make additional payments to Pfizer for the achievement of certain development and regulatory and sales milestones and royalties on sales as required by the license agreement. Prior to the FDA approval of rucaparib, discussed below, we made milestone payments of $1.4 million, which were recognized as acquired in-process research and development expense.

On August 30, 2016, we entered into a first amendment to the worldwide license agreement with Pfizer, which amends the June 2011 existing worldwide license agreement to permit us to defer payment of the milestone payments payable upon (i) FDA approval of an NDA for 1st Indication in US and (ii) EMA approval of an MAA for 1st Indication in EU, to a date that is 18 months after the date of achievement of such milestones.

On December 19, 2016, the FDA approved Rubraca (rucaparib) tablets as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. The FDA approval resulted in a $0.75 million milestone payment to Pfizer as required by the license agreement, which was made in the first quarter of 2017. The FDA approval also resulted in the obligation to pay a $20.0 million milestone payment, for which we exercised the option to defer payment by agreeing to pay $23.0 million within 18 months after the date of the FDA approval. We paid the $23.0 million milestone payment in June 2018.

On April 6, 2018, the FDA approved our sNDA for Rubraca as maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. This approval resulted in the obligation to pay a $15.0 million milestone payment, which we paid in April 2018.

Table of Contents

These milestone payments were recognized as intangible assets and will be amortized over the estimated remaining useful life of Rubraca.

We are obligated under the license agreement to use commercially reasonable efforts to develop and commercialize rucaparib and we are responsible for all remaining development and commercialization costs for rucaparib. We are required to make regulatory milestone payments to Pfizer of up to an additional $31.75 million in aggregate if specified clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, we are obligated to make sales milestone payments to Pfizer if specified annual sales targets for rucaparib are met, which relate to annual sales targets of $250.0 million and above, which, in the aggregate, could amount to total milestone payments of $170.0 million, and tiered royalty payments at a mid-teen percentage rate on our net sales, with standard provisions for royalty offsets to the extent we need to obtain any rights from third parties to commercialize rucaparib.

In April 2012, we entered into a license agreement with AstraZeneca UK Limited to acquire exclusive rights associated with rucaparib under a family of patents and patent applications that claim methods of treating patients with PARP inhibitors in certain indications. The license enables the development and commercialization of rucaparib for the uses claimed by these patents. AstraZeneca receives royalties on any net sales of rucaparib.

Lucitanib

In connection with our acquisition of EOS in November 2013, we gained rights to develop and commercialize lucitanib, an oral, selective tyrosine kinase inhibitor. As further described below, EOS licensed the worldwide rights, excluding China, to develop and commercialize lucitanib from Advenchen Laboratories LLC (“Advenchen”). Subsequently, rights to develop and commercialize lucitanib in markets outside the U.S. and Japan were sublicensed by EOS to Servier in exchange for upfront milestone fees, royalties on sales of lucitanib in the sublicensed territories and research and development funding commitments.

In October 2008, EOS entered into an exclusive license agreement with Advenchen to develop and commercialize lucitanib on a global basis, excluding China. We are obligated to pay Advenchen tiered royalties at percentage rates in the mid-single digits on net sales of lucitanib, based on the volume of annual net sales achieved. In addition, after giving effect to the first and second amendments to the license agreement, we are required to pay to Advenchen 25% of any consideration, excluding royalties, received pursuant to any sublicense agreements for lucitanib, including the agreement with Servier. We are obligated under the agreement to use commercially reasonable efforts to develop and commercialize at least one product candidate containing lucitanib, and we are also responsible for all remaining development and commercialization costs for lucitanib.

The license agreement with Advenchen will remain in effect until the expiration of all our royalty obligations to Advenchen, determined on a product-by-product and country-by-country basis, unless we elect to terminate the agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, Advenchen can terminate the agreement, resulting in a loss of our rights to lucitanib.

During 2017, we completed the committed on-going development activities related to lucitanib and received full reimbursement of our development costs from Servier. Reimbursements are recorded as a reduction to research and development expense on the Consolidated Statements of Operations. Lucitanib was originally developed by Clovis and Servier with the hypothesis of activity in FGFR driven tumors; however, data in breast and lung cancer were insufficient to move the program forward. We received notice from Servier of termination of their rights to lucitanib, resulting in the return of global rights (excluding China) for lucitanib to us during October 2018.

We are party to a product license agreement for our other drug candidate rociletinib (see our 2017 Form 10-K for additional details).

13. Net Loss Per Common Share

Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding using the treasury-stock method for the stock options and RSUs and the if-converted method for the 2021 Notes and 2025 Notes. As a result of our net losses for the periods presented, all

Table of Contents

potentially dilutive common share equivalents were considered anti-dilutive and were excluded from the computation of diluted net loss per share.

The shares outstanding at the end of the respective periods presented in the table below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands):


	Three and Nine months ended September 30,
	2018	2017
Common shares under option	3,381	5,696
Convertible senior notes	8,584	4,646
Total potential dilutive shares	11,965	10,342

14. Commitments and Contingencies

Royalty and License Fee Commitments

We have entered into certain license agreements, as identified in Note 12, License Agreements, with third parties that include the payment of development and regulatory milestones, as well as royalty payments, upon the achievement of pre-established development, regulatory and commercial targets. Our payment obligation related to these license agreements is contingent upon the successful development, regulatory approval and commercialization of the licensed products. Due to the nature of these arrangements, the future potential payments are inherently uncertain, and accordingly, we only recognize payment obligations which are probable and estimable as of the balance sheet date. Milestone liabilities of $0.0 million and $22.0 million are recorded on our Consolidated Balance Sheets at September 30, 2018 and December 31, 2017, respectively, and relate to milestone payments for the licensing of our rucaparib product, which was approved by the FDA on December 19, 2016.

Manufacture and Services Agreement Commitments

On October 3, 2016, we entered into a Manufacturing and Services Agreement (the “Agreement”) with a non-exclusive third-party supplier for the production of the active ingredient for Rubraca. Under the terms of the Agreement, we will provide the third-party supplier a rolling forecast for the supply of the active ingredient in Rubraca that will be updated by us on a quarterly basis. We are obligated to order material sufficient to satisfy an initial quantity specified in any forecast. In addition, the third-party supplier will construct, in its existing facility, a production train that will be exclusively dedicated to the manufacture of the Rubraca active ingredient. We are obligated to make scheduled capital program fee payments toward capital equipment and other costs associated with the construction of the dedicated production train. Further, once the facility is operational, we are obligated to pay a fixed facility fee each quarter for the duration of the Agreement, which expires on December 31, 2025, unless extended by mutual consent of the parties. As of September 30, 2018, $165.1 million of purchase commitments exist under the Agreement.

Legal Proceedings

We and certain of our officers were named as defendants in several lawsuits, as described below. We cannot reasonably predict the outcome of these legal proceedings, nor can we estimate the amount of loss or range of loss, if any, that may result. An adverse outcome in these proceedings could have a material adverse effect on our results of operations, cash flows or financial condition.

Rociletinib-Related Litigation

Following Clovis’ regulatory announcement in November 2015 of adverse developments in its ongoing clinical trials for rociletinib, Clovis and certain of its current and former executives were named in various securities lawsuits, the largest of which was a putative class action lawsuit in the District of Colorado (the “Medina Action”) which was settled on October 26, 2017 (the “Medina Settlement”). The open actions currently pending against Clovis are discussed below.

Table of Contents

making allegedly false statements to Antipodean and in the offering materials for the July 2015 Offering relating to the efficacy of rociletinib, its safety profile, and its prospects for market success. In addition to the Securities Act claims, the Antipodean Complaint also asserts Colorado state law claims and common law claims. Both the state law and common law claims are based on allegedly false and misleading statements regarding rociletinib’s progress toward FDA approval. The Antipodean Complaint seeks compensatory, recessionary, and punitive damages. On December 15, 2016, the Antipodean Plaintiffs filed an amended complaint (the “Antipodean Amended Complaint”) asserting substantially the same claims against the same defendants and purporting to correct certain details in the original Antipodean Complaint.

Following a stay that Justice Masley of the New York Supreme Court, County of New York entered in favor of the Medina Action and briefing on defendants’ motions to dismiss, the parties participated in a Preliminary Conference on April 17, 2018, following which the Court entered a preliminary conference order, providing deadlines for document productions, depositions, and other discovery. The Court has scheduled a status conference for January 21, 2019, following which the Court anticipates setting an end date for discovery.

On May 2, 2018, the Court issued an order denying the defendants’ motion to dismiss. Defendants filed an answer to the Antipodean Amended Complaint on June 6, 2018.

The Company intends to vigorously defend against the allegations in the Antipodean Amended Complaint. However, there can be no assurance that the defense will be successful.

In March 2017, two putative shareholders of the Company, Macalinao and McKenry (the “Derivative Plaintiffs”), filed shareholder derivative complaints against certain directors and officers of the Company in the Court of Chancery of the State of Delaware. On May 4, 2017, the Macalinao and McKenry actions were consolidated for all purposes in a single proceeding under the caption In re Clovis Oncology, Inc. Derivative Litigation, Case No, 2017-0222 (the “Consolidated Derivative Action”).

On May 18, 2017, the Derivative Plaintiffs filed a Consolidated Verified Shareholder Derivative Complaint (the “Consolidated Derivative Complaint”). The Consolidated Derivative Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by allegedly causing or allowing misrepresentations of the Company’s business operations and prospects, failing to ensure that the TIGER-X clinical trial was being conducted in accordance with applicable rules, regulations and protocols, and engaging in insider trading. The Consolidated Derivative Complaint purported to rely on documents produced by the Company in response to prior demands for inspection of the Company’s books and records served on the Company by each of Macalinao and McKenry under 8 Del. C. § 220. The Consolidated Derivative Complaint sought, among other things, an award of money damages.

On July 31, 2017, the defendants filed a motion to dismiss the Consolidated Derivative Complaint. Plaintiffs filed an opposition to the motion to dismiss on August 31, 2017, and the defendants filed a reply in further support of the motion to dismiss on September 26, 2017. Oral argument on the defendants’ motion to dismiss the Consolidated Derivative Complaint has been scheduled for February 4, 2019.

The Company intends to vigorously defend against the allegations in the Consolidated Derivative Complaint, but there can be no assurance that the defense will be successful.

On March 20, 2017, a purported shareholder of the Company, filed a shareholder derivative complaint (the “Guo Complaint”) against certain officers and directors of the Company in the United States District Court for the District of Colorado. The Guo Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by either recklessly or with gross negligence approving or permitting misrepresentations of the Company’s business operations and prospects. The Guo Complaint also alleged claims for waste of corporate assets and unjust enrichment. Finally, the Guo Complaint alleged that certain of the individual defendants violated Section 14(a) of the Securities Exchange Act, by allegedly negligently issuing, causing to be issued, and participating in the issuance of materially misleading statements to stockholders in the Company’s Proxy Statement on Schedule DEF 14A in connection with the 2015 Annual Meeting of Stockholders, held on June 11, 2015. The Guo Complaint sought, among other things, an award of money damages.

On June 19, 2017, the parties filed a joint motion to stay the Guo action pending resolution of the motion to dismiss the Consolidated Derivative Complaint. On June 20, 2017, the court granted the motion to stay.

Table of Contents

The Company intends to vigorously defend against the allegations in the Guo Complaint, but there can be no assurance that the defense will be successful.

As previously disclosed, the Company has received inquiries and requests for information from governmental agencies, including the U.S. Securities and Exchange Commission (“SEC”) and the U.S. Department of Justice, relating to the Company’s regulatory update announcement in November 2015 that the FDA requested additional clinical data on the efficacy and safety of rociletinib.

Earlier this year, the Company and Mr. Mahaffy engaged in discussions with the SEC staff to resolve this matter. On September 18, 2018, the SEC announced it had reached an agreement with the Company to settle this matter on negligence-based charges. Pursuant to the settlement, without admitting or denying the SEC’s allegations, the Company paid a $20.0 million civil penalty, which the Company reserved as a loss contingency on its consolidated balance sheet as of June 30, 2018, and stipulated to a standard injunction against future violations of those provisions of the federal securities laws. Also, on September 18, 2018, the SEC announced that Mr. Mahaffy also reached a settlement with the SEC on similar negligence-based allegations, to which he neither admits nor denies, and paid a civil penalty and will be similarly enjoined. Mr. Mahaffy will continue to serve as the Company’s Chief Executive Officer and as a member of the Company’s Board of Directors.

The settlements do not allege that the Company or any of its current or former officers engaged in any intentional fraud or misconduct. The settlements were approved by the United States District Court for the District of Colorado on September 19, 2018 and resolve the SEC’s nearly three year investigation into the regulatory approval process of rociletinib.

European Patent Opposition

Two oppositions were filed in the granted European counterpart of the rucaparib camsylate salt/polymorph patent on June 20, 2017. The grounds of opposition related to Rubraca were lack of novelty and lack of inventive step. A preliminary opinion and summons to oral proceedings were issued on April 4, 2018. The oral hearing is scheduled for December 4, 2018. The preliminary opinion provides a non-binding indication of the tribunal’s view. In the preliminary opinion, the tribunal agreed with some of our positions and agreed with certain objections made by the opponents. As part of the proceeding, we have the opportunity to submit further arguments and pursue alternative claims in the form of auxiliary requests. On October 3, 2018, we submitted further arguments and auxiliary requests and on October 4, 2018, both opponents submitted further arguments. While the ultimate results of patent challenges can be difficult to predict, we believe a number of factors, including a constellation of unexpected properties, support the novelty and non-obviousness of our rucaparib camsylate salt/polymorph composition of matter patent.

ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Information

This Quarterly Report on Form 10-Q and the information incorporated herein by reference includes statements that are, or may be deemed, “forward-looking statements.” In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout this Quarterly Report on Form 10-Q and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned non-clinical studies and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, the degree of clinical utility of our products, particularly in specific patient populations, expectations regarding clinical trial data, our results of operations, financial condition, liquidity, prospects, growth and strategies, the industry in which we operate and the trends that may affect the industry or us.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change and depend on the economic circumstances that may or may not occur in the

Table of Contents

future or may occur on longer or shorter timelines than anticipated. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity and the development of the industry in which we operate may differ materially from the forward-looking statements contained herein.

Any forward-looking statements that we make in this Quarterly Report on Form 10-Q speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence of unanticipated events.

You should also read carefully the factors described in the “Risk Factors” in Part I, Item 1A in our most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”), as updated from time to time in our subsequent SEC filings, to better understand the risks and uncertainties inherent in our business and underlying any forward-looking statements.

Overview

We are a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. We target our development programs for the treatment of specific subsets of cancer populations, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use.

In May 2018, the European Commission granted a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. As this is a conditional approval, it will be necessary to complete confirmatory post marketing commitments, including ensuring that sufficient partially platinum sensitive patients are enrolled in our ARIEL4 confirmatory trial to support the indication. This may require enrollment of additional patients into the study, increasing its overall size and extending the time for enrollment. In June 2018, we submitted to the EMA a variation to the marketing authorization for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy, for which we received EMA validation for this application in July 2018. We anticipate an opinion on this application from the CHMP of the EMA by the end of 2018 with a potential formal European Commission approval in early 2019.

Beyond our initial labeled indication, we have a robust Rubraca clinical development program underway in a variety of solid tumor types, also including prostate and bladder cancers, and in July 2017, we entered into a broad clinical collaboration with Bristol-Myers Squibb Company to evaluate the combination of their immunotherapy OPDIVO (nivolumab) with Rubraca in several tumor types. We hold worldwide rights for Rubraca.

In June 2011, we obtained an exclusive, worldwide license from Pfizer to develop and commercialize rucaparib. U.S. Patent 6,495,541, and its equivalent counterparts issued in dozens of countries, directed to the rucaparib

Table of Contents

composition of matter, expire in 2020 and are potentially eligible for up to five years patent term extension in various jurisdictions. We believe that patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 (the “Hatch-Waxman Act”) could be available to extend our patent exclusivity for rucaparib to the fourth quarter of 2023 in the United States. In Europe, we believe that patent term extension under a supplementary protection certificate could be available for an additional five years for one European patent directed to Rubraca. In April 2012, we obtained an exclusive license from AstraZeneca under a family of patents and patent applications which will permit the development and commercialization of rucaparib for certain methods of treating patients with PARP inhibitors. Additionally, other patents and patent applications are directed to methods of making, methods of using, dosing regimens, various salt and polymorphic forms and formulations and have expiration dates ranging from 2020 through potentially 2035, including the camsylate salt/polymorph patent family licensed from Pfizer, which expires in 2031 and a patent family directed to high dosage strength rucaparib tablets that expires in 2035. As of May 3, 2018, the rucaparib camsylate salt/polymorph patent was issued in 47 countries to date (including US and Europe), with applications pending in 9 countries, and the rucaparib composition of matter patent was issued in 48 countries. We are aware of a number of challenges of salt and polymorph patents. Two oppositions were filed in the granted European counterpart of the rucaparib camsylate salt/polymorph patent on June 20, 2017. European oppositions are commonly filed against patents related to pharmaceutical products. The grounds of opposition related to Rubraca were lack of novelty and lack of inventive step. The novelty and inventive step challenges are based on prior art references (or closely related disclosures) that were previously raised by the European patent examiner during prosecution of the application. The claims of the granted patent were found to be patentable over this prior art. A preliminary opinion and summons to oral proceedings were issued on April 4, 2018. The oral hearing is scheduled for December 4, 2018. The preliminary opinion provides a non-binding indication of the tribunal’s view. In the preliminary opinion, the tribunal agreed with some of our positions and agreed with certain objections made by the opponents. As part of the proceeding, we have the opportunity to submit further argument and pursue alternative claims in the form of auxiliary requests. On October 3, 2018, we submitted further arguments and auxiliary requests and on October 4, 2018, both opponents submitted further arguments. While the ultimate results of patent challenges can be difficult to predict, we believe a number of factors, including a constellation of unexpected properties, support the novelty and non-obviousness of our rucaparib camsylate salt/polymorph composition of matter patent. We believe a successful challenge of all claims relevant to Rubraca would be difficult. Our high dosage strength rucaparib tablets patent issued in the United States on June 5, 2018, with claims that cover the commercial Rubraca product, including all commercial dosage strengths expires in 2035. Additionally, in Europe, regulatory exclusivity is available for ten years, plus one year for a new indication, therefore, we have regulatory exclusivity for Rubraca in Europe until 2028, and if an additional indication is approved, until 2029.

In addition to Rubraca, we have two other product candidates.

Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFR α/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3). Lucitanib was originally developed by Clovis and Servier with the hypothesis of activity in FGFR driven tumors; however, data in breast and lung cancer were insufficient to move that program forward. We received notice from Servier of termination of their rights to lucitanib, resulting in the return of global rights (excluding China) for lucitanib to us during October 2018. We believe that recent data for a drug similar to lucitanib that inhibits these same pathways – when combined with a PD-1 inhibitor – provide support for development of lucitanib in combination with a PD-(L)1 inhibitor, and we intend to initiate a study of the combination. We also intend to initiate a study of lucitanib in combination with Rubraca, based on encouraging data of VEGF and PARP inhibitors in combination. Each of these studies is expected to initiate in the first quarter of 2019. We maintain certain development and commercialization rights for lucitanib. Because of termination of the Servier license agreement, we have global development and commercialization rights (except for China) for lucitanib.

We commenced operations in April 2009. To date, we have devoted substantially all of our resources to identifying and in-licensing product candidates, performing development activities with respect to those product candidates and the general and administrative support of these operations. Through September 30, 2018, we have generated $13.6 million in license and milestone revenue related to our collaboration and license agreement with Servier and for the nine months ended September 30, 2018 and 2017 have generated $65.0 million and $38.5 million, respectively, product revenue related to sales of Rubraca, which we began to commercialize on December 19, 2016. We

Table of Contents

have principally funded our operations using the net proceeds from the sale of convertible preferred stock, the issuance of convertible promissory notes, public offerings of our common stock and our convertible senior notes offering.

We have never been profitable and, as of September 30, 2018, we had an accumulated deficit of $1,743.8 million. We incurred net losses of $268.8 million and $294.5 million for the nine months ended September 30, 2018 and 2017, respectively. We had cash, cash equivalents and available-for-sale securities totaling $604.4 million at September 30, 2018.

We expect to incur significant losses for the foreseeable future, as we incur costs related to commercial activities associated with Rubraca. In April 2018, we sold 1,837,898 shares of our common stock in a public offering at $54.41 per share. The net proceeds from the offering were $93.9 million, after deducting underwriting discounts and commissions and offering expenses. Concurrently, we completed the public offering of $300.0 million aggregate principal amount of 1.25% convertible senior notes due 2025. The net proceeds from this offering were $290.9 million, after deducting underwriting discounts and commissions and offering expenses. We intend to use the net proceeds of the offerings for general corporate purposes, including sales and marketing expenses associated with Rubraca in the United States and Europe, funding of our development programs, selling, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. Based on current estimates, we believe that our existing cash, cash equivalents and available-for-sale securities will allow us to fund our operating plan through at least the next 12 months. Until we can generate a sufficient amount of revenue from Rubraca, we expect to finance our operations in part through additional public or private equity or debt offerings and may seek additional capital through arrangements with strategic partners or from other sources. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need to generate significant revenues to achieve profitability, and we may never do so.

On October 29, 2018, we announced that Corwin Dale Hooks, our Senior Vice President and Chief Commercial Officer, has resigned effective as of October 29, 2018. In connection with his termination of employment, Mr. Hooks will receive the severance payments and benefits set out in Section 8(d) of his employment agreement, except that Mr. Hooks will receive his severance in one lump sum payment and will receive a payment that equals the anticipated COBRA premiums for himself and his dependents for a period of 18, rather than six, months, also in one lump sum payment.

Product License Agreements

Rucaparib

Table of Contents

These milestone payments were recognized as intangible assets and will be amortized over the estimated remaining useful life of Rubraca.

We are obligated under the license agreement to use commercially reasonable efforts to develop and commercialize rucaparib and we are responsible for all remaining development and commercialization costs for rucaparib. We are required to make regulatory milestone payments to Pfizer of up to an additional $31.75 million in aggregate if specified clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, we are obligated to make sales milestone payments to Pfizer if specified annual sales targets for rucaparib are met which relate to annual sales targets of $250.0 million and above, which, in the aggregate, could amount to total milestone payments of $170.0 million, and tiered royalty payments at a mid-teen percentage rate on our net sales, with standard provisions for royalty offsets to the extent we need to obtain any rights from third parties to commercialize rucaparib.

Lucitanib

Table of Contents

Servier with the hypothesis of activity in FGFR driven tumors; however, data in breast and lung cancer were insufficient to move the program forward. We received notice from Servier of termination of their rights to lucitanib, resulting in the return of global rights (excluding China) for lucitanib to us during October 2018.

We are party to a product license agreement for our other drug candidate rociletinib (see our 2017 Form 10-K for additional details).

Financial Operations Overview

Revenue

Product revenue is derived from sales of our product, Rubraca, in the United States. We distribute our product in the U.S. principally through a limited number of specialty distributor and specialty pharmacy providers, collectively, our customers. Our customers subsequently sell our products to patients and healthcare providers. Separately, we have arrangements with certain payors and other third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and other discounts. Revenue is recorded net of estimated rebates, chargebacks, discounts and other deductions as well as estimated product returns (collectively, “variable considerations”). Revenue from product sales are recognized when customers obtain control of our product, which occurs at a point in time, typically upon delivery to the customers. For further discussion of our revenue recognition policy, see Note 2, Summary of Significant Accounting Polices in the Revenue Recognition section.

In the three and nine months ended September 30, 2018, we recorded product revenue of $22.8 million and $65.0 million, respectively, related to sales of Rubraca, which we began to commercialize on December 19, 2016. Our ability to generate revenue and become profitable depends upon our ability to successfully commercialize products. Any inability on our part to successfully commercialize Rubraca in the United States and any foreign territories where it may be approved, or any significant delay in such approvals, could have a material adverse impact on our ability to execute upon our business strategy and, ultimately, to generate sufficient revenues from Rubraca to reach or maintain profitability or sustain our anticipated levels of operations.

We supply commercially labeled Rubraca free of charge to eligible patients who qualify due to financial need through our patient assistance program and the majority of these patients are on Medicare. This product is distributed through a separate vendor who administers the program on our behalf. It is not distributed through our specialty distributor and specialty pharmacy network. This product is neither included in the transaction price nor the variable considerations to arrive at product revenue. Manufacturing costs associated with this free product is included in selling, general and administrative expenses. In the three months ended September 30, 2018, the supply of this free drug was approximately 30% of the overall commercial supply or the equivalent of $9.6 million in commercial value. In the nine months ended September 30, 2018, the supply of this free drug was approximately 26% of the overall commercial supply or the equivalent of $23.0 million in commercial value. We believe the increase in the free drug percentage not realized as revenue results primarily from an increase in the percentage of patients treated with Rubraca who qualify for our patient assistance program, the majority of whom are on Medicare, following label expansion to include the earlier-line, all-comers maintenance treatment label.

Cost of Sales – Product

Product cost of sales consists primarily of materials, third-party manufacturing costs as well as freight and royalties owed to our licensing partners for Rubraca sales.

Cost of Sales – Intangible Asset Amortization

Table of Contents

Research and Development Expenses

Research and development expenses consist of costs incurred for the development of our product candidates and companion diagnostics, which include:

license fees and milestone payments related to the acquisition of in-licensed products, which are reported on our Consolidated Statements of Operations as acquired in-process research and development;

employee-related expenses, including salaries, benefits, travel and share-based compensation expense;

expenses incurred under agreements with contract research organizations and investigational sites that conduct our clinical trials;

the cost of acquiring, developing and manufacturing clinical trial materials;

costs associated with non-clinical activities and regulatory operations;

market research, disease education and other commercial product planning activities, including the hiring of a U.S. sales and marketing and medical affairs organization in preparation for the commercial launch of rucaparib; and

activities associated with the development of companion diagnostics for our product candidates.

Research and development costs are expensed as incurred. License fees and milestone payments related to in-licensed products and technology are expensed if it is determined that they have no alternative future use. Costs for certain development activities, such as clinical trials and manufacturing of clinical supply, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors. Our research and development expenses increased in the three and nine months ended September 30, 2018 compared to the same period in the prior year. Our research and development expenses will continue to increase compared to last year as planned Rubraca studies progress.

The following table identifies research and development and acquired in-process research and development costs on a program-specific basis for our products under development. Personnel-related costs, depreciation and share-based compensation are not allocated to specific programs, as they are deployed across multiple projects under development and, as such, are separately classified as personnel and other expenses in the table below (in thousands):


	Three months ended September 30,				Nine months ended September 30,
	2018		2017		2018		2017
	(in thousands)
Rucaparib Expenses
Research and development	$	44,375	$	21,828	$	101,931	$	53,318
Rucaparib Total		44,375		21,828		101,931		53,318
Lucitanib Expenses
Research and development (a)		169		(222)		396		(321)
Lucitanib Total		169		(222)		396		(321)
Rociletinib Expenses
Research and development	$	399	$	1,752		1,993		6,471
Rociletinib Total		399		1,752		1,993		6,471
Personnel and other expenses		18,944		15,566		55,818		45,011
Total	$	63,887	$	38,924	$	160,138	$	104,479

(a)This amount reflects actual costs incurred less amounts due from Servier for reimbursable development expenses pursuant to the collaboration and license agreement described in Note 12, License Agreements to our unaudited consolidated financial statements included in this Quarterly Report on Form 10-Q.

Selling, General and Administrative Expenses

Selling, general and administrative expenses consist principally of salaries and related costs for personnel in executive, commercial, finance, legal, investor relations, human resources, and information technology functions. Other selling, general and administrative expenses include facilities expenses, communication expenses, information technology costs, corporate insurance and professional fees for legal, consulting and accounting services. With the FDA approval of Rubraca on December 19, 2016, all sales and marketing expenses associated with Rubraca are included in

Table of Contents

selling, general and administrative expenses. Our selling, general and administrative expenses will continue to increase compared to last year in support of our commercial activities related to Rubraca in the United States and Europe.

Acquired In-Process Research and Development Expenses

Acquired in-process research and development expenses consist of upfront payments to acquire a new drug compound, as well as subsequent milestone payments. Acquired in-process research and development payments are immediately expensed provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no alternative future use. Once regulatory approval is received, payments to acquire rights, and the related milestone payments, are capitalized and the amortization of such assets recorded to intangible asset amortization cost of sales.

Other Income and Expense

Other income and expense is primarily comprised of foreign currency gains and losses resulting from transactions with contract research organizations (“CROs”), investigational sites and contract manufacturers where payments are made in currencies other than the U.S. dollar. Other expense also includes interest expense recognized related to our convertible senior notes.

Critical Accounting Policies and Significant Judgments and Estimates

Our discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, expenses and revenue and related disclosures. On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue deductions, intangible asset impairment, clinical trial accruals and share-based compensation expense. We base our estimates on historical experience, known trends and events and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

For a description of our critical accounting policies, please see Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017. Other than the change to our revenue recognition policy discussed in Note 2, Summary of Significant Accounting Policies, there have not been any material changes to our critical accounting policies since December 31, 2017.

New Accounting Standards

From time to time, the Financial Accounting Standards Board (“FASB”) or other standards-setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification are communicated through the issuance of an Accounting Standards Update. Unless otherwise discussed, we believe that the impact of recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on our Consolidated Financial Statements upon adoption.

To understand the impact of recently issued guidance, whether adopted or to be adopted, please review the information provided in Note 2, Summary of Significant Accounting Policies, in the Notes to the Unaudited Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.

Table of Contents

Results of Operations

Comparison of Three Months Ended September 30, 2018 and 2017:

The following table summarizes the results of our operations for the three months ended September 30, 2018 and 2017 (in thousands):


					Change
	Three months ended September 30,				Favorable/(Unfavorable)
	2018		2017		$		%
Revenues:
Product revenue	$	22,757	$	16,806	$	5,951		35	%
Operating expenses:
Cost of sales - product		4,766		3,026		(1,740)		(58)	%
Cost of sales - intangible asset amortization		771		372		(399)		(107)	%
Research and development		63,887		38,924		(24,963)		(64)	%
Selling, general and administrative		42,495		35,011		(7,484)		(21)	%
Total expenses		111,919		77,333		(34,586)		(45)	%
Operating loss		(89,162)		(60,527)		(28,635)		(47)	%
Other income (expense):
Interest expense		(3,376)		(2,618)		(758)		(29)	%
Foreign currency gain (loss)		151		(44)		195		443	%
Other income		2,536		1,291		1,245		96	%
Other expense, net		(689)		(1,371)		682		50	%
Loss before income taxes		(89,851)		(61,898)		(27,953)		(45)	%
Income tax (expense) benefit		(13)		1,234		(1,247)		(101)	%
Net loss	$	(89,864)	$	(60,664)	$	(29,200)		(48)	%

Product Revenue. Product revenue for the three months ended September 30, 2018 increased compared to the same period in the prior year primarily due to continued growth in sales of Rubraca, which was approved for sale in the United States markets and we began shipping on December 19, 2016. Product revenue is recorded net of variable considerations comprised of rebates, chargebacks and other discounts. Variable considerations represented approximately 11.1% and 7.4% of the transaction price recognized in the three months ended September 30, 2018 and 2017, respectively. This increase primarily relates to an increase in older patients on Medicare as well as additional patients filling prescriptions at low-income clinics. Amounts are summarized as follows:


	Three months ended				Three months ended
	September 30, 2018				September 30, 2017
	$		% of Gross Sales		$		% of Gross Sales
	(in thousands)				(in thousands)

Transaction price	$	25,626		100.0%	$	18,144		100.0%
Variable considerations:
Government rebates and chargebacks		1,664		6.4%		748		4.1%
Discounts and fees		1,204		4.7%		590		3.3%
Total variable considerations		2,868		11.1%		1,338		7.4%
Product revenue	$	22,758		88.9%	$	16,806		92.6%

Cost of Sales – Product. Product cost of sales for the three months ended September 30, 2018 increased compared to the same period in the prior year primarily due to the increase in product revenue. Product cost of sales primarily relate to manufacturing, freight and royalties costs associated with Rubraca sales in the period. Manufacturing costs associated with sales in the three months ended September 30, 2017 were expensed as incurred based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, and therefore, a minimal amount is included as product cost of sales. These costs increased in the three months ended September 30, 2018, as we depleted these inventories as of the fourth quarter 2017.

Table of Contents

Cost of Sales – Intangible Asset Amortization. In the three months ended September 30, 2018 and 2017, we recognized cost of sales of $0.8 million and $0.4 million, respectively, associated with the amortization of capitalized milestone payments related to the approvals of Rubraca by the FDA in December 2016 and April 2018 and by the European Commission in May 2018.

Research and Development Expenses. Research and development expenses increased during the three months ended September 30, 2018 compared to the same period in the prior year primarily due to higher research and development costs for rucaparib. Clinical trial costs for rucaparib were higher compared to the same quarter a year ago due to increased enrollment in our TRITON2 and TRITON3 studies for prostate cancer. We have increased costs related to our new ATLAS study for bladder cancer and our ATHENA combination study with Bristol-Myers Squibb Company’s immunotherapy OPDIVO for ovarian cancer. In addition, personnel costs increased during the three months ended September 30, 2018 due to higher headcount to support increased rucaparib clinical trial activities.

Clinical trial costs for rociletinib were $1.4 million lower than the third quarter of 2017 primarily due to patients discontinuing drug treatment and investigational sites closing for all of the TIGER studies in non-small cell lung cancer.

Selling, General and Administrative Expenses. Selling, general and administrative expenses increased during the three months ended September 30, 2018 compared to the same period in the prior year primarily due to increased commercialization activities for Rubraca and the increase of costs associated with building out the European infrastructure in anticipation of commercialization there.

Interest Expense. Interest expense increased during the three months ended September 30, 2018 compared to the same period in the prior year primarily due to the issuance of the 2025 Notes on April 19, 2018.

Legal Settlement Loss. During the second quarter of 2017, we recorded a one-time charge of $117.0 million related to an agreement to resolve a litigation claim against us and certain of our officers.

Other Income. Other income increased during the three months ended September 30, 2018 compared to the same period in the prior year due to interest income earned on our available-for-sale securities.

Table of Contents

Comparison of Nine Months Ended September 30, 2018 and 2017:

The following table summarizes the results of our operations for the nine months ended September 30, 2018 and 2017 (in thousands):


					Change
	Nine months ended September 30,				Favorable/(Unfavorable)
	2018		2017		$		%
Revenues:
Product revenue	$	65,037	$	38,471	$	26,566		69	%
Operating expenses:
Cost of sales - product		13,262		6,920		(6,342)		(92)	%
Cost of sales - intangible asset amortization		1,851		1,115		(736)		(66)	%
Research and development		160,138		104,479		(55,659)		(53)	%
Selling, general and administrative		126,634		100,384		(26,250)		(26)	%
Total expenses		301,885		212,898		(88,987)		(42)	%
Operating loss		(236,848)		(174,427)		(62,421)		(36)	%
Other income (expense):
Interest expense		(9,592)		(7,796)		(1,796)		(23)	%
Foreign currency loss		(34)		(127)		93		73	%
Legal settlement loss		(7,975)		(117,000)		109,025		93	%
SEC settlement costs		(20,000)		—		(20,000)		(100)	%
Other income		5,419		2,237		3,182		142	%
Other expense, net		(32,182)		(122,686)		90,504		74	%
Loss before income taxes		(269,030)		(297,113)		28,083		9	%
Income tax benefit		280		2,599		(2,319)		(89)	%
Net loss	$	(268,750)	$	(294,514)	$	25,764		9	%

Product Revenue. Product revenue for the nine months ended September 30, 2018 increased compared to the same period in the prior year primarily due to continued growth in sales of Rubraca, which was approved for sale in the United States markets and we began shipping on December 19, 2016. Product revenue is recorded net of variable considerations comprised of rebates, chargebacks and other discounts. Variable considerations represented 10.6% and 8.2% of the transaction price recognized in the nine months ended September 30, 2018 and 2017, respectively. This increase primarily relates to an increase in older patients on Medicare as well as additional patients filling prescriptions at low-income clinics. Amounts are summarized as follows:


	Nine months ended				Nine months ended
	September 30, 2018				September 30, 2017
	$		% of Gross Sales		$		% of Gross Sales
	(in thousands)				(in thousands)

Gross product revenue	$	72,717		100.0%	$	41,923		100.0%
Sales deductions:
Government rebates and chargebacks		4,627		6.4%		1,820		4.3%
Discounts and fees		3,053		4.2%		1,632		3.9%
Total sales deductions		7,680		10.6%		3,452		8.2%
Product revenue, net	$	65,037		89.4%	$	38,471		91.8%

Cost of Sales – Product. Product cost of sales for the nine months ended September 30, 2018 increased compared to the same period in the prior year primarily due to the increase in product revenue. Product cost of sales primarily relate to manufacturing, freight and royalties costs associated with Rubraca sales in the period. Manufacturing costs associated with sales in the nine months ended September 30, 2017 were expensed as incurred based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, and therefore, a minimal amount is included as product cost of sales. These costs increased in the nine months ended September 30, 2018, as we depleted the these inventories as of the fourth quarter 2017.

Cost of Sales – Intangible Asset Amortization. In the nine months ended September 30, 2018 and 2017, we recognized cost of sales of $1.9 million and $1.1 million, respectively, associated with the amortization of capitalized

Table of Contents

milestone payments related to the approvals of Rubraca by the FDA in December 2016 and April 2018 and by the European Commission in May 2018.

Research and Development Expenses. Research and development expenses increased during the nine months ended September 30, 2018 compared to the same period in the prior year primarily due to higher research and development costs for rucaparib. Clinical trial costs for rucaparib were higher compared to the same period a year ago due to higher costs from increased enrollment in ARIEL4, our confirmatory ovarian cancer trials, and increased enrollment in our TRITON2 and TRITON3 studies for prostate cancer. We have increased costs related to our new ATLAS study for bladder cancer, our ATHENA combination study with Bristol-Myers Squibb Company’s immunotherapy OPDIVO for ovarian cancer and our RUCA-J study for ovarian cancer in Japan. In addition, personnel costs increased during the nine months ended September 30, 2018 due to higher headcount to support increased rucaparib clinical trial activities.

Clinical trial costs for rociletinib were $4.5 million lower than the nine months ended September 30, 2017 primarily due to patients discontinuing drug treatment and investigational sites closing for all of the TIGER studies in non-small cell lung cancer.

Selling, General and Administrative Expenses. Selling, general and administrative expenses increased during the nine months ended September 30, 2018 compared to the same period in the prior year primarily due to increased commercialization activities for Rubraca and the increase of costs associated with building out the European infrastructure in anticipation of commercialization there, which includes an increase of $2.3 million in facilities expense and $2.2 million in personnel costs. In addition, there was an increase of $3.8 million in legal expense and $3.7 million in stock compensation expense.

Interest Expense. Interest expense increased during the nine months ended September 30, 2018 compared to the same period in the prior year primarily due to the issuance of the 2025 Notes on April 19, 2018.

Legal Settlement Loss. During the first quarter of 2018, we recorded a one-time charge of $8.0 million related to an agreement to resolve a potential litigation claim against us and our officers. During the second quarter of 2017, we recorded a one-time charge of $117.0 million related to an agreement to resolve a litigation claim against us and certain of our officers.

SEC Settlement Costs. During the second quarter of 2018, we recorded a one-time charge of $20.0 million related to an agreement reached with the SEC to resolve its investigation. See Note 14, Commitments and Contingencies for further information regarding this investigation and other legal proceedings.

Other Income. Other income increased during the nine months ended September 30, 2018 compared to the same period in the prior year due to interest income earned on our available-for-sale securities.

Liquidity and Capital Resources

To date, we have funded our operations through the public offering of our common stock and the private placement of convertible debt securities and preferred stock. In April 2018, we sold 1,837,898 shares of our common stock in a public offering at $54.41 per share. The net proceeds from the offering were $93.9 million, after deducting underwriting discounts and commissions and offering expenses. Concurrently, we completed the public offering of $300.0 million aggregate principal amount of 1.25% convertible senior notes due 2025. The net proceeds from this offering were $290.9 million, after deducting underwriting discounts and commissions and offering expenses. At September 30, 2018, we had cash, cash equivalents and available-for-sale securities totaling $604.4 million.

Table of Contents

The following table sets forth the primary sources and uses of cash for the nine months ended September 30, 2018 and 2017 (in thousands):


	Nine months ended September 30,
	2018		2017

Net cash used in operating activities	$	(283,270)	$	(195,326)
Net cash (used in) provided by investing activities		(277,763)		29,469
Net cash provided by financing activities		387,974		560,257
Effect of exchange rate changes on cash and cash equivalents		(286)		886
Net (decrease) increase in cash and cash equivalents	$	(173,345)	$	395,286

Operating Activities

Net cash used in operating activities for all periods resulted primarily from our net losses adjusted for non-cash items and changes in components of working capital. Net cash used in operating activities was higher during the nine months ended September 30, 2018 compared to the same period in the prior year due to a higher net loss as adjusted for non-cash items and increases in the operating assets needed to support the commercialization of Rubraca, most notably related to inventory.

Investing Activities

Net cash used in investing activities for the nine months ended September 30, 2018 included purchases of available-for-sale securities of $320.0 million offset by cash from sales of available-for-sale securities of $105.0 million and milestone payments of $55.0 million. Net cash provided by investing activities in the same period in the prior year included purchases of available-for-sale securities of $180.0 million offset by cash from sales of available-for-sale securities of $213.5 million.

Financing Activities

Net cash provided by financing activities for the nine months ended September 30, 2018 and 2017 included $3.2 million and $14.4 million, respectively, received from employee stock option exercises. We completed the sale of $93.9 million and $545.8 million of common stock, net of issuance costs, respectively, during the nine months ended September 30, 2018 and September 30, 2017. In addition, we issued $290.9 million of convertible senior notes, net of issuance costs during the nine months ended September 30, 2018.

Operating Capital Requirements

We expect to incur significant losses for the foreseeable future, as we commercialize Rubraca and expand our selling, general and administrative functions to support the growth in our commercial organization. Additionally, our operating plan for the remainder of 2018 includes a significant investment in inventory to meet the projected commercial requirements for Rubraca. We receive the active pharmaceutical ingredient in Rubraca from one supplier and we experience long lead times associated with its production. Accordingly, we expect to experience a decrease in our liquidity at the beginning of a production cycle and an increase as the inventory produced is sold through.

As of September 30, 2018, we had cash, cash equivalents and available-for-sale securities totaling $604.4 million and total current liabilities of $76.5 million. In April 2018, we sold 1,837,898 shares of our common stock in a public offering at $54.41 per share. The net proceeds from the offering were $93.9 million, after deducting underwriting discounts and commissions and offering expenses. Concurrently, we completed the public offering of $300.0 million aggregate principal amount of 1.25% convertible senior notes due 2025. The net proceeds from this offering were $290.9 million, after deducting underwriting discounts and commissions and offering expenses. We intend to use the net proceeds of the offerings for general corporate purposes, including sales and marketing expenses associated with Rubraca in the United States and Europe, funding of our development programs, selling, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. Based on current estimates, we believe that our existing cash, cash equivalents and available-for-sale securities will allow us to fund our operating plan through at least the next 12 months.

Table of Contents

Our product supply costs will be approximately $23 million for the remainder of 2018. These costs reflect our plan to produce additional inventory in advance of the transition to a new manufacturing facility for Rubraca. We will also incur final capital costs for the new manufacturing facility of approximately $8 million during the fourth quarter of 2018.

Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amounts of our working capital requirements. Our future funding requirements will depend on many factors, including but not limited to:

the number and characteristics of the product candidates, companion diagnostics and indications we pursue;

the achievement of various development, regulatory and commercial milestones resulting in required payments to partners pursuant to the terms of our license agreements;

the scope, progress, results and costs of researching and developing our product candidates and related companion diagnostics and conducting clinical and non-clinical trials;

the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates and companion diagnostics;

the cost of commercialization activities, including marketing and distribution costs;

the cost of manufacturing any of our product candidates we successfully commercialize;

the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and outcome of such litigation; and

the timing, receipt and amount of sales, if any, of our product candidates.

Contractual Obligations and Commitments

For a discussion of our contractual obligations, see “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2017 Annual Report on Form 10-K. Other than the milestone payment to Pfizer triggered on April 6, 2018 upon the FDA’s approval of our sNDA for Rubraca as maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy, there have not been any material changes to such contractual obligations or potential milestone payments since December 31, 2017. For further information regarding our contractual obligations and commitments, see Note 14, Commitments and Contingencies to our unaudited consolidated financial statements included elsewhere in this report.

ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risk related to changes in interest rates. As of September 30, 2018, we had cash, cash equivalents and available-for-sale securities of $604.4 million, consisting of bank demand deposits, money market funds and U.S. treasury securities. The primary objectives of our investment policy are to preserve principal and maintain proper liquidity to meet operating needs. Our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of investment. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments are in short-term securities. Our available-for-sale securities are subject to interest rate risk and will decline in value if market interest rates increase. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair value of our portfolio.

We contract with contract research organizations, investigational sites and contract manufacturers globally where payments are made in currencies other than the U.S. dollar. In addition, on October 3, 2016, we entered into a Manufacturing and Services Agreement with a Swiss company for the production and supply of the active ingredient for Rubraca. Under the terms of this agreement, payments for the supply of the active ingredient in Rubraca as well as scheduled capital program fee payment toward capital equipment and other costs associated with the construction of a dedicated production train will be made in Swiss francs. Once the production facility is operational, we are obligated to pay a fixed facility fee each quarter for the duration of the agreement, which expires on December 31, 2025.

As of September 30, 2018, $165.1 million of purchase commitments exist under the Swiss Manufacturing and Services Agreement and we are required to remit amounts due in Swiss francs. Due to other variables that may exist, it is difficult to quantify the impact of a particular change in exchange rates. However, we estimate that if the value of the US dollar was to strengthen by 10% compared to the value of Swiss franc as of September 30, 2018, it would decrease the

Table of Contents

total US dollar purchase commitment under the Swiss Manufacturing and Services Agreement by $20.4 million. Similarly, a 10% weakening of the US dollar compared to the Swiss franc would increase the total US dollar purchase commitment by $11.8 million.

While we periodically hold foreign currencies, primarily Euro, Swiss Franc and Pound Sterling, we do not use other financial instruments to hedge our foreign exchange risk. Transactions denominated in currencies other than the functional currency are recorded based on exchange rates at the time such transactions arise. As of September 30, 2018 and December 31, 2017, approximately 3% and 1%, respectively, of our total liabilities were denominated in currencies other than the functional currency.

ITEM 4.CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended (“Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Principal Financial and Accounting Officer, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective. With the participation of our Chief Executive Officer and Principal Financial and Accounting Officer, management performed an evaluation as of September 30, 2018 of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on this evaluation, our Chief Executive Officer and Principal Financial and Accounting Officer concluded that, as of September 30, 2018, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended September 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

ITEM 1.LEGAL PROCEEDINGS

Rociletinib-Related Litigation

On November 10, 2016, Antipodean Domestic Partners (“Antipodean”) filed a complaint (the “Antipodean Complaint”) against Clovis and certain of its officers, directors and underwriters in New York Supreme Court, County of New York. The Antipodean Complaint alleges that the defendants violated certain sections of the Securities Act by making allegedly false statements to Antipodean and in the offering materials for the July 2015 Offering relating to the efficacy of rociletinib, its safety profile, and its prospects for market success. In addition to the Securities Act claims, the Antipodean Complaint also asserts Colorado state law claims and common law claims. Both the state law and common law claims are based on allegedly false and misleading statements regarding rociletinib’s progress toward FDA approval. The Antipodean Complaint seeks compensatory, recessionary, and punitive damages. On December 15, 2016, the Antipodean Plaintiffs filed an amended complaint (the “Antipodean Amended Complaint”) asserting substantially the same claims against the same defendants and purporting to correct certain details in the original Antipodean Complaint.

On May 2, 2018, the Court issued an order denying the defendants’ motion to dismiss. Defendants filed an answer to the Antipodean Amended Complaint on June 6, 2018.

The Company intends to vigorously defend against the allegations in the Antipodean Amended Complaint. However, there can be no assurance that the defense will be successful.

The Company intends to vigorously defend against the allegations in the Consolidated Derivative Complaint, but there can be no assurance that the defense will be successful.

Table of Contents

The Company intends to vigorously defend against the allegations in the Guo Complaint, but there can be no assurance that the defense will be successful.

European Patent Opposition

ITEM 1A.RISK FACTORS

Our business faces significant risks and uncertainties. Certain factors may have a material adverse effect on our business prospects, financial condition and results of operations, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to consider the risk factors described under the heading “Risk Factors” in

Table of Contents

Part I, Item 1A of our most recent Annual Report on Form 10-K as supplemented by our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, in addition to other information contained in or incorporated by reference into this Quarterly Report on Form 10-Q and our other public filings with the SEC. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our business, prospects, financial condition and results of operations.

There have no material changes to the risk factors included in our previously filed Annual Report on Form 10-K for the year ended December 31, 2017 as supplemented by our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018. Additional risks and uncertainties not presently known to us or that we currently believe are immaterial also may negatively impact our business.

ITEM 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3.DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5.OTHER INFORMATION

None.

ITEM 6.EXHIBITS

INDEX TO EXHIBITS

o
Exhibit
Number	Exhibit Description

3.1(5)	Amended and Restated Certificate of Incorporation of Clovis Oncology, Inc.

3.2(5)	Amended and Restated Bylaws of Clovis Oncology, Inc.

4.1(3)	Form of Common Stock Certificate of Clovis Oncology, Inc.

4.2(8)	Indenture dated as of September 9, 2014, by and between Clovis Oncology, Inc. and The Bank of New York Mellon Trust Company, N.A.

4.3(16)	Indenture dated as of April 19, 2018, by and between Clovis Oncology, Inc. and The Bank of New York Mellon Trust Company, N.A., as Trustee

4.4(16)	First Supplemental Indenture dated as of April 19, 2018, by and between Clovis Oncology, Inc. and The Bank of New York Mellon Trust Company, N.A.

10.1*(4)	Amended and Restated Strategic License Agreement, dated as of June 16, 2011, by and between Clovis Oncology, Inc. and Avila Therapeutics, Inc.

10.2*(4)	License Agreement, dated as of June 2, 2011, by and between Clovis Oncology, Inc. and Pfizer Inc.

10.3+(1)	Clovis Oncology, Inc. 2009 Equity Incentive Plan.

Table of Contents


10.4+(4)	Clovis Oncology, Inc. 2011 Stock Incentive Plan.

10.5+(1)	Form of Clovis Oncology, Inc. 2009 Equity Incentive Plan Stock Option Agreement.

10.6+(4)	Form of Clovis Oncology, Inc. 2011 Stock Incentive Plan Stock Option Agreement.

10.7+(3)	Employment Agreement, dated as of August 24, 2011, between Clovis Oncology, Inc. and Patrick J. Mahaffy.

10.8+(3)	Employment Agreement, dated as of August 24, 2011, between Clovis Oncology, Inc. and Gillian C. Ivers-Read.

10.9+(1)	Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Paul Klingenstein.

10.10+(1)	Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and James C. Blair.

10.11+(1)	Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Edward J. McKinley.

10.12+(1)	Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Thorlef Spickschen.

10.13+(1)	Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and M. James Barrett.

10.14+(1)	Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Brian G. Atwood.

10.15+(1)	Indemnification Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Patrick J. Mahaffy.

10.16+(1)	Indemnification Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Erle T. Mast.

10.17+(1)	Indemnification Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Gillian C. Ivers-Read.

10.18+(1)	Indemnification Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Andrew R. Allen.

10.19+(17)	Clovis Oncology, Inc. 2011 Employee Stock Purchase Plan, as amended.

10.20+(4)	Clovis Oncology, Inc. 2011 Cash Bonus Plan.

10.21+(6)	Indemnification Agreement, dated as of March 22, 2012, between Clovis Oncology, Inc. and Steven L. Hoerter.

10.22+(2)	Indemnification Agreement, dated as of June 13, 2013, between Clovis Oncology, Inc. and Ginger L. Graham.

Table of Contents


10.23+(2)	Indemnification Agreement, dated as of June 13, 2013, between Clovis Oncology, Inc. and Keith Flaherty.

10.24(7)	Stock Purchase Agreement, dated as of November 19, 2013, by and among the Company, EOS, the Sellers listed on Exhibit A thereto and Sofinnova Capital V FCPR, acting in its capacity as the Sellers’ Representative.

10.25*(7)	Development and Commercialization Agreement, dated as of October 24, 2008, by and between Advenchen Laboratories LLC and Ethical Oncology Science S.p.A., as amended by the First Amendment, dated as of April 13, 2010 and the Second Amendment, dated as of July 30, 2012.

10.26+(12)	Indemnification Agreement, effective as of August 3, 2015, by and between Clovis Oncology, Inc. and Lindsey Rolfe.

10.27+(12)	Employment Agreement, dated as of February 25, 2016, by and between Clovis Oncology, Inc. and Lindsey Rolfe.

10.28+(12)	Indemnification Agreement, effective as of February 1, 2016, by and between Clovis Oncology, Inc. and Dale Hooks.

10.29+(12)	Employment Agreement, effective as of February 1, 2016, by and between Clovis Oncology, Inc. and Dale Hooks.

10.30+(9)	Indemnification Agreement, dated as of February 17, 2016, by and between Clovis Oncology, Inc. and Daniel W. Muehl.

10.31+(15)	Employment Agreement, dated as of July 6, 2017, by and between Clovis Oncology, Inc. and Daniel W. Muehl.

10.32+(10)	Salary Waiver Letter, dated as of May 9, 2016, by and between Clovis Oncology, Inc. and Patrick J. Mahaffy.

10.33*(11)	First Amendment to License Agreement, by and between Clovis Oncology, Inc. and Pfizer Inc., dated as of August 30, 2016.

10.34+(13)	Form of Clovis Oncology, Inc. 2011 Stock Incentive Plan RSU Agreement.

10.35*(13)	Manufacturing Services Agreement, by and between Clovis Oncology, Inc. and Lonza Ltd, dated as of October 3, 2016.

10.36*(14)	Strata Trial Collaboration Agreement, by and between Clovis Oncology, Inc. and Strata Oncology, Inc., dated as of January 30, 2017

10.37+(18)	Indemnification Agreement, dated as of October 11, 2018, by and between Clovis Oncology, Inc. and Robert W. Azelby.

10.38+(18)	Indemnification Agreement, dated as of October 11, 2018, by and between Clovis Oncology, Inc. and Richard A. Fair.

21.1(17)	List of Subsidiaries of Clovis Oncology, Inc.

Table of Contents

31.1	Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.

31.2	Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.

32.1	Certification of principal executive officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2	Certification of principal financial officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101	The following materials from Clovis Oncology, Inc.’s Quarterly Report on Form 10-Q for the period ended September 30, 2018, formatted in XBRL (eXtensible Business Reporting Language): (i) the Consolidated Statements of Operations and Comprehensive Loss, (ii) the Consolidated Balance Sheets, (iii) the Consolidated Statements of Cash Flows and (iv) Notes to Unaudited Consolidated Financial Statements.

(1)

Filed as an exhibit with the Registrant’s Registration Statement on Form S-1 (File No. 333-175080) on June 23, 2011.

(2)

Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on June 14, 2013.

(3)

Filed as an exhibit with Amendment No. 2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-175080) on August 31, 2011.

(4)

Filed as an exhibit with Amendment No. 3 to the Registrant’s Registration Statement on Form S-1 (File No. 333-175080) on October 31, 2011.

(5)

Filed as an exhibit with the Registrant’s Annual Report on Form 10-K on March 15, 2012.

(6)

Filed as an exhibit with the Registrant’s Registration Statement on Form S-1 (File No. 333-180293) on March 23, 2012.

(7)

Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on November 19, 2013.

(8)

Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on September 9, 2014.

(9)

Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on April 1, 2016.

(10)

Filed as an exhibit with the Registrant’s Quarterly Report on Form 10-Q on May 9, 2016.

(11)

Filed as an exhibit with the Registrant’s Quarterly Report on Form 10-Q on November 4, 2016.

(12)

Filed as an exhibit with the Registrant’s Annual Report on Form 10-K on February 29, 2016.

(13)

Filed as an exhibit with the Registrant’s Annual Report on Form 10-K on February 23, 2017.

(14)

Filed as an exhibit with the Registrant’s Quarterly Report on Form 10-Q on May 4, 2017.

(15)

Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on July 7, 2017.

(16)

Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on April 19, 2018.

(17)

Filed as an exhibit with the Registrant’s Current Report on Form 10-Q on August 2, 2018.

(18)

Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on October 12, 2018.

+ Indicates management contract or compensatory plan.

* Confidential treatment has been granted with respect to portions of this exhibit, which portions have been omitted and filed separately with the Securities and Exchange Commission.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Date: October 31, 2018	CLOVIS ONCOLOGY, INC.

	By:	/s/ PATRICK J. MAHAFFY
		Patrick J. Mahaffy
		President and Chief Executive Officer; Director

	By:	/s/ DANIEL W. MUEHL
		Daniel W. Muehl
		Senior Vice President of Finance and Principal Financial and Accounting Officer

EX-31.1 2 clvs-20180930ex3112214d3.htm EX-31.1 clvs_Ex31_1

Exhibit 31.1

I, Patrick J. Mahaffy, certify that:

I have reviewed this quarterly report on Form 10-Q of Clovis Oncology, Inc. for the quarter ended September 30, 2018;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 31, 2018

/s/ PATRICK J. MAHAFFY
Patrick J. Mahaffy
President and Chief Executive Officer

EX-31.2 3 clvs-20180930ex31248b73d.htm EX-31.2 clvs_Ex31_2

Exhibit 31.2

I, Daniel W. Muehl, certify that:

I have reviewed this quarterly report on Form 10-Q of Clovis Oncology, Inc. for the quarter ended September 30, 2018;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 31, 2018

/s/ DANIEL W. MUEHL

Daniel W. Muehl

Senior Vice President of Finance and

Principal Financial and Accounting Officer

EX-32.1 4 clvs-20180930ex321689237.htm EX-32.1 clvs_Ex32_1

Exhibit 32.1

CERTIFICATIONS PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Clovis Oncology, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended September 30, 2018, as filed with the Securities and Exchange Commission (the “Report”), Patrick J. Mahaffy, as Chief Executive Officer of the Company, does hereby certify, pursuant to §906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. §1350), that to his knowledge:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: October 31, 2018

/s/ PATRICK J. MAHAFFY
Patrick J. Mahaffy
President and Chief Executive Officer

EX-32.2 5 clvs-20180930ex3224ad3ad.htm EX-32.2 clvs_Ex32_2

Exhibit 32.2

CERTIFICATIONS PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Clovis Oncology, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended September 30, 2018, as filed with the Securities and Exchange Commission (the “Report”), Daniel W. Muehl, as Senior Vice President of Finance and Principal Financial and Accounting Officer of the Company, does hereby certify, pursuant to §906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. §1350), that to his knowledge:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: October 31, 2018

/s/ DANIEL W. MUEHL

Daniel W. Muehl

Senior Vice President of Finance and

Principal Financial and Accounting Officer

EX-101.INS 6 clvs-20180930.xml EX-101.INS 0001466301 us-gaap:ConvertibleDebtMember 2018-09-30 0001466301 us-gaap:ConvertibleDebtMember 2017-12-31 0001466301 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0001466301 us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 2018-09-30 0001466301 2018-04-01 2018-04-30 0001466301 2018-09-18 0001466301 clvs:EthicalOncologyScienceSpAMember 2018-01-01 2018-09-30 0001466301 clvs:EthicalOncologyScienceSpAMember 2018-09-30 0001466301 clvs:EthicalOncologyScienceSpAMember 2017-12-31 0001466301 us-gaap:LicensingAgreementsMember 2018-09-30 0001466301 us-gaap:LicensingAgreementsMember 2017-12-31 0001466301 us-gaap:EmployeeStockOptionMember 2018-09-30 0001466301 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-09-30 0001466301 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001466301 us-gaap:FairValueInputsLevel2Member clvs:ConvertibleSeniorUnsecuredNotes2021NotesMember 2018-09-30 0001466301 2018-04-30 0001466301 us-gaap:ConvertibleDebtMember 2018-04-19 0001466301 us-gaap:ConvertibleDebtMember 2014-09-09 0001466301 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-07-01 2018-09-30 0001466301 us-gaap:AccountingStandardsUpdate201409Member us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-07-01 2018-09-30 0001466301 us-gaap:ProductMember 2018-07-01 2018-09-30 0001466301 us-gaap:IntangibleAssetsAmortizationPeriodMember 2018-07-01 2018-09-30 0001466301 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-09-30 0001466301 us-gaap:AccountingStandardsUpdate201409Member us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-09-30 0001466301 us-gaap:ProductMember 2018-01-01 2018-09-30 0001466301 us-gaap:IntangibleAssetsAmortizationPeriodMember 2018-01-01 2018-09-30 0001466301 us-gaap:ProductMember 2017-07-01 2017-09-30 0001466301 us-gaap:IntangibleAssetsAmortizationPeriodMember 2017-07-01 2017-09-30 0001466301 us-gaap:ProductMember 2017-01-01 2017-09-30 0001466301 us-gaap:IntangibleAssetsAmortizationPeriodMember 2017-01-01 2017-09-30 0001466301 clvs:ConvertibleSeniorUnsecuredNotes2025NotesMember 2018-09-30 0001466301 clvs:ConvertibleSeniorUnsecuredNotes2021NotesMember 2018-09-30 0001466301 us-gaap:USTreasurySecuritiesMember 2018-09-30 0001466301 us-gaap:USTreasurySecuritiesMember 2017-12-31 0001466301 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001466301 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001466301 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001466301 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001466301 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001466301 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001466301 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001466301 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001466301 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001466301 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001466301 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001466301 us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001466301 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001466301 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001466301 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001466301 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001466301 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001466301 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001466301 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001466301 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001466301 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001466301 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001466301 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001466301 us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001466301 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001466301 us-gaap:ConvertibleDebtSecuritiesMember 2018-01-01 2018-09-30 0001466301 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0001466301 us-gaap:ConvertibleDebtSecuritiesMember 2017-01-01 2017-09-30 0001466301 us-gaap:LicensingAgreementsMember 2018-07-01 2018-09-30 0001466301 us-gaap:LicensingAgreementsMember 2018-01-01 2018-09-30 0001466301 us-gaap:LicensingAgreementsMember 2017-07-01 2017-09-30 0001466301 us-gaap:LicensingAgreementsMember 2017-01-01 2017-09-30 0001466301 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-07-01 2018-09-30 0001466301 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-09-30 0001466301 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-09-30 0001466301 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0001466301 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-07-01 2017-09-30 0001466301 us-gaap:ResearchAndDevelopmentExpenseMember 2017-07-01 2017-09-30 0001466301 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-09-30 0001466301 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-09-30 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2018-09-30 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-09-30 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2018-06-30 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-06-30 0001466301 2018-06-30 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2017-09-30 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-09-30 0001466301 2017-09-30 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2017-06-30 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-06-30 0001466301 2017-06-30 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2016-12-31 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-12-31 0001466301 2016-12-31 0001466301 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-09-30 0001466301 us-gaap:AccountingStandardsUpdate201409Member us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-09-30 0001466301 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 0001466301 2018-01-01 0001466301 2018-10-26 0001466301 2018-06-29 0001466301 us-gaap:RestrictedStockUnitsRSUMember 2018-09-30 0001466301 clvs:LicenseAgreementsLicensorPfizerMember clvs:LicenseAgreementsRucaparibMember 2018-06-01 2018-06-30 0001466301 clvs:LicenseAgreementsRucaparibMember 2018-06-01 2018-06-30 0001466301 clvs:LicenseAgreementsRucaparibMember clvs:FirstApprovalOfNewDrugApplicationMember 2018-04-01 2018-04-30 0001466301 clvs:LicenseAgreementsLicensorPfizerMember clvs:LicenseAgreementsRucaparibMember 2017-01-01 2017-03-31 0001466301 clvs:AdvenchenLaboratoriesLLCMember clvs:LicenseAgreementsLucitanibMember us-gaap:LicenseAgreementTermsMember 2008-10-01 2008-10-31 0001466301 2017-03-01 2017-03-31 0001466301 2017-06-20 2017-06-20 0001466301 srt:MinimumMember 2018-01-01 2018-09-30 0001466301 2016-12-19 2016-12-19 0001466301 clvs:LicenseAgreementsLicensorPfizerMember clvs:LicenseAgreementsRucaparibMember us-gaap:LicenseAgreementTermsMember 2011-06-01 2011-06-30 0001466301 clvs:LicenseAgreementsLicensorPfizerMember clvs:LicenseAgreementsRucaparibMember srt:MinimumMember 2018-01-01 2018-09-30 0001466301 clvs:LicenseAgreementsLicensorPfizerMember clvs:LicenseAgreementsRucaparibMember srt:MaximumMember 2018-01-01 2018-09-30 0001466301 clvs:SemiAnnualPaymentSecondPaymentMember us-gaap:ConvertibleDebtMember 2018-04-19 2018-04-19 0001466301 clvs:SemiAnnualPaymentFirstPaymentMember us-gaap:ConvertibleDebtMember 2018-04-19 2018-04-19 0001466301 clvs:SemiAnnualPaymentSecondPaymentMember us-gaap:ConvertibleDebtMember 2014-09-09 2014-09-09 0001466301 clvs:SemiAnnualPaymentFirstPaymentMember us-gaap:ConvertibleDebtMember 2014-09-09 2014-09-09 0001466301 us-gaap:ConvertibleDebtMember 2018-04-19 2018-04-19 0001466301 us-gaap:ConvertibleDebtMember 2014-09-09 2014-09-09 0001466301 clvs:LicenseAgreementsLicensorPfizerMember clvs:LicenseAgreementsRucaparibMember srt:MaximumMember 2018-09-30 0001466301 clvs:LicenseAgreementsLicensorPfizerMember clvs:LicenseAgreementsRucaparibMember 2016-12-19 2016-12-19 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2018-07-01 2018-09-30 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-07-01 2018-09-30 0001466301 2018-07-01 2018-09-30 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-09-30 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-09-30 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2017-07-01 2017-09-30 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-07-01 2017-09-30 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2017-01-01 2017-09-30 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 2017-09-30 0001466301 2018-09-30 0001466301 2017-12-31 0001466301 2018-01-01 2018-09-30 0001466301 2017-07-01 2017-09-30 0001466301 2017-01-01 2017-09-30 clvs:segment iso4217:USD xbrli:shares xbrli:shares clvs:Vote clvs:shareholder clvs:product xbrli:pure clvs:D clvs:item iso4217:USD 1449000 500000 978000 415000 731000 18465000 21259000 1008000 2407000 -39877000 -138000 -39739000 -41781000 -136000 -41645000 -44550000 -185000 -44365000 -44550000 -185000 -44365000 1100000 55000000 20000000 170000000 0 0 44600000 0 31119000 2 2 --03-15 --09-15 --05-01 --11-01 1.00 1.00 23000000 20461000 13514000 31750000 250000000 31818000 24173000 16284000 -1390000 7000000 <div> <div> 12. License Agreements   Rucaparib   In June 2011, we entered into a worldwide license agreement with Pfizer, Inc. to obtain exclusive global rights to develop and commercialize rucaparib, a small molecule inhibitor of poly (ADP-ribose) polymerase (“PARP”), used for the treatment of selected solid tumors. The exclusive rights are exclusive even as to Pfizer and include the right to grant sublicenses. Pursuant to the terms of the license agreement, we made a $7.0 million upfront payment to Pfizer and are required to make additional payments to Pfizer for the achievement of certain development and regulatory and sales milestones and royalties on sales as required by the license agreement. Prior to the FDA approval of rucaparib, discussed below, we made milestone payments of $1.4 million, which were recognized as acquired in-process research and development expense.   On August 30, 2016, we entered into a first amendment to the worldwide license agreement with Pfizer, which amends the June 2011 existing worldwide license agreement to permit us to defer payment of the milestone payments payable upon (i) FDA approval of an NDA for 1st Indication in US and (ii) EMA approval of an MAA for 1st Indication in EU, to a date that is 18 months after the date of achievement of such milestones.   On December 19, 2016, the FDA approved Rubraca (rucaparib) tablets as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. The FDA approval resulted in a $0.75 million milestone payment to Pfizer as required by the license agreement, which was made in the first quarter of 2017. The FDA approval also resulted in the obligation to pay a $20.0 million milestone payment, for which we exercised the option to defer payment by agreeing to pay $23.0 million within 18 months after the date of the FDA approval. We paid the $23.0 million milestone payment in June 2018.   On April 6, 2018, the FDA approved our sNDA for Rubraca as maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. This approval resulted in the obligation to pay a $15.0 million milestone payment, which we paid in April 2018.   In May 2018, the European Commission granted a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. This approval resulted in the obligation to pay a $20.0 million milestone payment, which we paid in June 2018. These milestone payments were recognized as intangible assets and will be amortized over the estimated remaining useful life of Rubraca.   We are obligated under the license agreement to use commercially reasonable efforts to develop and commercialize rucaparib and we are responsible for all remaining development and commercialization costs for rucaparib. We are required to make regulatory milestone payments to Pfizer of up to an additional $31.75 million in aggregate if specified clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, we are obligated to make sales milestone payments to Pfizer if specified annual sales targets for rucaparib are met, which relate to annual sales targets of $250.0 million and above, which, in the aggregate, could amount to total milestone payments of $170.0 million, and tiered royalty payments at a mid-teen percentage rate on our net sales, with standard provisions for royalty offsets to the extent we need to obtain any rights from third parties to commercialize rucaparib.   In April 2012, we entered into a license agreement with AstraZeneca UK Limited to acquire exclusive rights associated with rucaparib under a family of patents and patent applications that claim methods of treating patients with PARP inhibitors in certain indications. The license enables the development and commercialization of rucaparib for the uses claimed by these patents. AstraZeneca receives royalties on any net sales of rucaparib.   Lucitanib   In connection with our acquisition of EOS in November 2013, we gained rights to develop and commercialize lucitanib, an oral, selective tyrosine kinase inhibitor. As further described below, EOS licensed the worldwide rights, excluding China, to develop and commercialize lucitanib from Advenchen Laboratories LLC (“Advenchen”). Subsequently, rights to develop and commercialize lucitanib in markets outside the U.S. and Japan were sublicensed by EOS to Servier in exchange for upfront milestone fees, royalties on sales of lucitanib in the sublicensed territories and research and development funding commitments.     In October 2008, EOS entered into an exclusive license agreement with Advenchen to develop and commercialize lucitanib on a global basis, excluding China. We are obligated to pay Advenchen tiered royalties at percentage rates in the mid-single digits on net sales of lucitanib, based on the volume of annual net sales achieved. In addition, after giving effect to the first and second amendments to the license agreement, we are required to pay to Advenchen 25% of any consideration, excluding royalties, received pursuant to any sublicense agreements for lucitanib, including the agreement with Servier. We are obligated under the agreement to use commercially reasonable efforts to develop and commercialize at least one product candidate containing lucitanib, and we are also responsible for all remaining development and commercialization costs for lucitanib.     The license agreement with Advenchen will remain in effect until the expiration of all our royalty obligations to Advenchen, determined on a product-by-product and country-by-country basis, unless we elect to terminate the agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, Advenchen can terminate the agreement, resulting in a loss of our rights to lucitanib.   During 2017, we completed the committed on-going development activities related to lucitanib and received full reimbursement of our development costs from Servier. Reimbursements are recorded as a reduction to research and development expense on the Consolidated Statements of Operations. Lucitanib was originally developed by Clovis and Servier with the hypothesis of activity in FGFR driven tumors; however, data in breast and lung cancer were insufficient to move the program forward. We received notice from Servier of termination of their rights to lucitanib, resulting in the return of global rights (excluding China) for lucitanib to us during October 2018.   We are party to a product license agreement for our other drug candidate rociletinib (see our 2017 Form 10-K for additional details).   <div /></div> </div> <div> <div> Liquidity   We have incurred significant net losses since inception and have relied on our ability to fund our operations through debt and equity financings. We expect operating losses and negative cash flows to continue for the foreseeable future. As we continue to incur losses, transition to profitability is dependent upon achieving a level of revenues from Rubraca adequate to support our cost structure. We may never achieve profitability, and unless or until we do, we will continue to need to raise additional cash.   In April 2018, we sold 1,837,898 shares of our common stock in a public offering at $54.41 per share. The net proceeds from the offering were $93.9 million, after deducting underwriting discounts and commissions and offering expenses. Concurrently, we completed the public offering of $300.0 million aggregate principal amount of 1.25% convertible senior notes due 2025. The net proceeds from this offering were $290.9 million, after deducting underwriting discounts and commissions and offering expenses. We intend to use the net proceeds of the offerings for general corporate purposes, including sales and marketing expenses associated with Rubraca in the United States and Europe, funding of our development programs, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. Based on current estimates, we believe that our existing cash, cash equivalents and available-for-sale securities will allow us to fund our operating plan through at least the next 12 months. <div /></div> </div> 117000000 1400000 2 P12M 2 P18M P12M 2 2 2 2 1 2515000 0 P30D 0.25 <div> <div> Recently Adopted Accounting Standards   In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, “Revenue from Contracts with Customers”, and has subsequently issued several supplemental and/or clarifying ASUs (collectively, “ASC 606”). ASC 606 prescribes a single common revenue standard that replaces most existing U.S. GAAP revenue recognition guidance. ASC 606 is intended to provide a more consistent interpretation and application of the principles outlined in the standard across filers in multiple industries and within the same industries compared to current practices, which should improve comparability. We adopted the new standard using the modified retrospective method on January 1, 2018 for contracts that are not completed as of the adoption date.   Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 also impacts certain other areas, such as the accounting for costs to obtain or fulfill a contract. The standard also requires disclosure of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.     We examined our revenue recognition policy specific to revenue streams from contracts governing product sales from Rubraca and have come to conclusions on the impact of the new standard using the 5-step process prescribed by ASC 606. We reviewed all of our contracts, including our collaboration agreements with Servier and Bristol-Myers Squibb, and determined the potential impact to our accounting policies, financial controls and operations. Our conclusions include recognizing revenue on product sales once the product is sold to the specialty distributor and specialty pharmacy providers.   As noted above, we used the modified retrospective method to adopt the new standard. This means that we did not restate previously issued financial statements, but we recorded a one-time adjustment to retained earnings of $2.4 million. This adjustment represents the sales of our product to our customers prior to January 1, 2018, that had not been sold to patients or healthcare providers, offset by related gross-to-net adjustments and other direct costs, including royalties and sales incentive compensation.   The cumulative effect of the changes made to our consolidated January 1, 2018 balance sheet for the adoption of ASC 606 was as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 90.00%;"> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balance at </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Adjustments due to </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balance at </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, 2017 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Adoption of ASC 606 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> January 1, 2018 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> ASSETS </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accounts receivable, net </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6,181 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,336 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 9,517 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Inventories </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 27,508 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (62) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 27,446 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">     Total assets </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 735,230 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,274 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 738,504 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> LIABILITIES AND STOCKHOLDERS' EQUITY </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Other accrued expenses </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 25,883 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 918 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 26,801 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accumulated deficit </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,477,440) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,356 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,475,084) </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">     Total liabilities and stockholders' equity </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 735,230 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,274 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 738,504 </td> </tr> </table></div>   Previously, we recognized revenue on product sales once the product was sold to the patient or healthcare provider by the specialty distributor or specialty pharmacy provider, i.e. when product is sold through the channel. Effective January 1, 2018, we began recognizing revenue when our customers, the specialty distributors and specialty pharmacy providers, take control of our product or when product is sold into the channel. This will have the impact of us recognizing revenue approximately two to four weeks earlier than before adopting the new standard and will also increase the significance of estimating variable consideration. The following financial statement line items for the three and nine months ended September 30, 2018 were affected as a result of the adoption.   CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except for per share amounts)   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="middle" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="8" valign="bottom" style="width:39.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months ended September 30, 2018 </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balances without </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Effect of Change </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As reported </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Adoption of ASC 606 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Higher/(Lower) </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Product revenue </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 22,757 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 25,213 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (2,456) </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Cost of sales - product </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,766 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5,158 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 392 </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Selling, general and administrative </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 42,495 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 42,689 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 194 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Net loss </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (89,864) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (87,994) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,870) </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Loss per basic and diluted common share: </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Basic and diluted net loss per common share </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (1.71) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (1.67) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (0.04) </td> </tr> </table></div>     <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="middle" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="8" valign="bottom" style="width:39.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine months ended September 30, 2018 </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balances without </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Effect of Change </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As reported </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Adoption of ASC 606 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Higher/(Lower) </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Product revenue </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 65,037 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 63,541 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,496 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Cost of sales - product </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 13,262 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 12,697 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (565) </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Selling, general and administrative </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 126,634 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 126,602 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (32) </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Net loss </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (268,750) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (269,648) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 898 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Loss per basic and diluted common share: </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Basic and diluted net loss per common share </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (5.18) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (5.20) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.02 </td> </tr> </table></div>     CONSOLIDATED BALANCE SHEET (In thousands) <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="middle" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="8" valign="bottom" style="width:39.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, 2018 </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balances without </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Effect of Change </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As reported </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Adoption of ASC 606 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Higher/(Lower) </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> ASSETS </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accounts receivable, net </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 14,495 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 12,907 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,588 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Inventories </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 63,687 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 63,992 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (305) </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> LIABILITIES AND STOCKHOLDERS' EQUITY </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Other accrued expenses </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 24,732 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 24,347 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 385 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accumulated deficit </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (1,743,834) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (1,744,732) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 898 </td> </tr> </table></div>     ASC 606 did not have an aggregate impact on our net cash provided by operating activities but resulted in offsetting changes in certain assets and liabilities presented within net cash used in operating activities in our consolidated statement of cash flows, as reflected in the above tables.   <div /></div> </div> <div> <div> Reimbursements are recorded as a reduction to research and development expense on the Consolidated Statements of Operations. Lucitanib was originally developed by Clovis and Servier with the hypothesis of activity in FGFR driven tumors; however, data in breast and lung cancer were insufficient to move the program forward. We received notice from Servier of termination of their rights to lucitanib, resulting in the return of global rights (excluding China) for lucitanib to us during October 2018. <div /></div> </div> 750000 15000000 20000000 23000000 706795 49.25 9449000 10130000 29.37 2661000 14000 false --12-31 Q3 2018 2018-09-30 10-Q 0001466301 52711827 Yes false Large Accelerated Filer Clovis Oncology, Inc. false CLVS

<div> <div> 8. Other Accrued Expenses   Other accrued expenses were comprised of the following (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued personnel costs </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14,217 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 13,889 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued interest payable </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,096 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Income tax payable </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 186 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued corporate legal fees and professional services </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 731 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 415 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued royalties </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,187 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,984 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued variable considerations </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,407 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,008 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Payable to third party logistics provider </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,661 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued expenses - other </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,990 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,830 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 24,732 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 25,883 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

15147000

30501000

6181000

9517000

3336000

14495000

12907000

1588000

-6000

-1079000

25883000

26801000

918000

24732000

24347000

385000

2984000

4187000

-47580000

-146000

-47434000

-44306000

-151000

-44155000

-42701000

-141000

-42560000

-42173000

-256000

-41917000

-44045000

-175000

-43870000

-44550000

-185000

-44365000

1887198000

2021997000

32201000

14628000

17573000

12637000

5636000

7001000

37715000

15380000

22335000

10947000

5038000

5909000

956000

321000

1536000

641000

1200000

400000

1900000

800000

10342000

4646000

5696000

11965000

8584000

3381000

735230000

738504000

3274000

891464000

626940000

690756000

532669000

433136000

99533000

433136000

99533000

433136000

99533000

568668000

255143000

313525000

255143000

313525000

255143000

313525000

117000

45000

99650000

313570000

313525000

99533000

313525000

99533000

313525000

<div> <div> 1. Nature of Business and Basis of Presentation   Clovis Oncology, Inc. (together with its consolidated subsidiaries, the “Company”, “Clovis”, “we”, “our”, “us”) is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. We target our development programs for the treatment of specific subsets of cancer populations, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. We have and intend to continue to license or acquire rights to oncology compounds in all stages of clinical development. In exchange for the right to develop and commercialize these compounds, we generally expect to provide the licensor with a combination of upfront payments, milestone payments and royalties on future sales. In addition, we generally expect to assume the responsibility for future drug development and commercialization costs. We currently operate in one segment. Since inception, our operations have consisted primarily of developing in-licensed compounds, evaluating new product acquisition candidates and general corporate activities and since 2016 we have also marketed and sold products.   Our marketed product Rubraca® (rucaparib) is approved in the United States by the Food and Drug Administration (“FDA”) for two indications, encompassing two settings for the treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The initial treatment indication received in December 2016 covers the treatment of adult patients with deleterious BRCA (human genes associated with the repair of damaged DNA) mutation (germline and/or somatic) epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. In April 2018, the FDA also approved Rubraca for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. The FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Diagnostic testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.   In May 2018, the European Commission granted a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. As this is a conditional approval, it will be necessary to complete confirmatory post marketing commitments, including ensuring that sufficient partially platinum sensitive patients are enrolled in our ARIEL4 confirmatory trial to support the indication. This may require enrollment of additional patients into the study, increasing its overall size and extending the time for enrollment. In June 2018, we submitted to the European Union’s European Medicines Agency (“EMA”) a variation to the marketing authorization for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy, for which we received EMA validation for this application in July 2018. We anticipate an opinion on this application from the Committee for Medicinal Products for Human Use (“CHMP”) of the EMA by the end of 2018, with a potential formal European Commission approval in early 2019.    Beyond our initial labeled indication, we have a robust Rubraca clinical development program underway in a variety of solid tumor types, also including prostate and bladder cancers, and in July 2017, we entered into a broad clinical collaboration with Bristol-Myers Squibb Company to evaluate the combination of their immunotherapy OPDIVO® (nivolumab) with Rubraca in several tumor types. We hold worldwide rights for Rubraca.   In October 2018, the FDA granted breakthrough therapy designation for Rubraca as a monotherapy treatment of adult patients with BRCA1/2-mutated metastatic castration resistant prostate cancer (mCRPC) who have received at least one prior androgen receptor (AR)-directed therapy and taxane-based chemotherapy.   In addition to Rubraca, we have two other product candidates.   Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFR α/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3). Lucitanib was originally developed by Clovis and Servier with the hypothesis of activity in FGFR driven tumors; however, data in breast and lung cancer were insufficient to move that program forward. We received notice from Servier of termination of their rights to lucitanib, resulting in the return of global rights (excluding China) for lucitanib to us during October 2018. We believe that recent data for a drug similar to lucitanib that inhibits these same pathways – when combined with a PD-1 inhibitor – provide support for development of lucitanib in combination with a PD-(L)1 inhibitor, and we intend to initiate a study of the combination. We also intend to initiate a study of lucitanib in combination with Rubraca, based on encouraging data of VEGF and PARP inhibitors in combination. Each of these studies is expected to initiate in the first quarter of 2019. We maintain certain development and commercialization rights for lucitanib. Because of termination of the Servier license agreement, we have global development and commercialization rights (except for China) for lucitanib.   Rociletinib is an oral mutant-selective inhibitor of epidermal growth factor receptor (“EGFR”). While we have stopped enrollment in ongoing trials for rociletinib, we continue to provide drug to patients whose clinicians recommend continuing therapy. We have global development and commercialization rights for rociletinib.   Basis of Presentation   All financial information presented includes the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.   The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments that, in the opinion of management, are necessary to fairly state our financial position, results of operations and cash flows for the periods presented herein. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, 2017 (“2017 Form 10-K”) for a broader discussion of our business and the opportunities and risks inherent in such business.   Use of Estimates   The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and revenue and related disclosures. On an ongoing basis, we evaluate our estimates, including estimates related to revenue deductions, intangible asset impairment, clinical trial accruals and share-based compensation expense. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.   Liquidity   We have incurred significant net losses since inception and have relied on our ability to fund our operations through debt and equity financings. We expect operating losses and negative cash flows to continue for the foreseeable future. As we continue to incur losses, transition to profitability is dependent upon achieving a level of revenues from Rubraca adequate to support our cost structure. We may never achieve profitability, and unless or until we do, we will continue to need to raise additional cash.   In April 2018, we sold 1,837,898 shares of our common stock in a public offering at $54.41 per share. The net proceeds from the offering were $93.9 million, after deducting underwriting discounts and commissions and offering expenses. Concurrently, we completed the public offering of $300.0 million aggregate principal amount of 1.25% convertible senior notes due 2025. The net proceeds from this offering were $290.9 million, after deducting underwriting discounts and commissions and offering expenses. We intend to use the net proceeds of the offerings for general corporate purposes, including sales and marketing expenses associated with Rubraca in the United States and Europe, funding of our development programs, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. Based on current estimates, we believe that our existing cash, cash equivalents and available-for-sale securities will allow us to fund our operating plan through at least the next 12 months. <div /></div> </div>

464198000

290853000

216186000

611472000

464198000

290853000

395286000

-173345000

<div> <div> 14. Commitments and Contingencies   Royalty and License Fee Commitments   We have entered into certain license agreements, as identified in Note 12, License Agreements, with third parties that include the payment of development and regulatory milestones, as well as royalty payments, upon the achievement of pre-established development, regulatory and commercial targets. Our payment obligation related to these license agreements is contingent upon the successful development, regulatory approval and commercialization of the licensed products. Due to the nature of these arrangements, the future potential payments are inherently uncertain, and accordingly, we only recognize payment obligations which are probable and estimable as of the balance sheet date. Milestone liabilities of $0.0 million and $22.0 million are recorded on our Consolidated Balance Sheets at September 30, 2018 and December 31, 2017, respectively, and relate to milestone payments for the licensing of our rucaparib product, which was approved by the FDA on December 19, 2016.   Manufacture and Services Agreement Commitments   On October 3, 2016, we entered into a Manufacturing and Services Agreement (the “Agreement”) with a non-exclusive third-party supplier for the production of the active ingredient for Rubraca. Under the terms of the Agreement, we will provide the third-party supplier a rolling forecast for the supply of the active ingredient in Rubraca that will be updated by us on a quarterly basis. We are obligated to order material sufficient to satisfy an initial quantity specified in any forecast. In addition, the third-party supplier will construct, in its existing facility, a production train that will be exclusively dedicated to the manufacture of the Rubraca active ingredient. We are obligated to make scheduled capital program fee payments toward capital equipment and other costs associated with the construction of the dedicated production train. Further, once the facility is operational, we are obligated to pay a fixed facility fee each quarter for the duration of the Agreement, which expires on December 31, 2025, unless extended by mutual consent of the parties. As of September 30, 2018, $165.1 million of purchase commitments exist under the Agreement.    Legal Proceedings   We and certain of our officers were named as defendants in several lawsuits, as described below. We cannot reasonably predict the outcome of these legal proceedings, nor can we estimate the amount of loss or range of loss, if any, that may result. An adverse outcome in these proceedings could have a material adverse effect on our results of operations, cash flows or financial condition.   Rociletinib-Related Litigation   Following Clovis’ regulatory announcement in November 2015 of adverse developments in its ongoing clinical trials for rociletinib, Clovis and certain of its current and former executives were named in various securities lawsuits, the largest of which was a putative class action lawsuit in the District of Colorado (the “Medina Action”) which was settled on October 26, 2017 (the “Medina Settlement”).  The open actions currently pending against Clovis are discussed below.   On November 10, 2016, Antipodean Domestic Partners (“Antipodean”) filed a complaint (the “Antipodean Complaint”) against Clovis and certain of its officers, directors and underwriters in New York Supreme Court, County of New York. The Antipodean Complaint alleges that the defendants violated certain sections of the Securities Act by making allegedly false statements to Antipodean and in the offering materials for the July 2015 Offering relating to the efficacy of rociletinib, its safety profile, and its prospects for market success. In addition to the Securities Act claims, the Antipodean Complaint also asserts Colorado state law claims and common law claims. Both the state law and common law claims are based on allegedly false and misleading statements regarding rociletinib’s progress toward FDA approval. The Antipodean Complaint seeks compensatory, recessionary, and punitive damages. On December 15, 2016, the Antipodean Plaintiffs filed an amended complaint (the “Antipodean Amended Complaint”) asserting substantially the same claims against the same defendants and purporting to correct certain details in the original Antipodean Complaint.   Following a stay that Justice Masley of the New York Supreme Court, County of New York entered in favor of the Medina Action and briefing on defendants’ motions to dismiss, the parties participated in a Preliminary Conference on April 17, 2018, following which the Court entered a preliminary conference order, providing deadlines for document productions, depositions, and other discovery. The Court has scheduled a status conference for January 21, 2019, following which the Court anticipates setting an end date for discovery.     On May 2, 2018, the Court issued an order denying the defendants’ motion to dismiss. Defendants filed an answer to the Antipodean Amended Complaint on June 6, 2018.     The Company intends to vigorously defend against the allegations in the Antipodean Amended Complaint.  However, there can be no assurance that the defense will be successful.   In March 2017, two putative shareholders of the Company, Macalinao and McKenry (the “Derivative Plaintiffs”), filed shareholder derivative complaints against certain directors and officers of the Company in the Court of Chancery of the State of Delaware. On May 4, 2017, the Macalinao and McKenry actions were consolidated for all purposes in a single proceeding under the caption In re Clovis Oncology, Inc. Derivative Litigation, Case No, 2017-0222 (the “Consolidated Derivative Action”).     On May 18, 2017, the Derivative Plaintiffs filed a Consolidated Verified Shareholder Derivative Complaint (the “Consolidated Derivative Complaint”). The Consolidated Derivative Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by allegedly causing or allowing misrepresentations of the Company’s business operations and prospects, failing to ensure that the TIGER-X clinical trial was being conducted in accordance with applicable rules, regulations and protocols, and engaging in insider trading. The Consolidated Derivative Complaint purported to rely on documents produced by the Company in response to prior demands for inspection of the Company’s books and records served on the Company by each of Macalinao and McKenry under 8 Del. C. § 220. The Consolidated Derivative Complaint sought, among other things, an award of money damages.     On July 31, 2017, the defendants filed a motion to dismiss the Consolidated Derivative Complaint. Plaintiffs filed an opposition to the motion to dismiss on August 31, 2017, and the defendants filed a reply in further support of the motion to dismiss on September 26, 2017. Oral argument on the defendants’ motion to dismiss the Consolidated Derivative Complaint has been scheduled for February 4, 2019.   The Company intends to vigorously defend against the allegations in the Consolidated Derivative Complaint, but there can be no assurance that the defense will be successful.       On March 20, 2017, a purported shareholder of the Company, filed a shareholder derivative complaint (the “Guo Complaint”) against certain officers and directors of the Company in the United States District Court for the District of Colorado. The Guo Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by either recklessly or with gross negligence approving or permitting misrepresentations of the Company’s business operations and prospects. The Guo Complaint also alleged claims for waste of corporate assets and unjust enrichment. Finally, the Guo Complaint alleged that certain of the individual defendants violated Section 14(a) of the Securities Exchange Act, by allegedly negligently issuing, causing to be issued, and participating in the issuance of materially misleading statements to stockholders in the Company’s Proxy Statement on Schedule DEF 14A in connection with the 2015 Annual Meeting of Stockholders, held on June 11, 2015. The Guo Complaint sought, among other things, an award of money damages.     On June 19, 2017, the parties filed a joint motion to stay the Guo action pending resolution of the motion to dismiss the Consolidated Derivative Complaint. On June 20, 2017, the court granted the motion to stay.    The Company intends to vigorously defend against the allegations in the Guo Complaint, but there can be no assurance that the defense will be successful.   As previously disclosed, the Company has received inquiries and requests for information from governmental agencies, including the U.S. Securities and Exchange Commission (“SEC”) and the U.S. Department of Justice, relating to the Company’s regulatory update announcement in November 2015 that the FDA requested additional clinical data on the efficacy and safety of rociletinib.   Earlier this year, the Company and Mr. Mahaffy engaged in discussions with the SEC staff to resolve this matter. On September 18, 2018, the SEC announced it had reached an agreement with the Company to settle this matter on negligence-based charges. Pursuant to the settlement, without admitting or denying the SEC’s allegations, the Company paid a $20.0 million civil penalty, which the Company reserved as a loss contingency on its consolidated balance sheet as of June 30, 2018, and stipulated to a standard injunction against future violations of those provisions of the federal securities laws. Also, on September 18, 2018, the SEC announced that Mr. Mahaffy also reached a settlement with the SEC on similar negligence-based allegations, to which he neither admits nor denies, and paid a civil penalty and will be similarly enjoined. Mr. Mahaffy will continue to serve as the Company’s Chief Executive Officer and as a member of the Company’s Board of Directors.   The settlements do not allege that the Company or any of its current or former officers engaged in any intentional fraud or misconduct.  The settlements were approved by the United States District Court for the District of Colorado on September 19, 2018 and resolve the SEC’s nearly three year investigation into the regulatory approval process of rociletinib.    European Patent Opposition   Two oppositions were filed in the granted European counterpart of the rucaparib camsylate salt/polymorph patent on June 20, 2017. The grounds of opposition related to Rubraca were lack of novelty and lack of inventive step. A preliminary opinion and summons to oral proceedings were issued on April 4, 2018. The oral hearing is scheduled for December 4, 2018. The preliminary opinion provides a non-binding indication of the tribunal’s view. In the preliminary opinion, the tribunal agreed with some of our positions and agreed with certain objections made by the opponents. As part of the proceeding, we have the opportunity to submit further arguments and pursue alternative claims in the form of auxiliary requests. On October 3, 2018, we submitted further arguments and auxiliary requests and on October 4, 2018, both opponents submitted further arguments. While the ultimate results of patent challenges can be difficult to predict, we believe a number of factors, including a constellation of unexpected properties, support the novelty and non-obviousness of our rucaparib camsylate salt/polymorph composition of matter patent.   <div /></div> </div>

0.001

100000000

50565119

52708767

50565119

52708767

51000

53000

-289635000

-59059000

-271127000

-90369000

282406000

574828000

283400000

291400000

1115000

6920000

372000

3026000

13262000

1851000

13262000

12697000

-565000

4766000

771000

4766000

5158000

392000

61.88

76.17

16.1616

13.1278

1.50

287500000

300000000

232800000

268200000

0.025

0.0125

2021-09-15

2018-09-15

1.00

P7Y

<div> <div> The debt issuance costs are presented as a deduction from the convertible senior notes on the Consolidated Balance Sheets and are amortized as interest expense over the expected life of the 2021 Notes using the effective interest method. We determined the expected life of the debt was equal to the seven-year term of the 2021 Notes. <div /></div> </div>

9200000

9100000

22022000

3671000

6478000

1911000

2497000

<div> <div> 11. Share-Based Compensation   Share-based compensation expense for all equity based programs, including stock options, restricted stock units and the employee stock purchase plan, for the three and nine months ended September 30, 2018 and 2017 was recognized in the accompanying Consolidated Statements of Operations as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:32.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:32.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:31.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months ended September 30,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:30.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine months ended September 30,  </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:32.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:32.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,038 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,636 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 15,380 </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14,628 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:32.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Selling, general and administrative </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5,909 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,001 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 22,335 </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 17,573 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:32.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total share-based compensation expense </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 10,947 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 12,637 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 37,715 </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 32,201 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   We did not recognize a tax benefit related to share-based compensation expense during the three and nine months ended September 30, 2018 and 2017, respectively, as we maintain net operating loss carryforwards and have established a valuation allowance against the entire net deferred tax asset as of September 30, 2018.   Stock Options   The following table summarizes the activity relating to our options to purchase common stock for the nine months ended September 30, 2018:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:47.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Term (Years) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Thousands) </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at December 31, 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,789,735 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 46.77 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 639,793 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 52.33 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (70,480) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 25.82 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (217,007) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 60.47 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at September 30, 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,142,041 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 47.11 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.6 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 24,884 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Vested and expected to vest at September 30, 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5,919,341 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 47.00 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6.5 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 24,555 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Vested and exercisable at September 30, 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,284,706 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 45.70 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.8 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 21,421 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   The aggregate intrinsic value in the table above represents the pretax intrinsic value, based on our closing stock price of $29.37 as of September 28, 2018, which would have been received by the option holders had all option holders with in-the-money options exercised their options as of that date.   The following table summarizes information about our stock options as of and for the three and nine months ended September 30, 2018 and 2017 (in thousands, except per share amounts):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:34.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:34.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:31.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months ended September 30,  </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:30.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine months ended September 30,  </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:34.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">     </td> <td colspan="2" valign="bottom" style="width:14.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">     </td> <td colspan="2" valign="bottom" style="width:14.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">     </td> <td colspan="2" valign="bottom" style="width:13.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">     </td> <td colspan="2" valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:34.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Weighted-average grant date fair value per share </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 28.97 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 60.81 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 38.52 </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 48.39 </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:34.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Intrinsic value of options exercised </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 325 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,400 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,697 </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 17,684 </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:34.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash received from stock option exercises </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 604 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,149 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,820 </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 13,262 </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   As of September 30, 2018, the unrecognized share-based compensation expense related to unvested options, adjusted for expected forfeitures, was $60.4 million and the estimated weighted-average remaining vesting period was 2.46 years.   Restricted Stock   The following table summarizes the activity relating to our unvested restricted stock units (“RSUs”) for the nine months ended September 30, 2018: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Grant Date </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Units </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair Value </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested at December 31, 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 589,529 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 41.67 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 479,255 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 55.05 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Vested </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (199,602) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 40.43 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (44,686) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 46.65 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested as of September 30, 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 824,496 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 49.48 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected to vest after September 30, 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 706,795 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 49.25 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   As of September 30, 2018, the unrecognized share-based compensation expense related to unvested RSUs, adjusted for expected forfeitures, was $31.2 million and the estimated weighted-average remaining vesting period was 3.0 years. <div /></div> </div>

<div> <div> The following table summarizes information about our stock options as of and for the three and nine months ended September 30, 2018 and 2017 (in thousands, except per share amounts):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:34.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:34.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:31.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months ended September 30,  </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:30.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine months ended September 30,  </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:34.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">     </td> <td colspan="2" valign="bottom" style="width:14.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">     </td> <td colspan="2" valign="bottom" style="width:14.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">     </td> <td colspan="2" valign="bottom" style="width:13.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">     </td> <td colspan="2" valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:34.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Weighted-average grant date fair value per share </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 28.97 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 60.81 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 38.52 </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 48.39 </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:34.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Intrinsic value of options exercised </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 325 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,400 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,697 </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 17,684 </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:34.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash received from stock option exercises </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 604 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,149 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,820 </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 13,262 </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

-6.39

-1.24

-5.18

-5.20

0.02

-1.71

-1.67

-0.04

<div> <div> Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding using the treasury-stock method for the stock options and RSUs and the if-converted method for the 2021 Notes and 2025 Notes. As a result of our net losses for the periods presented, all potentially dilutive common share equivalents were considered anti-dilutive and were excluded from the computation of diluted net loss per share. <div /></div> </div>

<div> <div> 13. Net Loss Per Common Share   Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding using the treasury-stock method for the stock options and RSUs and the if-converted method for the 2021 Notes and 2025 Notes. As a result of our net losses for the periods presented, all potentially dilutive common share equivalents were considered anti-dilutive and were excluded from the computation of diluted net loss per share.   The shares outstanding at the end of the respective periods presented in the table below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:57.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:19.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:18.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:40.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three and Nine months ended September 30,  </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:19.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:18.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Common shares under option </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:19.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,381 </td> <td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,696 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Convertible senior notes </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:19.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 8,584 </td> <td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:18.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,646 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total potential dilutive shares </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:19.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11,965 </td> <td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 10,342 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

886000

-286000

13889000

14217000

P2Y5M16D

P3Y

31200000

60400000

<div> <div> 3. Financial Instruments and Fair Value Measurements   Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.   The three levels of inputs that may be used to measure fair value include:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 95.00%;margin-left:24.5pt;"> <tr> <td valign="top" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Level 1: </td> <td valign="top" style="width:91.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Quoted prices in active markets for identical assets or liabilities. Our Level 1 assets consist of money market investments. We do not have Level 1 liabilities. </td> </tr> <tr> <td valign="top" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="top" style="width:91.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Level 2: </td> <td valign="top" style="width:91.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Our Level 2 assets consist of U.S. treasury securities. We do not have Level 2 liabilities. </td> </tr> <tr> <td valign="top" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="top" style="width:91.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Level 3: </td> <td valign="top" style="width:91.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Unobservable inputs that are supported by little or no market activity. We do not have Level 3 assets or liabilities that are measured at fair value on a recurring basis. </td> </tr> </table></div>   The following table identifies our assets and liabilities that were measured at fair value on a recurring basis (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:51.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balance </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level 1 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level 2 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:06.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level 3 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> September 30, 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Assets: </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Money market </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 255,143 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 255,143 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> U.S. treasury securities </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 313,525 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 313,525 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total assets at fair value </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 568,668 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 255,143 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 313,525 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Assets: </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Money market </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 433,136 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 433,136 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> U.S. treasury securities </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 99,533 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 99,533 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total assets at fair value </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 532,669 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 433,136 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 99,533 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   There were no transfers between the Level 1 and Level 2 categories or into or out of the Level 3 category during the three and nine months ended September 30, 2018.   Financial instruments not recorded at fair value include our convertible senior notes. At September 30 2018, the carrying amount of the 2021 Notes was $283.4 million, which represents the aggregate principal amount net of remaining debt issuance costs, and the fair value was $268.2 million. At September 30 2018, the carrying amount of the 2025 Notes was $291.4 million, which represents the aggregate principal amount net of remaining debt issuance costs, and the fair value was $232.8 million. The fair value was determined using Level 2 inputs based on the indicative pricing published by certain investment banks or trading levels of these notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system. See Note 9, Convertible Senior Notes for discussion of the convertible senior notes. <div /></div> </div>

1539000

3391000

39466000

779000

3116000

21100000

56100000

19561000

52709000

-127000

-44000

-34000

151000

-117000000

-7975000

65217000

63074000

<div> <div> 7. Intangible Assets and Goodwill   Intangible assets related to capitalized milestones under license agreements consisted of the following (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.42%;"> <tr> <td valign="bottom" style="width:74.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> </tr> <tr> <td valign="bottom" style="width:74.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> </tr> <tr> <td valign="bottom" style="width:74.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Intangible asset - milestones </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 56,100 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 21,100 </td> </tr> <tr> <td valign="bottom" style="width:74.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accumulated amortization </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (3,391) </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,539) </td> </tr> <tr> <td valign="bottom" style="width:74.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total intangible asset, net </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 52,709 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 19,561 </td> </tr> </table></div>    The increase in our intangible asset – milestones since December 31, 2017 is due to a $15.0 million milestone payment to Pfizer related to the April 6, 2018 FDA approval of our sNDA for Rubraca as maintenance treatment and a $20.0 million milestone payment to Pfizer related to the European Commission approval of Rubraca in May 2018. See Note 12, License Agreements for further discussion of these approvals.   The estimated useful lives of these intangible assets are based on the estimated remaining patent life of Rubraca and extend through 2035.   We recorded amortization expense of $0.8 million and $1.9 million related to capitalized milestone payments during the three and nine months ended September 30, 2018, respectively. We recorded amortization expense of $0.4 million and $1.2 million related to capitalized milestone payments during the three and nine months ended September 30, 2017, respectively. Amortization expense is included in cost of sales – intangible asset amortization on the Consolidated Statements of Operations and Comprehensive Loss.   Estimated future amortization expense associated with intangibles is expected to be as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 779 </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,116 </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,116 </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,116 </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2022 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,116 </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Thereafter </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 39,466 </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 52,709 </td> </tr> </table></div>   The change in goodwill established as part of the purchase accounting of EOS in November 2013 consisted of the following (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:84.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at December 31, 2017 </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 65,217 </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Change in foreign currency gains and losses </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (2,143) </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at September 30, 2018 </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 63,074 </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

-2143000

-297113000

-61898000

-269030000

-89851000

-2599000

-1234000

-280000

13000

5050000

4765000

-121000

4978000

-2403000

5345000

25540000

1949000

-1304000

4156000

7507000

19561000

52709000

7796000

2618000

9592000

3376000

5391000

1797000

7078000

2735000

7188000

9188000

2096000

<div> <div> 5. Inventories   The following table presents current and long-term inventories as of September 30, 2018 and December 31, 2017:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:73.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> </tr> <tr> <td valign="bottom" style="width:73.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> </tr> <tr> <td valign="bottom" style="width:73.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Work-in-process </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 51,707 </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 24,721 </td> </tr> <tr> <td valign="bottom" style="width:73.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Finished goods </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11,980 </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,787 </td> </tr> <tr> <td valign="bottom" style="width:73.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total inventories </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 63,687 </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 27,508 </td> </tr> </table></div>   Some of the costs related to our finished goods on-hand as of September 30, 2018 were expensed as incurred prior to the commercialization of Rubraca on December 19, 2016.   At September 30, 2018, deposit on inventory on the Consolidated Balance Sheets is a cash deposit of $44.6 million made to a manufacturer for the purchase of work-in-process inventory which we expect to be converted to finished goods during the next twelve months and beyond. <div /></div> </div>

2787000

11980000

63687000

63992000

-305000

27508000

27446000

-62000

43682000

20005000

24721000

51707000

<div> <div> As of September 30, 2018, the amortized cost and fair value of available-for-sale securities by contractual maturity were (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:71.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortized </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Due in one year or less </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 313,570 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 313,525 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Due in one year to two years </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 313,570 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 313,525 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> 4. Available-for-Sale Securities   As of September 30, 2018, available-for-sale securities consisted of the following (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:59.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortized </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gains </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Losses </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> U.S. treasury securities </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 313,570 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (45) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 313,525 </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   As of December 31, 2017, available-for-sale securities consisted of the following (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 81.82%;"> <tr> <td valign="bottom" style="width:59.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortized </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gains </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Losses </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> U.S. treasury securities </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 99,650 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (117) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 99,533 </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   As of September 30, 2018, our available-for-sale securities have been in a continuous loss position for less than 12 months. We have concluded that decline in the market value of the available-for-sale securities is temporary. A decline in the market value of a security below its cost that is deemed to be other than temporary is charged to earnings and results in the establishment of a new cost basis for the security. Factors evaluated to determine if an investment is other-than-temporarily impaired include significant deterioration in earnings performance, credit rating, asset quality or business prospects of the issuer; adverse changes in the general market conditions in which the issuer operates; and our intent and ability to hold the security until an anticipated recovery in value occurs.   As of September 30, 2018, the amortized cost and fair value of available-for-sale securities by contractual maturity were (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:71.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortized </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Due in one year or less </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 313,570 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 313,525 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Due in one year to two years </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 313,570 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 313,525 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

367594000

657798000

735230000

738504000

3274000

891464000

81517000

76492000

20000000

<div> <div> 9. Convertible Senior Notes   2021 Notes   On September 9, 2014, we completed a private placement of $287.5 million aggregate principal amount of 2.5% convertible senior notes due 2021 (the “2021 Notes”) resulting in net proceeds of $278.3 million after deducting offering expenses. In accordance with the accounting guidance, the conversion feature did not meet the criteria for bifurcation, and the entire principal amount was recorded as a long-term liability on the Consolidated Balance Sheets.   The 2021 Notes are governed by the terms of the indenture between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee. The 2021 Notes are senior unsecured obligations and bear interest at a rate of 2.5% per year, payable semi-annually in arrears on March 15 and September 15 of each year. The 2021 Notes will mature on September 15, 2021, unless earlier converted, redeemed or repurchased.   Holders may convert all or any portion of the 2021 Notes at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the holders will receive shares of our common stock at an initial conversion rate of 16.1616 shares per $1,000 in principal amount of 2021 Notes, equivalent to a conversion price of approximately $61.88 per share. The conversion rate is subject to adjustment upon the occurrence of certain events described in the indenture. In addition, following certain corporate events that occur prior to the maturity date or upon our issuance of a notice of redemption, we will increase the conversion rate for holders who elect to convert the 2021 Notes in connection with such a corporate event or during the related redemption period in certain circumstances.   On or after September 15, 2018, we may redeem the 2021 Notes, at our option, in whole or in part, if the last reported sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending not more than two trading days preceding the date on which we provide written notice of redemption at a redemption price equal to 100% of the principal amount of the 2021 Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2021 Notes.   If we undergo a fundamental change, as defined in the indenture, prior to the maturity date of the 2021 Notes, holders may require us to repurchase for cash all or any portion of the 2021 Notes at a fundamental change repurchase price equal to 100% of the principal amount of the 2021 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.   The 2021 Notes rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the 2021 Notes; equal in right of payment to all of our liabilities that are not so subordinated; effectively junior in right of payment to any secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries.   In connection with the issuance of the 2021 Notes, we incurred $9.2 million of debt issuance costs. The debt issuance costs are presented as a deduction from the convertible senior notes on the Consolidated Balance Sheets and are amortized as interest expense over the expected life of the 2021 Notes using the effective interest method. We determined the expected life of the debt was equal to the seven-year term of the 2021 Notes.    2025 Notes   On April 19, 2018, we completed an underwritten public offering of $300.0 million aggregate principal amount of 1.25% convertible senior notes due 2025 (the “2025 Notes”) resulting in net proceeds of $290.9 million, after deducting underwriting discounts and commissions and offering expenses. In accordance with the accounting guidance, the conversion feature did not meet the criteria for bifurcation, and the entire principal amount was recorded as a long-term liability on the Consolidated Balance Sheets.   The 2025 Notes are governed by the terms of the indenture between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee, as supplemented by the terms of that certain first supplemental indenture thereto. The 2025 Notes are senior unsecured obligations and bear interest at a rate of 1.25% per year, payable semi-annually in arrears on May 1 and November 1 of each year. The 2025 Notes will mature on May 1, 2025, unless earlier converted, redeemed or repurchased.   Holders may convert all or any portion of the 2025 Notes at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the holders will receive shares of our common stock at an initial conversion rate of 13.1278 shares per $1,000 in principal amount of 2025 Notes, equivalent to a conversion price of approximately $76.17 per share. The conversion rate is subject to adjustment upon the occurrence of certain events described in the indenture. In addition, following certain corporate events that occur prior to the maturity date or upon our issuance of a notice of redemption, we will increase the conversion rate for holders who elect to convert the 2025 Notes in connection with such a corporate event or during the related redemption period in certain circumstances.   On or after May 2, 2022, we may redeem the 2025 Notes, at our option, in whole or in part, if the last reported sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending not more than two trading days preceding the date on which we provide written notice of redemption at a redemption price equal to 100% of the principal amount of the 2025 Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2025 Notes.   If we undergo a fundamental change, as defined in the indenture, prior to the maturity date of the 2025 Notes, holders may require us to repurchase for cash all or any portion of the 2025 Notes at a fundamental change repurchase price equal to 100% of the principal amount of the 2025 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.   The 2025 Notes rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the 2025 Notes; equal in right of payment to all of our liabilities that are not so subordinated, including the 2021 Notes; effectively junior in right of payment to any secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries.   In connection with the issuance of the 2025 Notes, we incurred $9.1 million of debt issuance costs. The debt issuance costs are presented as a deduction from the convertible senior notes on the Consolidated Balance Sheets and are amortized as interest expense over the expected life of the 2025 Notes using the effective interest method. We determined the expected life of the debt was equal to the seven-year term of the 2025 Notes.   As of September 30, 2018 and December 31, 2017, the balance of unamortized debt issuance costs was $12.7 million and $5.1 million, respectively.   The following table sets forth total interest expense recognized during the three and nine months ended September 30, 2018 and 2017 (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:59.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months ended September 30,  </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine months ended September 30,  </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Contractual interest expense </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,735 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,797 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,078 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,391 </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accretion of interest on milestone liability </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 500 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 978 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,449 </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Amortization of debt issuance costs </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 641 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 321 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,536 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 956 </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total interest expense </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,376 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,618 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 9,592 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,796 </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

20000000

560257000

387974000

29469000

-277763000

-195326000

-283270000

-294514000

-60664000

-268750000

-269648000

898000

-89864000

-87994000

-1870000

-122686000

-1371000

-32182000

-689000

212898000

77333000

301885000

111919000

-174427000

-60527000

-236848000

-89162000

2830000

2990000

7500000

11780000

196000

256000

19505000

22766000

7703000

8000

7695000

2525000

15000

2510000

-2377000

71000

-2448000

-505000

-10000

-495000

4874000

1595000

-2448000

-495000

4879000

1605000

-2377000

-505000

-2824000

-3000

-2821000

-920000

-5000

-915000

5000

10000

71000

-10000

<div> <div>   6. Other Current Assets   Other current assets were comprised of the following (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Prepaid insurance </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 752 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,926 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Prepaid expenses - other </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,031 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,355 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Receivable - other </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,741 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,023 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Other </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 256 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 196 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11,780 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,500 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

2237000

1291000

5419000

2536000

2023000

3741000

180000000

320000000

416000

7763000

0.001

10000000

3355000

7031000

1559000

2907000

1926000

752000

278300000

290887000

290900000

545838000

93890000

93900000

14419000

3197000

213500000

105000000

13262

2149

1820

604

-294514000

-268750000

4007000

11035000

165100000

104479000

38924000

160138000

63887000

-1477440000

-1475084000

2356000

-1743834000

-1744732000

898000

65037000

63541000

1496000

22757000

25213000

-2456000

<div> <div> Revenue Recognition   We are currently approved to sell Rubraca in the United States market. We distribute our product principally through a limited number of specialty distributor and specialty pharmacy providers, collectively, our customers.  Our customers subsequently sell our products to patients and health care providers.  Separately, we have arrangements with certain payors and other third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts.    Product Revenue   Revenue from product sales are recognized when the performance obligation is satisfied, which is when customers obtain control of our product at a point in time, typically upon delivery. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less.   Reserves for Variable Consideration     Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from rebates, chargebacks, discounts, co-pay assistance, estimated product returns and other allowances that are offered within contracts between us and our customers, health care providers, payors and other indirect customers relating to the sales of our product. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customers) or a current liability (if the amount is payable to a party other than a customer). Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known.   Rebates. Rebates include mandated discounts under the Medicaid Drug Rebate Program and the Medicare coverage gap program. Rebates are amounts owed after the final dispensing of products to a benefit plan participant and are based upon contractual agreements or legal requirements with the public-sector benefit providers. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the consolidated balance sheet. We estimate our Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. The accrual for rebates is based on statutory discount rates and known sales to specialty pharmacy patients or expected utilization for specialty distributor sales to healthcare providers. As we gain more historical experience, the accrual will be based solely on the expected utilization from historical data we have accumulated since the Rubraca product launch. Rebates are generally invoiced and paid quarterly in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter’s activity, plus an accrual balance for known or estimated prior quarters’ unpaid rebates.   Chargebacks. Chargebacks are discounts that occur when contracted customers, which currently consist primarily of group purchasing organizations, Public Health Service organizations and federal government entities purchasing via the Federal Supply Schedule, purchase directly from our specialty distributors at a discounted price. The specialty distributor, in turn, charges back the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the healthcare provider. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. The accrual for specialty distributor chargebacks is estimated based on known chargeback rates and known sales to specialty distributors adjusted for the estimated utilization by healthcare providers.   Discounts and Fees. Our payment terms are generally 30 days. Specialty distributors and specialty pharmacies are offered various forms of consideration, including service fees and prompt pay discounts for payment within a specified period. We expect these customers will earn prompt pay discounts and therefore, we deduct the full amount of these discounts and service fees from product sales when revenue is recognized.   Co-pay assistance. Patients who have commercial insurance and meet certain eligibility requirements may receive co-pay assistance. The intent of this program is to reduce the patient’s out of pocket costs. Liabilities for co-pay assistance are based on actual program participation provided by third-party administrators at month end.       Returns. Consistent with industry practice, we generally offer customers a right of return limited only to product that will expire in six months or product that is six months beyond the expiration date. To date, we have had minimal product returns and we currently do not have an accrual for product returns. We will continue to assess our estimate for product returns as we gain additional historical experience. <div /></div> </div>

true

38471000

16806000

65037000

22757000

<div> <div> Other accrued expenses were comprised of the following (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued personnel costs </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14,217 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 13,889 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued interest payable </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,096 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Income tax payable </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 186 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued corporate legal fees and professional services </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 731 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 415 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued royalties </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,187 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,984 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued variable considerations </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,407 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,008 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Payable to third party logistics provider </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,661 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued expenses - other </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,990 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,830 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 24,732 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 25,883 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the three months ended September 30, 2018 and 2017, as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:22.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Foreign Currency </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:20.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:14.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total Accumulated </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:22.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Translation Adjustments </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:20.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Losses) Gains </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:14.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Other Comprehensive Loss </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at July 1, </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (43,870) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,155) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (175) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (151) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,045) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,306) </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Other comprehensive income (loss) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (495) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,510 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (10) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 15 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (505) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,525 </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total before tax </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,365) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (41,645) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (185) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (136) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,550) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (41,781) </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Tax effect </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (915) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (5) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (920) </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at September 30,  </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,365) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (42,560) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (185) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (141) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,550) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (42,701) </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the nine months ended September 30, 2018 and 2017, as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:22.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Foreign Currency </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:20.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:14.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total Accumulated </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:22.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Translation Adjustments </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:20.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Losses) Gains </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:14.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Other Comprehensive Loss </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at January 1, </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (41,917) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (47,434) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (256) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (146) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (42,173) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (47,580) </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Other comprehensive income (loss) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (2,448) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,695 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 71 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  8 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (2,377) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,703 </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total before tax </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,365) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (39,739) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (185) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (138) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,550) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (39,877) </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Tax effect </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (2,821) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (3) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (2,824) </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at September 30,  </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,365) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (42,560) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (185) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (141) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,550) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (42,701) </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> The shares outstanding at the end of the respective periods presented in the table below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:57.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:19.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:18.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:40.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three and Nine months ended September 30,  </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:19.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:18.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Common shares under option </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:19.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,381 </td> <td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,696 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Convertible senior notes </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:19.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 8,584 </td> <td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:18.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,646 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total potential dilutive shares </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:19.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11,965 </td> <td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 10,342 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> As of September 30, 2018, available-for-sale securities consisted of the following (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:59.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortized </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gains </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Losses </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> U.S. treasury securities </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 313,570 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (45) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 313,525 </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   As of December 31, 2017, available-for-sale securities consisted of the following (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 81.82%;"> <tr> <td valign="bottom" style="width:59.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortized </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gains </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Losses </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> U.S. treasury securities </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 99,650 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (117) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 99,533 </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> Share-based compensation expense for all equity based programs, including stock options, restricted stock units and the employee stock purchase plan, for the three and nine months ended September 30, 2018 and 2017 was recognized in the accompanying Consolidated Statements of Operations as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:32.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:32.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:31.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months ended September 30,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:30.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine months ended September 30,  </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:32.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:32.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,038 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,636 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 15,380 </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14,628 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:32.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Selling, general and administrative </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5,909 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,001 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 22,335 </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 17,573 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:32.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total share-based compensation expense </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 10,947 </td> <td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 12,637 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 37,715 </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 32,201 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> The following table identifies our assets and liabilities that were measured at fair value on a recurring basis (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:51.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balance </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level 1 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level 2 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:06.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level 3 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> September 30, 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Assets: </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Money market </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 255,143 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 255,143 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> U.S. treasury securities </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 313,525 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 313,525 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total assets at fair value </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 568,668 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 255,143 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 313,525 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Assets: </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Money market </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 433,136 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 433,136 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> U.S. treasury securities </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 99,533 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 99,533 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total assets at fair value </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 532,669 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 433,136 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 99,533 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> Estimated future amortization expense associated with intangibles is expected to be as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 779 </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,116 </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,116 </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,116 </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2022 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,116 </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Thereafter </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 39,466 </td> </tr> <tr> <td valign="bottom" style="width:75.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 52,709 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> Intangible assets related to capitalized milestones under license agreements consisted of the following (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.42%;"> <tr> <td valign="bottom" style="width:74.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> </tr> <tr> <td valign="bottom" style="width:74.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> </tr> <tr> <td valign="bottom" style="width:74.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Intangible asset - milestones </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 56,100 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 21,100 </td> </tr> <tr> <td valign="bottom" style="width:74.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accumulated amortization </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (3,391) </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,539) </td> </tr> <tr> <td valign="bottom" style="width:74.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total intangible asset, net </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 52,709 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 19,561 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> The change in goodwill established as part of the purchase accounting of EOS in November 2013 consisted of the following (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:84.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at December 31, 2017 </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 65,217 </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Change in foreign currency gains and losses </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (2,143) </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at September 30, 2018 </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 63,074 </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> The cumulative effect of the changes made to our consolidated January 1, 2018 balance sheet for the adoption of ASC 606 was as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 90.00%;"> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balance at </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Adjustments due to </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balance at </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, 2017 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Adoption of ASC 606 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> January 1, 2018 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> ASSETS </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accounts receivable, net </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6,181 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,336 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 9,517 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Inventories </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 27,508 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (62) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 27,446 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">     Total assets </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 735,230 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,274 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 738,504 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> LIABILITIES AND STOCKHOLDERS' EQUITY </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Other accrued expenses </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 25,883 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 918 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 26,801 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accumulated deficit </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,477,440) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,356 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,475,084) </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">     Total liabilities and stockholders' equity </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 735,230 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,274 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 738,504 </td> </tr> </table></div>   Previously, we recognized revenue on product sales once the product was sold to the patient or healthcare provider by the specialty distributor or specialty pharmacy provider, i.e. when product is sold through the channel. Effective January 1, 2018, we began recognizing revenue when our customers, the specialty distributors and specialty pharmacy providers, take control of our product or when product is sold into the channel. This will have the impact of us recognizing revenue approximately two to four weeks earlier than before adopting the new standard and will also increase the significance of estimating variable consideration. The following financial statement line items for the three and nine months ended September 30, 2018 were affected as a result of the adoption.   CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except for per share amounts)   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="middle" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="8" valign="bottom" style="width:39.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months ended September 30, 2018 </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balances without </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Effect of Change </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As reported </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Adoption of ASC 606 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Higher/(Lower) </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Product revenue </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 22,757 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 25,213 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (2,456) </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Cost of sales - product </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,766 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5,158 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 392 </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Selling, general and administrative </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 42,495 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 42,689 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 194 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Net loss </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (89,864) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (87,994) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,870) </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Loss per basic and diluted common share: </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Basic and diluted net loss per common share </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (1.71) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (1.67) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (0.04) </td> </tr> </table></div>     <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="middle" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="8" valign="bottom" style="width:39.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine months ended September 30, 2018 </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balances without </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Effect of Change </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As reported </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Adoption of ASC 606 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Higher/(Lower) </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Product revenue </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 65,037 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 63,541 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,496 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Cost of sales - product </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 13,262 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 12,697 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (565) </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Selling, general and administrative </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 126,634 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 126,602 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (32) </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Net loss </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (268,750) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (269,648) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 898 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Loss per basic and diluted common share: </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Basic and diluted net loss per common share </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (5.18) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (5.20) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.02 </td> </tr> </table></div>     CONSOLIDATED BALANCE SHEET (In thousands) <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="middle" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="8" valign="bottom" style="width:39.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, 2018 </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balances without </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Effect of Change </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As reported </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Adoption of ASC 606 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Higher/(Lower) </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> ASSETS </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accounts receivable, net </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 14,495 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 12,907 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,588 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Inventories </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 63,687 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 63,992 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (305) </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> LIABILITIES AND STOCKHOLDERS' EQUITY </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Other accrued expenses </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 24,732 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 24,347 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 385 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accumulated deficit </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (1,743,834) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (1,744,732) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 898 </td> </tr> </table></div>   <div /></div> </div>

<div> <div>   Other current assets were comprised of the following (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Prepaid insurance </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 752 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,926 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Prepaid expenses - other </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,031 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,355 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Receivable - other </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,741 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,023 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Other </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 256 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 196 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11,780 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,500 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:47.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Term (Years) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Thousands) </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at December 31, 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,789,735 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 46.77 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 639,793 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 52.33 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (70,480) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 25.82 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (217,007) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 60.47 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at September 30, 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,142,041 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 47.11 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.6 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 24,884 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Vested and expected to vest at September 30, 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5,919,341 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 47.00 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6.5 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 24,555 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Vested and exercisable at September 30, 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,284,706 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 45.70 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.8 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 21,421 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

100384000

35011000

126634000

126602000

-32000

42495000

42689000

194000

32201000

37715000

44686

46.65

479255

55.05

589529

824496

41.67

49.48

199602

40.43

17684

3400

1697

325

217007

639793

48.39

60.81

38.52

28.97

24884000

5789735

6142041

46.77

47.11

P6Y7M6D

21421000

4284706

45.70

P5Y9M18D

24555000

5919341

47.00

P6Y6M

25.82

60.47

52.33

54.41

<div> <div> 2. Summary of Significant Accounting Policies   Recently Adopted Accounting Standards   In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, “Revenue from Contracts with Customers”, and has subsequently issued several supplemental and/or clarifying ASUs (collectively, “ASC 606”). ASC 606 prescribes a single common revenue standard that replaces most existing U.S. GAAP revenue recognition guidance. ASC 606 is intended to provide a more consistent interpretation and application of the principles outlined in the standard across filers in multiple industries and within the same industries compared to current practices, which should improve comparability. We adopted the new standard using the modified retrospective method on January 1, 2018 for contracts that are not completed as of the adoption date.   Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 also impacts certain other areas, such as the accounting for costs to obtain or fulfill a contract. The standard also requires disclosure of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.     We examined our revenue recognition policy specific to revenue streams from contracts governing product sales from Rubraca and have come to conclusions on the impact of the new standard using the 5-step process prescribed by ASC 606. We reviewed all of our contracts, including our collaboration agreements with Servier and Bristol-Myers Squibb, and determined the potential impact to our accounting policies, financial controls and operations. Our conclusions include recognizing revenue on product sales once the product is sold to the specialty distributor and specialty pharmacy providers.   As noted above, we used the modified retrospective method to adopt the new standard. This means that we did not restate previously issued financial statements, but we recorded a one-time adjustment to retained earnings of $2.4 million. This adjustment represents the sales of our product to our customers prior to January 1, 2018, that had not been sold to patients or healthcare providers, offset by related gross-to-net adjustments and other direct costs, including royalties and sales incentive compensation.   The cumulative effect of the changes made to our consolidated January 1, 2018 balance sheet for the adoption of ASC 606 was as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 90.00%;"> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balance at </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Adjustments due to </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balance at </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, 2017 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Adoption of ASC 606 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> January 1, 2018 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> ASSETS </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accounts receivable, net </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6,181 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,336 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 9,517 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Inventories </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 27,508 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (62) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 27,446 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">     Total assets </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 735,230 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,274 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 738,504 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> LIABILITIES AND STOCKHOLDERS' EQUITY </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Other accrued expenses </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 25,883 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 918 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 26,801 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accumulated deficit </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,477,440) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,356 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,475,084) </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">     Total liabilities and stockholders' equity </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 735,230 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,274 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 738,504 </td> </tr> </table></div>   Previously, we recognized revenue on product sales once the product was sold to the patient or healthcare provider by the specialty distributor or specialty pharmacy provider, i.e. when product is sold through the channel. Effective January 1, 2018, we began recognizing revenue when our customers, the specialty distributors and specialty pharmacy providers, take control of our product or when product is sold into the channel. This will have the impact of us recognizing revenue approximately two to four weeks earlier than before adopting the new standard and will also increase the significance of estimating variable consideration. The following financial statement line items for the three and nine months ended September 30, 2018 were affected as a result of the adoption.   CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except for per share amounts)   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="middle" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="8" valign="bottom" style="width:39.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months ended September 30, 2018 </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balances without </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Effect of Change </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As reported </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Adoption of ASC 606 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Higher/(Lower) </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Product revenue </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 22,757 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 25,213 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (2,456) </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Cost of sales - product </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,766 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5,158 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 392 </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Selling, general and administrative </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 42,495 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 42,689 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 194 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Net loss </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (89,864) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (87,994) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,870) </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Loss per basic and diluted common share: </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Basic and diluted net loss per common share </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (1.71) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (1.67) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (0.04) </td> </tr> </table></div>     <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="middle" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="8" valign="bottom" style="width:39.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine months ended September 30, 2018 </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balances without </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Effect of Change </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As reported </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Adoption of ASC 606 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Higher/(Lower) </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Product revenue </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 65,037 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 63,541 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,496 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Cost of sales - product </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 13,262 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 12,697 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (565) </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Selling, general and administrative </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 126,634 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 126,602 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (32) </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Net loss </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (268,750) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (269,648) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 898 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Loss per basic and diluted common share: </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Basic and diluted net loss per common share </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (5.18) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (5.20) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.02 </td> </tr> </table></div>     CONSOLIDATED BALANCE SHEET (In thousands) <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="middle" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="8" valign="bottom" style="width:39.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, 2018 </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balances without </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Effect of Change </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As reported </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Adoption of ASC 606 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Higher/(Lower) </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> ASSETS </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accounts receivable, net </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 14,495 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 12,907 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,588 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Inventories </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 63,687 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 63,992 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (305) </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> LIABILITIES AND STOCKHOLDERS' EQUITY </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Other accrued expenses </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 24,732 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 24,347 </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 385 </td> </tr> <tr> <td valign="middle" style="width:59.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accumulated deficit </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (1,743,834) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (1,744,732) </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 898 </td> </tr> </table></div>     ASC 606 did not have an aggregate impact on our net cash provided by operating activities but resulted in offsetting changes in certain assets and liabilities presented within net cash used in operating activities in our consolidated statement of cash flows, as reflected in the above tables.   Recently Issued Accounting Standards   From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification (“ASC”) are communicated through issuance of an ASU.   In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”, which requires lessees to recognize assets and liabilities for the rights and obligations created by most leases on their balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. ASU 2016-02 requires modified retrospective adoption for all leases existing at, or entered after, the date of initial application, with an option to use certain transition relief. We will adopt ASU 2016-02 as of January 1, 2019 using the effective date method which leaves the comparative period reporting unchanged. Comparative reporting periods are presented in accordance with Topic 840, while periods subsequent to the effective date are presented in accordance with Topic 842. We expect to recognize substantially all our leases on the balance sheet by recording a right-of-use asset and corresponding lease liability. We are currently evaluating the impact the standard may have on our consolidated financial statements and related disclosures.   In February 2018, the FASB issued ASU 2018-02, “Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income”, which allow a reclassification from accumulated other comprehensive income (loss) (“AOCI”) to retained earnings for stranded tax effects resulting from the change in the U.S. federal corporate income tax rate on the gross deferred tax amounts at the date of enactment of the Tax Cuts and Jobs Act of 2017 (the “2017 Tax Act”). The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We will adopt ASU 2018-02 as of January 1, 2019. We are currently evaluating the impact the standard may have on our consolidated financial statements and related disclosures.   In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting”, simplifies the accounting for share-based payment granted to nonemployees for goods and services. Under the standard, most of the guidance on such payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We will adopt ASU 2018-07 as of January 1, 2019. We do not expect significant impact on our consolidated financial statements and related disclosures since our accounting for share-based payments to employees and nonemployees is similar.   In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement”. The guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. We will adopt ASU 2018-02 as of January 1, 2020. We will evaluate the impact the standard may have on our consolidated financial statements and related disclosures as the adoption date approaches.   Revenue Recognition   We are currently approved to sell Rubraca in the United States market. We distribute our product principally through a limited number of specialty distributor and specialty pharmacy providers, collectively, our customers.  Our customers subsequently sell our products to patients and health care providers.  Separately, we have arrangements with certain payors and other third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts.    Product Revenue   Revenue from product sales are recognized when the performance obligation is satisfied, which is when customers obtain control of our product at a point in time, typically upon delivery. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less.   Reserves for Variable Consideration     Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from rebates, chargebacks, discounts, co-pay assistance, estimated product returns and other allowances that are offered within contracts between us and our customers, health care providers, payors and other indirect customers relating to the sales of our product. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customers) or a current liability (if the amount is payable to a party other than a customer). Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known.   Rebates. Rebates include mandated discounts under the Medicaid Drug Rebate Program and the Medicare coverage gap program. Rebates are amounts owed after the final dispensing of products to a benefit plan participant and are based upon contractual agreements or legal requirements with the public-sector benefit providers. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the consolidated balance sheet. We estimate our Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. The accrual for rebates is based on statutory discount rates and known sales to specialty pharmacy patients or expected utilization for specialty distributor sales to healthcare providers. As we gain more historical experience, the accrual will be based solely on the expected utilization from historical data we have accumulated since the Rubraca product launch. Rebates are generally invoiced and paid quarterly in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter’s activity, plus an accrual balance for known or estimated prior quarters’ unpaid rebates.   Chargebacks. Chargebacks are discounts that occur when contracted customers, which currently consist primarily of group purchasing organizations, Public Health Service organizations and federal government entities purchasing via the Federal Supply Schedule, purchase directly from our specialty distributors at a discounted price. The specialty distributor, in turn, charges back the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the healthcare provider. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. The accrual for specialty distributor chargebacks is estimated based on known chargeback rates and known sales to specialty distributors adjusted for the estimated utilization by healthcare providers.   Discounts and Fees. Our payment terms are generally 30 days. Specialty distributors and specialty pharmacies are offered various forms of consideration, including service fees and prompt pay discounts for payment within a specified period. We expect these customers will earn prompt pay discounts and therefore, we deduct the full amount of these discounts and service fees from product sales when revenue is recognized.   Co-pay assistance. Patients who have commercial insurance and meet certain eligibility requirements may receive co-pay assistance. The intent of this program is to reduce the patient’s out of pocket costs. Liabilities for co-pay assistance are based on actual program participation provided by third-party administrators at month end.       Returns. Consistent with industry practice, we generally offer customers a right of return limited only to product that will expire in six months or product that is six months beyond the expiration date. To date, we have had minimal product returns and we currently do not have an accrual for product returns. We will continue to assess our estimate for product returns as we gain additional historical experience.   Cost of Sales – Product   Product cost of sales consists primarily of materials, third-party manufacturing costs as well as freight and royalties owed to our licensing partners for Rubraca sales.   Cost of Sales – Intangible Asset Amortization   Cost of sales for intangible asset amortization consists of the amortization of capitalized milestone payments made to our licensing partners upon FDA approval of Rubraca. Milestone payments are amortized on a straight-line basis over the estimated remaining patent life of Rubraca. Inventory   Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out (“FIFO”) basis. We began capitalizing incurred inventory related costs upon the regulatory approval of Rubraca. Prior to the regulatory approval of Rubraca, we incurred costs for the manufacture of the drug that could potentially be available to support the commercial launch of Rubraca and all such costs were recognized as research and development expense. We periodically analyze our inventory levels, and write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and/or inventory in excess of expected sales requirements as cost of product revenues. Expired inventory would be disposed of and the related costs would be written off as cost of product revenues.    The active pharmaceutical ingredient (“API”) in Rubraca is currently produced by a single supplier. As the API has undergone significant manufacturing specific to its intended purpose at the point it is purchased by us, we classify the API as work-in-process inventory. Inventory used in clinical trials is expensed as research and development expense when it has been identified for such use.        Our other significant accounting policies are described in Note 2, Summary of Significant Accounting Policies of the Notes to the Consolidated Financial Statements included in our 2017 Form 10-K. <div /></div> </div>

367636000

233666000

<div> <div> 10. Stockholders’ Equity   Common Stock   In April 2018, we sold 1,837,898 shares of our common stock in a public offering at $54.41 per share. The net proceeds from the offering were $93.9 million, after deducting underwriting discounts and commissions and offering expenses.   The holders of common stock are entitled to one vote per share on all matters to be voted upon by our stockholders. Subject to the preferences that may be applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by our Board of Directors.   Accumulated Other Comprehensive Loss   Accumulated other comprehensive loss consists of changes in foreign currency translation adjustments, which includes changes in a subsidiary’s functional currency, and unrealized gains and losses on available-for-sale securities.   The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the three months ended September 30, 2018 and 2017, as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:22.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Foreign Currency </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:20.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:14.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total Accumulated </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:22.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Translation Adjustments </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:20.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Losses) Gains </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:14.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Other Comprehensive Loss </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at July 1, </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (43,870) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,155) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (175) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (151) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,045) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,306) </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Other comprehensive income (loss) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (495) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,510 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (10) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 15 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (505) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,525 </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total before tax </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,365) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (41,645) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (185) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (136) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,550) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (41,781) </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Tax effect </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (915) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (5) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (920) </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at September 30,  </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,365) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (42,560) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (185) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (141) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,550) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (42,701) </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the nine months ended September 30, 2018 and 2017, as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:22.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Foreign Currency </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:20.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:14.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total Accumulated </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:22.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Translation Adjustments </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:20.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Losses) Gains </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:14.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Other Comprehensive Loss </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at January 1, </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (41,917) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (47,434) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (256) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (146) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (42,173) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (47,580) </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Other comprehensive income (loss) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (2,448) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,695 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 71 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  8 </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (2,377) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,703 </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total before tax </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,365) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (39,739) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (185) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (138) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,550) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (39,877) </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Tax effect </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (2,821) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (3) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (2,824) </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:37.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at September 30,  </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,365) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (42,560) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (185) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (141) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,550) </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (42,701) </td> <td valign="bottom" style="width:00.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   The period change in each of the periods was primarily due to the currency translation of the goodwill and deferred income taxes associated with the acquisition of EOS in November 2013. There were no reclassifications out of accumulated other comprehensive loss in each of the three and nine months ended September 30, 2018 and 2017. <div /></div> </div>

1837898

70480

186000

us-gaap:ProductMember

5100000

12700000

46062000

48917000

51844000

52669000

EX-101.SCH 7 clvs-20180930.xsd EX-101.SCH 00100 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Available-for-Sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Available-for-Sale Securities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Intangible Assets and Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 40703 - Disclosure - Intangible Assets and Goodwill - Estimated Future Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Other Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Convertible Senior Notes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00205 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Nature of Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Financial Instruments and Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Available-for-Sale Securities link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Other Current Assets link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Intangible Assets and Goodwill link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Other Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Convertible Senior Notes link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - License Agreements link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Net Loss Per Common Share link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Financial Instruments and Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Available-for-Sale Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Intangible Assets and Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Other Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Convertible Senior Notes (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 31303 - Disclosure - Net Loss Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Nature of Business and Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Financial Instruments and Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Financial Instruments and Fair Value Measurements - More Information (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Intangible Assets and Goodwill - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40704 - Disclosure - Intangible Assets and Goodwill - Summary of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Convertible Senior Notes (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - Stockholders' Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Share-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - Share-Based Compensation - Summary of Stock Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 41103 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Details) link:presentationLink link:calculationLink link:definitionLink 41104 - Disclosure - Share-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - License Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Net Loss Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 clvs-20180930_cal.xml EX-101.CAL EX-101.DEF 9 clvs-20180930_def.xml EX-101.DEF EX-101.LAB 10 clvs-20180930_lab.xml EX-101.LAB Document and entity information. Document And Entity Information [Abstract] Statement [Table] Statement [Line Items] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Current Reporting Status Entity Current Reporting Status Entity Filer Category Entity Filer Category Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Entity Small Business Entity Emerging Growth Company CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Products and Services [Axis] Products And Services [Domain] Products and Services [Domain] Product [Member] Product Change in Accounting Estimate by Type [Axis] Change In Accounting Estimate Type [Domain] Change in Accounting Estimate, Type [Domain] Intangible Assets Amortization Period [Member] Intangible asset amortization Revenues [Abstract] Revenues: Revenues Product revenue Type of Revenue [Extensible List] Operating Expenses [Abstract] Operating expenses: Cost of Goods and Services Sold Cost of sales Cost of sales - product Research And Development Expense Excluding Acquired In Process Cost Research and development General And Administrative Expense Selling, general and administrative Operating Expenses Total expenses Operating Income Loss Operating loss Nonoperating Income Expense [Abstract] Other income (expense): Interest Expense Debt Interest expense Total interest expense Foreign Currency Transaction Gain Loss Before Tax Foreign currency gain (loss) Gain (Loss) Related to Litigation Settlement Legal settlement loss Litigation Settlement, Expense SEC settlement costs Other Nonoperating Income Expense Other income Nonoperating Income Expense Other expense, net Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Loss before income taxes Income Tax Expense Benefit Income tax (expense) benefit Net Income Loss Net loss Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract] Other comprehensive income (loss): Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax Foreign currency translation adjustments, net of tax Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax Net unrealized (loss) gain on available-for-sale securities, net of tax Other Comprehensive Income Loss Net Of Tax Other comprehensive (loss) income: Comprehensive Income Net Of Tax Comprehensive loss Net Loss Per Common Share Loss per basic and diluted common share: Earnings Per Share Basic And Diluted Basic and diluted net loss per common share Weighted Average Number Of Share Outstanding Basic And Diluted Basic and diluted weighted average common shares outstanding CONSOLIDATED BALANCE SHEETS Assets [Abstract] ASSETS Assets Assets Current [Abstract] Current assets: Cash And Cash Equivalents At Carrying Value Cash and cash equivalents Accounts Receivable, Net, Current Accounts receivable, net Inventory, Net Total inventories Inventories Available-for-sale Securities, Debt Securities, Current Available-for-sale securities Prepaid Expense Current Prepaid research and development expenses The carrying amount of the asset transferred to a third party to serve as a cash deposit for the purchase of inventory. Deposit Assets For Purchase Inventory Deposit on inventory Other Assets Current Other current assets Total Assets Current Total current assets Inventory, Noncurrent Inventories The carrying amount of the asset transferred to a third party to serve as a cash deposit for the purchase of inventory expected to be transferred from work-in-process to finished goods beyond twelve months. Cash Deposit To Manufacturer For Non Current Inventory Deposit on inventory Property Plant And Equipment Net Property and equipment, net Intangible Assets Net Excluding Goodwill Intangible assets, net Goodwill Balance at end of period Balance at beginning of period Goodwill Other Assets Noncurrent Other assets Assets Total assets Liabilities And Stockholders Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities Current [Abstract] Current liabilities: Liabilities Accounts Payable Current Accounts payable Carrying value as of the balance sheet date of obligations incurred and payable for research and development activities which are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include contract research organizations, contract manufacturers and other research and development vendors. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Research And Development Expenses Accrued research and development expenses Deferred Long-term Liability Charges Milestone liability Accrued Liabilities Current Other accrued expenses Total Liabilities Current Total current liabilities Convertible Debt, Noncurrent Convertible senior notes Deferred Rent Credit Noncurrent Deferred rent, long-term Liabilities Total liabilities Commitments And Contingencies. Commitments and contingencies (Note 14) Stockholders Equity [Abstract] Stockholders' equity: Equity Preferred Stock Value Preferred stock, par value $0.001 per share; 10,000,000 shares authorized, no shares issued and outstanding at September 30, 2018 and December 31, 2017 Common Stock Value Common stock, $0.001 par value per share, 100,000,000 shares authorized at September 30, 2018 and December 31, 2017; 52,708,767 and 50,565,119 shares issued and outstanding at September 30, 2018 and December 31, 2017 respectively Additional Paid In Capital Common Stock Additional paid-in capital Accumulated Other Comprehensive Income Loss Net Of Tax Ending balance Beginning balance Accumulated other comprehensive loss Retained Earnings Accumulated Deficit Accumulated deficit Stockholders Equity Total stockholders' equity Liabilities And Stockholders Equity Total liabilities and stockholders' equity Preferred Stock Par Or Stated Value Per Share Preferred stock, par value Preferred Stock Shares Authorized Preferred stock, shares authorized Preferred Stock Shares Issued Preferred stock, shares issued Preferred Stock Shares Outstanding Preferred stock, shares outstanding Common Stock Par Or Stated Value Per Share Common stock, par value Common Stock Shares Authorized Common stock, shares authorized Common Stock Shares Issued Common stock, shares issued Common Stock Shares Outstanding Common stock, shares outstanding CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] Operating activities Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Share Based Compensation Share-based compensation expense Depreciation Depletion And Amortization Depreciation and amortization Accretion Amortization Of Discounts And Premiums Investments Amortization of premiums and discounts on available-for-sale securities Amortization Of Financing Costs Amortization of debt issuance costs Represents a loss on a legal settlement. Loss On Legal Settlement Legal settlement loss Increase (Decrease) in Income Taxes Deferred income taxes Increase Decrease In Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Inventories Inventory The net increase (decrease) during the reporting period in the amount of outstanding money paid in advance for research and development goods and services that bring economic benefits for future periods or in the amount of other research and development expenses incurred but not yet paid. Increase (decrease) relates to amounts paid in advance, or incurred and not yet paid, to contract research organizations, contract manufacturers or other research and development vendors. Increase Decrease In Prepaid And Accrued Research And Development Expenses Prepaid and accrued research and development expenses The carrying amount of the operating liabilities transferred to a third party to serve as a prepaid deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement. Increase Decrease In Deposit Deposit on inventory Increase Decrease In Other Operating Assets Other operating assets Increase Decrease In Accounts Payable Accounts payable Increase Decrease In Other Accrued Liabilities Other accrued expenses Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Investing activities Payments To Acquire Property Plant And Equipment Purchases of property and equipment The cash outflow in the form of deposits associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. Payments to Acquire Property, Plant, and Equipment , Deposits Deposits for purchases of property and equipment Payments To Acquire Available For Sale Securities Debt Purchases of available-for-sale securities Proceeds from Sale of Available-for-sale Securities, Debt Sales of available-for-sale securities The amount of acquired In process research and development milestone paid Acquired In Process Research And Development Milestone Paid Acquired in-process research and development - milestone payment Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Financing activities Proceeds From Issuance Of Common Stock Proceeds from the sale of common stock, net of issuance costs Proceeds from offering Proceeds From Convertible Debt Proceeds from the issuance of convertible senior notes, net of issuance costs Net proceeds from convertible senior notes Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options Proceeds from the exercise of stock options and employee stock purchases Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Effect of exchange rate changes on cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (Decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information: Interest Paid, Net Cash paid for interest Noncash Investing And Financing Items [Abstract] Non-cash investing and financing activities: The value of restricted stock units, that vested during the reporting period. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vesting of Restricted Stock Units, Value Vesting of restricted stock units Nature of Business and Basis of Presentation Business Description And Basis Of Presentation [Text Block] Nature of Business and Basis of Presentation Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Financial Instruments and Fair Value Measurements Fair Value Disclosures [Text Block] Financial Instruments and Fair Value Measurements Debt Securities, Available-for-sale [Abstract] Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block] Available-for-Sale Securities Inventories Inventory Disclosure [Text Block] Inventories Other Current Assets Other Current Assets [Text Block] Other Current Assets Intangible Assets and Goodwill Goodwill And Intangible Assets Disclosure [Text Block] Intangible Assets and Goodwill Other Accrued Expenses Accounts Payable And Accrued Liabilities Disclosure [Text Block] Other Accrued Expenses Convertible Senior Notes Long Term Debt [Text Block] Convertible Senior Notes Stockholders’ Equity Stockholders Equity Note Disclosure [Text Block] Stockholders' Equity Share-Based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Share-Based Compensation License Agreements License Agreements. License Agreements [Text Block] License Agreements Earnings Per Share [Text Block] Net Loss Per Common Share Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Commitments and Contingencies Basis Of Accounting Policy Policy [Text Block] Basis of Presentation Use Of Estimates Use of Estimates Liquidity. Liquidity Policy [Text Block] Liquidity Recently adopted accounting standards. Recently Adopted Accounting Standards Policy [Text Block] Recently Adopted Accounting Standards New Accounting Pronouncements Policy Policy [Text Block] Recently Issued Accounting Standards Revenue from Contract with Customer [Policy Text Block] Revenue Recognition Cost of Sales, Policy [Policy Text Block] Cost of Sales Debt Policy [Text Block] Convertible Senior Notes Reimbursement. Reimbursement Policy [Text Block] Lucitanib Earnings Per Share Policy [Text Block] Net Loss Per Common Share Revenue, Initial Application Period Cumulative Effect Transition [Table] Adjustments for New Accounting Pronouncements [Axis] Type Of Adoption [Member] Type of Adoption [Domain] Accounting Standards Update201409 [Member] ASU 2014-09 Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Revenue Recognition Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Schedule of new accounting pronouncements Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block] Assets Measured at Fair Value on Recurring Basis Schedule Of Available For Sale Securities Reconciliation Table [Text Block] Summary of Available-for-Sale Securities Investments Classified by Contractual Maturity Date [Table Text Block] Schedule of Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity Schedule of Inventory, Current [Table Text Block] Schedule of Inventories Schedule Of Other Current Assets Table [Text Block] Other Current Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Intangible assets related to capitalized milestones under license agreements Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Estimated future amortization expense for intangible assets Schedule of Goodwill [Table Text Block] Summary of Goodwill Schedule Of Accrued Liabilities Table [Text Block] Other Accrued Expenses Interest Income And Interest Expense Disclosure Table [Text Block] Schedule of Total Interest Expense Recognized Related to Notes Schedule Of Accumulated Other Comprehensive Income Loss Table [Text Block] Component of Other Comprehensive Income (Loss) Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Share-Based Compensation Expense Recognized in Accompanying Statements of Operations Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Summary of Stock Options Activity Disclosure Of Share Based Compensation Arrangements By Share Based Payment Award [Text Block] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block] Summary of activity related to our unvested RSUs Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Shares Outstanding Excluded from Calculation of Diluted Net Loss Per Share Range [Axis] EX-101.PRE 11 clvs-20180930_pre.xml EX-101.PRE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2018	Oct. 26, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q3
Trading Symbol	CLVS
Entity Registrant Name	Clovis Oncology, Inc.
Entity Central Index Key	0001466301
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		52,711,827
Entity Small Business	false
Entity Emerging Growth Company	false

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues:
Product revenue	$ 22,757	$ 16,806	$ 65,037	$ 38,471
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Operating expenses:
Cost of sales	$ 4,766		$ 13,262
Research and development	63,887	$ 38,924	160,138	$ 104,479
Selling, general and administrative	42,495	35,011	126,634	100,384
Total expenses	111,919	77,333	301,885	212,898
Operating loss	(89,162)	(60,527)	(236,848)	(174,427)
Other income (expense):
Interest expense	(3,376)	(2,618)	(9,592)	(7,796)
Foreign currency gain (loss)	151	(44)	(34)	(127)
Legal settlement loss			(7,975)	(117,000)
SEC settlement costs			(20,000)
Other income	2,536	1,291	5,419	2,237
Other expense, net	(689)	(1,371)	(32,182)	(122,686)
Loss before income taxes	(89,851)	(61,898)	(269,030)	(297,113)
Income tax (expense) benefit	(13)	1,234	280	2,599
Net loss	(89,864)	(60,664)	(268,750)	(294,514)
Other comprehensive income (loss):
Foreign currency translation adjustments, net of tax	(495)	1,595	(2,448)	4,874
Net unrealized (loss) gain on available-for-sale securities, net of tax	(10)	10	71	5
Other comprehensive (loss) income:	(505)	1,605	(2,377)	4,879
Comprehensive loss	$ (90,369)	$ (59,059)	$ (271,127)	$ (289,635)
Loss per basic and diluted common share:
Basic and diluted net loss per common share	$ (1.71)	$ (1.24)	$ (5.18)	$ (6.39)
Basic and diluted weighted average common shares outstanding	52,669	48,917	51,844	46,062
Intangible asset amortization
Operating expenses:
Cost of sales	$ 771	$ 372	$ 1,851	$ 1,115
Product
Operating expenses:
Cost of sales	$ 4,766	$ 3,026	$ 13,262	$ 6,920

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 290,853	$ 464,198
Accounts receivable, net	14,495	6,181
Inventories	43,682	27,508
Available-for-sale securities	313,525	99,533
Prepaid research and development expenses	2,907	1,559
Deposit on inventory	13,514	20,461
Other current assets	11,780	7,500
Total current assets	690,756	626,940
Inventories	20,005
Deposit on inventory	31,119	0
Property and equipment, net	11,035	4,007
Intangible assets, net	52,709	19,561
Goodwill	63,074	65,217
Other assets	22,766	19,505
Total assets	891,464	735,230
Current liabilities:
Accounts payable	30,501	15,147
Accrued research and development expenses	21,259	18,465
Milestone liability	0	22,022
Other accrued expenses	24,732	25,883
Total current liabilities	76,492	81,517
Convertible senior notes	574,828	282,406
Deferred rent, long-term	6,478	3,671
Total liabilities	657,798	367,594
Commitments and contingencies (Note 14)
Stockholders' equity:
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized, no shares issued and outstanding at September 30, 2018 and December 31, 2017
Common stock, $0.001 par value per share, 100,000,000 shares authorized at September 30, 2018 and December 31, 2017; 52,708,767 and 50,565,119 shares issued and outstanding at September 30, 2018 and December 31, 2017 respectively	53	51
Additional paid-in capital	2,021,997	1,887,198
Accumulated other comprehensive loss	(44,550)	(42,173)
Accumulated deficit	(1,743,834)	(1,477,440)
Total stockholders' equity	233,666	367,636
Total liabilities and stockholders' equity	$ 891,464	$ 735,230

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
CONSOLIDATED BALANCE SHEETS
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	52,708,767	50,565,119
Common stock, shares outstanding	52,708,767	50,565,119

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Operating activities
Net loss	$ (268,750)	$ (294,514)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	37,715	32,201
Depreciation and amortization	2,497	1,911
Amortization of premiums and discounts on available-for-sale securities	1,079	6
Amortization of debt issuance costs	1,536	956
Legal settlement loss		117,000
Deferred income taxes		(2,403)
Changes in operating assets and liabilities:
Accounts receivable	(4,978)	121
Inventory	(25,540)	(5,345)
Prepaid and accrued research and development expenses	1,390	(16,284)
Deposit on inventory	(24,173)	(31,818)
Other operating assets	(7,507)	(4,156)
Accounts payable	4,765	5,050
Other accrued expenses	(1,304)	1,949
Net cash used in operating activities	(283,270)	(195,326)
Investing activities
Purchases of property and equipment	(7,763)	(416)
Deposits for purchases of property and equipment	0	(2,515)
Purchases of available-for-sale securities	(320,000)	(180,000)
Sales of available-for-sale securities	105,000	213,500
Acquired in-process research and development - milestone payment	(55,000)	(1,100)
Net cash used in investing activities	(277,763)	29,469
Financing activities
Proceeds from the sale of common stock, net of issuance costs	93,890	545,838
Proceeds from the issuance of convertible senior notes, net of issuance costs	290,887	0
Proceeds from the exercise of stock options and employee stock purchases	3,197	14,419
Net cash provided by financing activities	387,974	560,257
Effect of exchange rate changes on cash and cash equivalents	(286)	886
(Decrease) increase in cash and cash equivalents	(173,345)	395,286
Cash and cash equivalents at beginning of period	464,198	216,186
Cash and cash equivalents at end of period	290,853	611,472
Supplemental disclosure of cash flow information:
Cash paid for interest	9,188	7,188
Non-cash investing and financing activities:
Vesting of restricted stock units	$ 10,130	$ 9,449

XML 17 R6.htm IDEA: XBRL DOCUMENT

Nature of Business and Basis of Presentation	9 Months Ended
Nature of Business and Basis of Presentation	Sep. 30, 2018
Nature of Business and Basis of Presentation
Nature of Business and Basis of Presentation	1. Nature of Business and Basis of Presentation Clovis Oncology, Inc. (together with its consolidated subsidiaries, the “Company”, “Clovis”, “we”, “our”, “us”) is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. We target our development programs for the treatment of specific subsets of cancer populations, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. We have and intend to continue to license or acquire rights to oncology compounds in all stages of clinical development. In exchange for the right to develop and commercialize these compounds, we generally expect to provide the licensor with a combination of upfront payments, milestone payments and royalties on future sales. In addition, we generally expect to assume the responsibility for future drug development and commercialization costs. We currently operate in one segment. Since inception, our operations have consisted primarily of developing in-licensed compounds, evaluating new product acquisition candidates and general corporate activities and since 2016 we have also marketed and sold products. Our marketed product Rubraca® (rucaparib) is approved in the United States by the Food and Drug Administration (“FDA”) for two indications, encompassing two settings for the treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The initial treatment indication received in December 2016 covers the treatment of adult patients with deleterious BRCA (human genes associated with the repair of damaged DNA) mutation (germline and/or somatic) epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. In April 2018, the FDA also approved Rubraca for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. The FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Diagnostic testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication. In May 2018, the European Commission granted a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. As this is a conditional approval, it will be necessary to complete confirmatory post marketing commitments, including ensuring that sufficient partially platinum sensitive patients are enrolled in our ARIEL4 confirmatory trial to support the indication. This may require enrollment of additional patients into the study, increasing its overall size and extending the time for enrollment. In June 2018, we submitted to the European Union’s European Medicines Agency (“EMA”) a variation to the marketing authorization for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy, for which we received EMA validation for this application in July 2018. We anticipate an opinion on this application from the Committee for Medicinal Products for Human Use (“CHMP”) of the EMA by the end of 2018, with a potential formal European Commission approval in early 2019. Beyond our initial labeled indication, we have a robust Rubraca clinical development program underway in a variety of solid tumor types, also including prostate and bladder cancers, and in July 2017, we entered into a broad clinical collaboration with Bristol-Myers Squibb Company to evaluate the combination of their immunotherapy OPDIVO® (nivolumab) with Rubraca in several tumor types. We hold worldwide rights for Rubraca. In October 2018, the FDA granted breakthrough therapy designation for Rubraca as a monotherapy treatment of adult patients with BRCA1/2-mutated metastatic castration resistant prostate cancer (mCRPC) who have received at least one prior androgen receptor (AR)-directed therapy and taxane-based chemotherapy. In addition to Rubraca, we have two other product candidates. Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFR α/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3). Lucitanib was originally developed by Clovis and Servier with the hypothesis of activity in FGFR driven tumors; however, data in breast and lung cancer were insufficient to move that program forward. We received notice from Servier of termination of their rights to lucitanib, resulting in the return of global rights (excluding China) for lucitanib to us during October 2018. We believe that recent data for a drug similar to lucitanib that inhibits these same pathways – when combined with a PD-1 inhibitor – provide support for development of lucitanib in combination with a PD-(L)1 inhibitor, and we intend to initiate a study of the combination. We also intend to initiate a study of lucitanib in combination with Rubraca, based on encouraging data of VEGF and PARP inhibitors in combination. Each of these studies is expected to initiate in the first quarter of 2019. We maintain certain development and commercialization rights for lucitanib. Because of termination of the Servier license agreement, we have global development and commercialization rights (except for China) for lucitanib. Rociletinib is an oral mutant-selective inhibitor of epidermal growth factor receptor (“EGFR”). While we have stopped enrollment in ongoing trials for rociletinib, we continue to provide drug to patients whose clinicians recommend continuing therapy. We have global development and commercialization rights for rociletinib. Basis of Presentation All financial information presented includes the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments that, in the opinion of management, are necessary to fairly state our financial position, results of operations and cash flows for the periods presented herein. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, 2017 (“2017 Form 10-K”) for a broader discussion of our business and the opportunities and risks inherent in such business. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and revenue and related disclosures. On an ongoing basis, we evaluate our estimates, including estimates related to revenue deductions, intangible asset impairment, clinical trial accruals and share-based compensation expense. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. Liquidity We have incurred significant net losses since inception and have relied on our ability to fund our operations through debt and equity financings. We expect operating losses and negative cash flows to continue for the foreseeable future. As we continue to incur losses, transition to profitability is dependent upon achieving a level of revenues from Rubraca adequate to support our cost structure. We may never achieve profitability, and unless or until we do, we will continue to need to raise additional cash. In April 2018, we sold 1,837,898 shares of our common stock in a public offering at $54.41 per share. The net proceeds from the offering were $93.9 million, after deducting underwriting discounts and commissions and offering expenses. Concurrently, we completed the public offering of $300.0 million aggregate principal amount of 1.25% convertible senior notes due 2025. The net proceeds from this offering were $290.9 million, after deducting underwriting discounts and commissions and offering expenses. We intend to use the net proceeds of the offerings for general corporate purposes, including sales and marketing expenses associated with Rubraca in the United States and Europe, funding of our development programs, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. Based on current estimates, we believe that our existing cash, cash equivalents and available-for-sale securities will allow us to fund our operating plan through at least the next 12 months.

XML 18 R7.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2018

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Recently Adopted Accounting Standards

The cumulative effect of the changes made to our consolidated January 1, 2018 balance sheet for the adoption of ASC 606 was as follows (in thousands):


	Balance at		Adjustments due to		Balance at
	December 31, 2017		Adoption of ASC 606		January 1, 2018
ASSETS
Accounts receivable, net	$	6,181	$	3,336	$	9,517
Inventories	$	27,508		(62)	$	27,446
Total assets	$	735,230	$	3,274	$	738,504

LIABILITIES AND STOCKHOLDERS' EQUITY
Other accrued expenses	$	25,883	$	918	$	26,801
Accumulated deficit	$	(1,477,440)		2,356	$	(1,475,084)
Total liabilities and stockholders' equity	$	735,230	$	3,274	$	738,504

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except for per share amounts)


	Three months ended September 30, 2018
			Balances without		Effect of Change
	As reported		Adoption of ASC 606		Higher/(Lower)
Product revenue	$	22,757	$	25,213	$	(2,456)
Cost of sales - product	$	4,766	$	5,158	$	392
Selling, general and administrative	$	42,495	$	42,689	$	194
Net loss	$	(89,864)	$	(87,994)	$	(1,870)

Loss per basic and diluted common share:
Basic and diluted net loss per common share	$	(1.71)	$	(1.67)	$	(0.04)


	Nine months ended September 30, 2018
			Balances without		Effect of Change
	As reported		Adoption of ASC 606		Higher/(Lower)
Product revenue	$	65,037	$	63,541	$	1,496
Cost of sales - product	$	13,262	$	12,697	$	(565)
Selling, general and administrative	$	126,634	$	126,602	$	(32)
Net loss	$	(268,750)	$	(269,648)	$	898

Loss per basic and diluted common share:
Basic and diluted net loss per common share	$	(5.18)	$	(5.20)	$	0.02

CONSOLIDATED BALANCE SHEET

(In thousands)


	September 30, 2018
			Balances without		Effect of Change
	As reported		Adoption of ASC 606		Higher/(Lower)
ASSETS
Accounts receivable, net	$	14,495	$	12,907	$	1,588
Inventories	$	63,687	$	63,992	$	(305)

LIABILITIES AND STOCKHOLDERS' EQUITY
Other accrued expenses	$	24,732	$	24,347	$	385
Accumulated deficit	$	(1,743,834)	$	(1,744,732)	$	898

Recently Issued Accounting Standards

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”, which requires lessees to recognize assets and liabilities for the rights and obligations created by most leases on their balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. ASU 2016-02 requires modified retrospective adoption for all leases existing at, or entered after, the date of initial application, with an option to use certain transition relief. We will adopt ASU 2016-02 as of January 1, 2019 using the effective date method which leaves the comparative period reporting unchanged. Comparative reporting periods are presented in accordance with Topic 840, while periods subsequent to the effective date are presented in accordance with Topic 842. We expect to recognize substantially all our leases on the balance sheet by recording a right-of-use asset and corresponding lease liability. We are currently evaluating the impact the standard may have on our consolidated financial statements and related disclosures.

Revenue Recognition

Product Revenue

Reserves for Variable Consideration

Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from rebates, chargebacks, discounts, co-pay assistance, estimated product returns and other allowances that are offered within contracts between us and our customers, health care providers, payors and other indirect customers relating to the sales of our product. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customers) or a current liability (if the amount is payable to a party other than a customer). Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known.

Cost of Sales – Product

Product cost of sales consists primarily of materials, third-party manufacturing costs as well as freight and royalties owed to our licensing partners for Rubraca sales.

Cost of Sales – Intangible Asset Amortization

Inventory

Our other significant accounting policies are described in Note 2, Summary of Significant Accounting Policies of the Notes to the Consolidated Financial Statements included in our 2017 Form 10-K.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Financial Instruments and Fair Value Measurements

9 Months Ended

Sep. 30, 2018

Financial Instruments and Fair Value Measurements

Financial Instruments and Fair Value Measurements

3. Financial Instruments and Fair Value Measurements

The three levels of inputs that may be used to measure fair value include:

Level 1:	Quoted prices in active markets for identical assets or liabilities. Our Level 1 assets consist of money market investments. We do not have Level 1 liabilities.

Level 2:	Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Our Level 2 assets consist of U.S. treasury securities. We do not have Level 2 liabilities.

Level 3:	Unobservable inputs that are supported by little or no market activity. We do not have Level 3 assets or liabilities that are measured at fair value on a recurring basis.

The following table identifies our assets and liabilities that were measured at fair value on a recurring basis (in thousands):


	Balance		Level 1		Level 2		Level 3
September 30, 2018
Assets:
Money market	$	255,143	$	255,143	$	—	$	—
U.S. treasury securities		313,525		—		313,525		—
Total assets at fair value	$	568,668	$	255,143	$	313,525	$	—
December 31, 2017
Assets:
Money market	$	433,136	$	433,136	$	—	$	—
U.S. treasury securities		99,533		—		99,533		—
Total assets at fair value	$	532,669	$	433,136	$	99,533	$	—

There were no transfers between the Level 1 and Level 2 categories or into or out of the Level 3 category during the three and nine months ended September 30, 2018.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 20 R9.htm IDEA: XBRL DOCUMENT

Available-for-Sale Securities

9 Months Ended

Sep. 30, 2018

Debt Securities, Available-for-sale [Abstract]

Available-for-Sale Securities

4. Available-for-Sale Securities

As of September 30, 2018, available-for-sale securities consisted of the following (in thousands):


			Gross		Gross		Aggregate
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
U.S. treasury securities	$	313,570	$	—	$	(45)	$	313,525

As of December 31, 2017, available-for-sale securities consisted of the following (in thousands):


			Gross		Gross		Aggregate
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
U.S. treasury securities	$	99,650	$	—	$	(117)	$	99,533

As of September 30, 2018, the amortized cost and fair value of available-for-sale securities by contractual maturity were (in thousands):


	Amortized		Fair
	Cost		Value
Due in one year or less	$	313,570	$	313,525
Due in one year to two years		—		—
Total	$	313,570	$	313,525

XML 21 R10.htm IDEA: XBRL DOCUMENT

Inventories

9 Months Ended

Sep. 30, 2018

Inventories

Inventories

5. Inventories

The following table presents current and long-term inventories as of September 30, 2018 and December 31, 2017:


	September 30,		December 31,
	2018		2017
Work-in-process	$	51,707	$	24,721
Finished goods		11,980		2,787
Total inventories	$	63,687	$	27,508

Some of the costs related to our finished goods on-hand as of September 30, 2018 were expensed as incurred prior to the commercialization of Rubraca on December 19, 2016.

XML 22 R11.htm IDEA: XBRL DOCUMENT

Other Current Assets

9 Months Ended

Sep. 30, 2018

Other Current Assets

Other Current Assets

6. Other Current Assets

Other current assets were comprised of the following (in thousands):


	September 30,		December 31,
	2018		2017
Prepaid insurance	$	752	$	1,926
Prepaid expenses - other		7,031		3,355
Receivable - other		3,741		2,023
Other		256		196
Total	$	11,780	$	7,500

XML 23 R12.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill

9 Months Ended

Sep. 30, 2018

Intangible Assets and Goodwill

Intangible Assets and Goodwill

7. Intangible Assets and Goodwill

Intangible assets related to capitalized milestones under license agreements consisted of the following (in thousands):


	September 30,		December 31,
	2018		2017
Intangible asset - milestones	$	56,100	$	21,100
Accumulated amortization		(3,391)		(1,539)
Total intangible asset, net	$	52,709	$	19,561

The estimated useful lives of these intangible assets are based on the estimated remaining patent life of Rubraca and extend through 2035.

Estimated future amortization expense associated with intangibles is expected to be as follows (in thousands):


2018	$	779
2019		3,116
2020		3,116
2021		3,116
2022		3,116
Thereafter		39,466
	$	52,709

The change in goodwill established as part of the purchase accounting of EOS in November 2013 consisted of the following (in thousands):


Balance at December 31, 2017	$	65,217
Change in foreign currency gains and losses		(2,143)
Balance at September 30, 2018	$	63,074

XML 24 R13.htm IDEA: XBRL DOCUMENT

Other Accrued Expenses

9 Months Ended

Sep. 30, 2018

Other Accrued Expenses

Other Accrued Expenses

8. Other Accrued Expenses

Other accrued expenses were comprised of the following (in thousands):


	September 30,		December 31,
	2018		2017
Accrued personnel costs	$	14,217	$	13,889
Accrued interest payable		—		2,096
Income tax payable		186		—
Accrued corporate legal fees and professional services		731		415
Accrued royalties		4,187		2,984
Accrued variable considerations		2,407		1,008
Payable to third party logistics provider		14		2,661
Accrued expenses - other		2,990		2,830
Total	$	24,732	$	25,883

XML 25 R14.htm IDEA: XBRL DOCUMENT

Convertible Senior Notes

9 Months Ended

Sep. 30, 2018

Convertible Senior Notes

Convertible Senior Notes

9. Convertible Senior Notes

2021 Notes

In connection with the issuance of the 2021 Notes, we incurred $9.2 million of debt issuance costs. The debt issuance costs are presented as a deduction from the convertible senior notes on the Consolidated Balance Sheets and are amortized as interest expense over the expected life of the 2021 Notes using the effective interest method. We determined the expected life of the debt was equal to the seven-year term of the 2021 Notes.

2025 Notes

As of September 30, 2018 and December 31, 2017, the balance of unamortized debt issuance costs was $12.7 million and $5.1 million, respectively.

The following table sets forth total interest expense recognized during the three and nine months ended September 30, 2018 and 2017 (in thousands):


	Three months ended September 30,				Nine months ended September 30,
	2018		2017		2018		2017
Contractual interest expense	$	2,735	$	1,797	$	7,078	$	5,391
Accretion of interest on milestone liability		—		500		978		1,449
Amortization of debt issuance costs		641		321		1,536		956
Total interest expense	$	3,376	$	2,618	$	9,592	$	7,796

XML 26 R15.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Sep. 30, 2018

Stockholders’ Equity

Stockholders' Equity

10. Stockholders’ Equity

Common Stock

Accumulated Other Comprehensive Loss

The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the three months ended September 30, 2018 and 2017, as follows (in thousands):


	Foreign Currency				Unrealized				Total Accumulated
	Translation Adjustments				(Losses) Gains				Other Comprehensive Loss
	2018		2017		2018		2017		2018		2017
Balance at July 1,	$	(43,870)	$	(44,155)	$	(175)	$	(151)	$	(44,045)	$	(44,306)
Other comprehensive income (loss)		(495)		2,510		(10)		15		(505)		2,525
Total before tax		(44,365)		(41,645)		(185)		(136)		(44,550)		(41,781)
Tax effect		—		(915)		—		(5)		—		(920)
Balance at September 30,	$	(44,365)	$	(42,560)	$	(185)	$	(141)	$	(44,550)	$	(42,701)

The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the nine months ended September 30, 2018 and 2017, as follows (in thousands):


	Foreign Currency				Unrealized				Total Accumulated
	Translation Adjustments				(Losses) Gains				Other Comprehensive Loss
	2018		2017		2018		2017		2018		2017
Balance at January 1,	$	(41,917)	$	(47,434)	$	(256)	$	(146)	$	(42,173)	$	(47,580)
Other comprehensive income (loss)		(2,448)		7,695		71		8		(2,377)		7,703
Total before tax		(44,365)		(39,739)		(185)		(138)		(44,550)		(39,877)
Tax effect		—		(2,821)		—		(3)		—		(2,824)
Balance at September 30,	$	(44,365)	$	(42,560)	$	(185)	$	(141)	$	(44,550)	$	(42,701)

XML 27 R16.htm IDEA: XBRL DOCUMENT

Share-Based Compensation

9 Months Ended

Sep. 30, 2018

Share-Based Compensation

Share-Based Compensation

11. Share-Based Compensation


	Three months ended September 30,				Nine months ended September 30,
	2018		2017		2018		2017
Research and development	$	5,038	$	5,636	$	15,380	$	14,628
Selling, general and administrative		5,909		7,001		22,335		17,573
Total share-based compensation expense	$	10,947	$	12,637	$	37,715	$	32,201

Stock Options

The following table summarizes the activity relating to our options to purchase common stock for the nine months ended September 30, 2018:


				Weighted
		Weighted		Average	Aggregate
		Average		Remaining	Intrinsic
	Number of	Exercise		Contractual	Value
	Options	Price		Term (Years)	(Thousands)
Outstanding at December 31, 2017	5,789,735	$	46.77
Granted	639,793		52.33
Exercised	(70,480)		25.82
Forfeited	(217,007)		60.47
Outstanding at September 30, 2018	6,142,041	$	47.11	6.6	$	24,884
Vested and expected to vest at September 30, 2018	5,919,341	$	47.00	6.5	$	24,555
Vested and exercisable at September 30, 2018	4,284,706	$	45.70	5.8	$	21,421

The following table summarizes information about our stock options as of and for the three and nine months ended September 30, 2018 and 2017 (in thousands, except per share amounts):


	Three months ended September 30,				Nine months ended September 30,
	2018		2017		2018		2017
Weighted-average grant date fair value per share	$	28.97	$	60.81	$	38.52	$	48.39
Intrinsic value of options exercised	$	325	$	3,400	$	1,697	$	17,684
Cash received from stock option exercises	$	604	$	2,149	$	1,820	$	13,262

Restricted Stock

The following table summarizes the activity relating to our unvested restricted stock units (“RSUs”) for the nine months ended September 30, 2018:



		Weighted
		Average
	Number of	Grant Date
	Units	Fair Value
Unvested at December 31, 2017	589,529	$	41.67
Granted	479,255		55.05
Vested	(199,602)		40.43
Forfeited	(44,686)		46.65
Unvested as of September 30, 2018	824,496	$	49.48
Expected to vest after September 30, 2018	706,795	$	49.25

XML 28 R17.htm IDEA: XBRL DOCUMENT

License Agreements	9 Months Ended
License Agreements	Sep. 30, 2018
License Agreements
License Agreements	12. License Agreements Rucaparib In June 2011, we entered into a worldwide license agreement with Pfizer, Inc. to obtain exclusive global rights to develop and commercialize rucaparib, a small molecule inhibitor of poly (ADP-ribose) polymerase (“PARP”), used for the treatment of selected solid tumors. The exclusive rights are exclusive even as to Pfizer and include the right to grant sublicenses. Pursuant to the terms of the license agreement, we made a $7.0 million upfront payment to Pfizer and are required to make additional payments to Pfizer for the achievement of certain development and regulatory and sales milestones and royalties on sales as required by the license agreement. Prior to the FDA approval of rucaparib, discussed below, we made milestone payments of $1.4 million, which were recognized as acquired in-process research and development expense. On August 30, 2016, we entered into a first amendment to the worldwide license agreement with Pfizer, which amends the June 2011 existing worldwide license agreement to permit us to defer payment of the milestone payments payable upon (i) FDA approval of an NDA for 1st Indication in US and (ii) EMA approval of an MAA for 1st Indication in EU, to a date that is 18 months after the date of achievement of such milestones. On December 19, 2016, the FDA approved Rubraca (rucaparib) tablets as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. The FDA approval resulted in a $0.75 million milestone payment to Pfizer as required by the license agreement, which was made in the first quarter of 2017. The FDA approval also resulted in the obligation to pay a $20.0 million milestone payment, for which we exercised the option to defer payment by agreeing to pay $23.0 million within 18 months after the date of the FDA approval. We paid the $23.0 million milestone payment in June 2018. On April 6, 2018, the FDA approved our sNDA for Rubraca as maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. This approval resulted in the obligation to pay a $15.0 million milestone payment, which we paid in April 2018. In May 2018, the European Commission granted a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. This approval resulted in the obligation to pay a $20.0 million milestone payment, which we paid in June 2018. These milestone payments were recognized as intangible assets and will be amortized over the estimated remaining useful life of Rubraca. We are obligated under the license agreement to use commercially reasonable efforts to develop and commercialize rucaparib and we are responsible for all remaining development and commercialization costs for rucaparib. We are required to make regulatory milestone payments to Pfizer of up to an additional $31.75 million in aggregate if specified clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, we are obligated to make sales milestone payments to Pfizer if specified annual sales targets for rucaparib are met, which relate to annual sales targets of $250.0 million and above, which, in the aggregate, could amount to total milestone payments of $170.0 million, and tiered royalty payments at a mid-teen percentage rate on our net sales, with standard provisions for royalty offsets to the extent we need to obtain any rights from third parties to commercialize rucaparib. In April 2012, we entered into a license agreement with AstraZeneca UK Limited to acquire exclusive rights associated with rucaparib under a family of patents and patent applications that claim methods of treating patients with PARP inhibitors in certain indications. The license enables the development and commercialization of rucaparib for the uses claimed by these patents. AstraZeneca receives royalties on any net sales of rucaparib. Lucitanib In connection with our acquisition of EOS in November 2013, we gained rights to develop and commercialize lucitanib, an oral, selective tyrosine kinase inhibitor. As further described below, EOS licensed the worldwide rights, excluding China, to develop and commercialize lucitanib from Advenchen Laboratories LLC (“Advenchen”). Subsequently, rights to develop and commercialize lucitanib in markets outside the U.S. and Japan were sublicensed by EOS to Servier in exchange for upfront milestone fees, royalties on sales of lucitanib in the sublicensed territories and research and development funding commitments. In October 2008, EOS entered into an exclusive license agreement with Advenchen to develop and commercialize lucitanib on a global basis, excluding China. We are obligated to pay Advenchen tiered royalties at percentage rates in the mid-single digits on net sales of lucitanib, based on the volume of annual net sales achieved. In addition, after giving effect to the first and second amendments to the license agreement, we are required to pay to Advenchen 25% of any consideration, excluding royalties, received pursuant to any sublicense agreements for lucitanib, including the agreement with Servier. We are obligated under the agreement to use commercially reasonable efforts to develop and commercialize at least one product candidate containing lucitanib, and we are also responsible for all remaining development and commercialization costs for lucitanib. The license agreement with Advenchen will remain in effect until the expiration of all our royalty obligations to Advenchen, determined on a product-by-product and country-by-country basis, unless we elect to terminate the agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, Advenchen can terminate the agreement, resulting in a loss of our rights to lucitanib. During 2017, we completed the committed on-going development activities related to lucitanib and received full reimbursement of our development costs from Servier. Reimbursements are recorded as a reduction to research and development expense on the Consolidated Statements of Operations. Lucitanib was originally developed by Clovis and Servier with the hypothesis of activity in FGFR driven tumors; however, data in breast and lung cancer were insufficient to move the program forward. We received notice from Servier of termination of their rights to lucitanib, resulting in the return of global rights (excluding China) for lucitanib to us during October 2018. We are party to a product license agreement for our other drug candidate rociletinib (see our 2017 Form 10-K for additional details).

XML 29 R18.htm IDEA: XBRL DOCUMENT

Net Loss Per Common Share

9 Months Ended

Sep. 30, 2018

Net Loss Per Common Share

Net Loss Per Common Share

13. Net Loss Per Common Share


	Three and Nine months ended September 30,
	2018	2017
Common shares under option	3,381	5,696
Convertible senior notes	8,584	4,646
Total potential dilutive shares	11,965	10,342

XML 30 R19.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2018
Commitments and Contingencies
Commitments and Contingencies	14. Commitments and Contingencies Royalty and License Fee Commitments We have entered into certain license agreements, as identified in Note 12, License Agreements, with third parties that include the payment of development and regulatory milestones, as well as royalty payments, upon the achievement of pre-established development, regulatory and commercial targets. Our payment obligation related to these license agreements is contingent upon the successful development, regulatory approval and commercialization of the licensed products. Due to the nature of these arrangements, the future potential payments are inherently uncertain, and accordingly, we only recognize payment obligations which are probable and estimable as of the balance sheet date. Milestone liabilities of $0.0 million and $22.0 million are recorded on our Consolidated Balance Sheets at September 30, 2018 and December 31, 2017, respectively, and relate to milestone payments for the licensing of our rucaparib product, which was approved by the FDA on December 19, 2016. Manufacture and Services Agreement Commitments On October 3, 2016, we entered into a Manufacturing and Services Agreement (the “Agreement”) with a non-exclusive third-party supplier for the production of the active ingredient for Rubraca. Under the terms of the Agreement, we will provide the third-party supplier a rolling forecast for the supply of the active ingredient in Rubraca that will be updated by us on a quarterly basis. We are obligated to order material sufficient to satisfy an initial quantity specified in any forecast. In addition, the third-party supplier will construct, in its existing facility, a production train that will be exclusively dedicated to the manufacture of the Rubraca active ingredient. We are obligated to make scheduled capital program fee payments toward capital equipment and other costs associated with the construction of the dedicated production train. Further, once the facility is operational, we are obligated to pay a fixed facility fee each quarter for the duration of the Agreement, which expires on December 31, 2025, unless extended by mutual consent of the parties. As of September 30, 2018, $165.1 million of purchase commitments exist under the Agreement. Legal Proceedings We and certain of our officers were named as defendants in several lawsuits, as described below. We cannot reasonably predict the outcome of these legal proceedings, nor can we estimate the amount of loss or range of loss, if any, that may result. An adverse outcome in these proceedings could have a material adverse effect on our results of operations, cash flows or financial condition. Rociletinib-Related Litigation Following Clovis’ regulatory announcement in November 2015 of adverse developments in its ongoing clinical trials for rociletinib, Clovis and certain of its current and former executives were named in various securities lawsuits, the largest of which was a putative class action lawsuit in the District of Colorado (the “Medina Action”) which was settled on October 26, 2017 (the “Medina Settlement”). The open actions currently pending against Clovis are discussed below. On November 10, 2016, Antipodean Domestic Partners (“Antipodean”) filed a complaint (the “Antipodean Complaint”) against Clovis and certain of its officers, directors and underwriters in New York Supreme Court, County of New York. The Antipodean Complaint alleges that the defendants violated certain sections of the Securities Act by making allegedly false statements to Antipodean and in the offering materials for the July 2015 Offering relating to the efficacy of rociletinib, its safety profile, and its prospects for market success. In addition to the Securities Act claims, the Antipodean Complaint also asserts Colorado state law claims and common law claims. Both the state law and common law claims are based on allegedly false and misleading statements regarding rociletinib’s progress toward FDA approval. The Antipodean Complaint seeks compensatory, recessionary, and punitive damages. On December 15, 2016, the Antipodean Plaintiffs filed an amended complaint (the “Antipodean Amended Complaint”) asserting substantially the same claims against the same defendants and purporting to correct certain details in the original Antipodean Complaint. Following a stay that Justice Masley of the New York Supreme Court, County of New York entered in favor of the Medina Action and briefing on defendants’ motions to dismiss, the parties participated in a Preliminary Conference on April 17, 2018, following which the Court entered a preliminary conference order, providing deadlines for document productions, depositions, and other discovery. The Court has scheduled a status conference for January 21, 2019, following which the Court anticipates setting an end date for discovery. On May 2, 2018, the Court issued an order denying the defendants’ motion to dismiss. Defendants filed an answer to the Antipodean Amended Complaint on June 6, 2018. The Company intends to vigorously defend against the allegations in the Antipodean Amended Complaint. However, there can be no assurance that the defense will be successful. In March 2017, two putative shareholders of the Company, Macalinao and McKenry (the “Derivative Plaintiffs”), filed shareholder derivative complaints against certain directors and officers of the Company in the Court of Chancery of the State of Delaware. On May 4, 2017, the Macalinao and McKenry actions were consolidated for all purposes in a single proceeding under the caption In re Clovis Oncology, Inc. Derivative Litigation, Case No, 2017-0222 (the “Consolidated Derivative Action”). On May 18, 2017, the Derivative Plaintiffs filed a Consolidated Verified Shareholder Derivative Complaint (the “Consolidated Derivative Complaint”). The Consolidated Derivative Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by allegedly causing or allowing misrepresentations of the Company’s business operations and prospects, failing to ensure that the TIGER-X clinical trial was being conducted in accordance with applicable rules, regulations and protocols, and engaging in insider trading. The Consolidated Derivative Complaint purported to rely on documents produced by the Company in response to prior demands for inspection of the Company’s books and records served on the Company by each of Macalinao and McKenry under 8 Del. C. § 220. The Consolidated Derivative Complaint sought, among other things, an award of money damages. On July 31, 2017, the defendants filed a motion to dismiss the Consolidated Derivative Complaint. Plaintiffs filed an opposition to the motion to dismiss on August 31, 2017, and the defendants filed a reply in further support of the motion to dismiss on September 26, 2017. Oral argument on the defendants’ motion to dismiss the Consolidated Derivative Complaint has been scheduled for February 4, 2019. The Company intends to vigorously defend against the allegations in the Consolidated Derivative Complaint, but there can be no assurance that the defense will be successful. On March 20, 2017, a purported shareholder of the Company, filed a shareholder derivative complaint (the “Guo Complaint”) against certain officers and directors of the Company in the United States District Court for the District of Colorado. The Guo Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by either recklessly or with gross negligence approving or permitting misrepresentations of the Company’s business operations and prospects. The Guo Complaint also alleged claims for waste of corporate assets and unjust enrichment. Finally, the Guo Complaint alleged that certain of the individual defendants violated Section 14(a) of the Securities Exchange Act, by allegedly negligently issuing, causing to be issued, and participating in the issuance of materially misleading statements to stockholders in the Company’s Proxy Statement on Schedule DEF 14A in connection with the 2015 Annual Meeting of Stockholders, held on June 11, 2015. The Guo Complaint sought, among other things, an award of money damages. On June 19, 2017, the parties filed a joint motion to stay the Guo action pending resolution of the motion to dismiss the Consolidated Derivative Complaint. On June 20, 2017, the court granted the motion to stay. The Company intends to vigorously defend against the allegations in the Guo Complaint, but there can be no assurance that the defense will be successful. As previously disclosed, the Company has received inquiries and requests for information from governmental agencies, including the U.S. Securities and Exchange Commission (“SEC”) and the U.S. Department of Justice, relating to the Company’s regulatory update announcement in November 2015 that the FDA requested additional clinical data on the efficacy and safety of rociletinib. Earlier this year, the Company and Mr. Mahaffy engaged in discussions with the SEC staff to resolve this matter. On September 18, 2018, the SEC announced it had reached an agreement with the Company to settle this matter on negligence-based charges. Pursuant to the settlement, without admitting or denying the SEC’s allegations, the Company paid a $20.0 million civil penalty, which the Company reserved as a loss contingency on its consolidated balance sheet as of June 30, 2018, and stipulated to a standard injunction against future violations of those provisions of the federal securities laws. Also, on September 18, 2018, the SEC announced that Mr. Mahaffy also reached a settlement with the SEC on similar negligence-based allegations, to which he neither admits nor denies, and paid a civil penalty and will be similarly enjoined. Mr. Mahaffy will continue to serve as the Company’s Chief Executive Officer and as a member of the Company’s Board of Directors. The settlements do not allege that the Company or any of its current or former officers engaged in any intentional fraud or misconduct. The settlements were approved by the United States District Court for the District of Colorado on September 19, 2018 and resolve the SEC’s nearly three year investigation into the regulatory approval process of rociletinib. European Patent Opposition Two oppositions were filed in the granted European counterpart of the rucaparib camsylate salt/polymorph patent on June 20, 2017. The grounds of opposition related to Rubraca were lack of novelty and lack of inventive step. A preliminary opinion and summons to oral proceedings were issued on April 4, 2018. The oral hearing is scheduled for December 4, 2018. The preliminary opinion provides a non-binding indication of the tribunal’s view. In the preliminary opinion, the tribunal agreed with some of our positions and agreed with certain objections made by the opponents. As part of the proceeding, we have the opportunity to submit further arguments and pursue alternative claims in the form of auxiliary requests. On October 3, 2018, we submitted further arguments and auxiliary requests and on October 4, 2018, both opponents submitted further arguments. While the ultimate results of patent challenges can be difficult to predict, we believe a number of factors, including a constellation of unexpected properties, support the novelty and non-obviousness of our rucaparib camsylate salt/polymorph composition of matter patent.

XML 31 R20.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2018

Summary of Significant Accounting Policies

Basis of Presentation

Use of Estimates

Liquidity

Recently Adopted Accounting Standards

The cumulative effect of the changes made to our consolidated January 1, 2018 balance sheet for the adoption of ASC 606 was as follows (in thousands):


	Balance at		Adjustments due to		Balance at
	December 31, 2017		Adoption of ASC 606		January 1, 2018
ASSETS
Accounts receivable, net	$	6,181	$	3,336	$	9,517
Inventories	$	27,508		(62)	$	27,446
Total assets	$	735,230	$	3,274	$	738,504

LIABILITIES AND STOCKHOLDERS' EQUITY
Other accrued expenses	$	25,883	$	918	$	26,801
Accumulated deficit	$	(1,477,440)		2,356	$	(1,475,084)
Total liabilities and stockholders' equity	$	735,230	$	3,274	$	738,504

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except for per share amounts)


	Three months ended September 30, 2018
			Balances without		Effect of Change
	As reported		Adoption of ASC 606		Higher/(Lower)
Product revenue	$	22,757	$	25,213	$	(2,456)
Cost of sales - product	$	4,766	$	5,158	$	392
Selling, general and administrative	$	42,495	$	42,689	$	194
Net loss	$	(89,864)	$	(87,994)	$	(1,870)

Loss per basic and diluted common share:
Basic and diluted net loss per common share	$	(1.71)	$	(1.67)	$	(0.04)


	Nine months ended September 30, 2018
			Balances without		Effect of Change
	As reported		Adoption of ASC 606		Higher/(Lower)
Product revenue	$	65,037	$	63,541	$	1,496
Cost of sales - product	$	13,262	$	12,697	$	(565)
Selling, general and administrative	$	126,634	$	126,602	$	(32)
Net loss	$	(268,750)	$	(269,648)	$	898

Loss per basic and diluted common share:
Basic and diluted net loss per common share	$	(5.18)	$	(5.20)	$	0.02

CONSOLIDATED BALANCE SHEET

(In thousands)


	September 30, 2018
			Balances without		Effect of Change
	As reported		Adoption of ASC 606		Higher/(Lower)
ASSETS
Accounts receivable, net	$	14,495	$	12,907	$	1,588
Inventories	$	63,687	$	63,992	$	(305)

LIABILITIES AND STOCKHOLDERS' EQUITY
Other accrued expenses	$	24,732	$	24,347	$	385
Accumulated deficit	$	(1,743,834)	$	(1,744,732)	$	898

Recently Issued Accounting Standards

Revenue Recognition

Product Revenue

Reserves for Variable Consideration

Cost of Sales

Cost of Sales – Product

Product cost of sales consists primarily of materials, third-party manufacturing costs as well as freight and royalties owed to our licensing partners for Rubraca sales.

Cost of Sales – Intangible Asset Amortization

Convertible Senior Notes

The debt issuance costs are presented as a deduction from the convertible senior notes on the Consolidated Balance Sheets and are amortized as interest expense over the expected life of the 2021 Notes using the effective interest method. We determined the expected life of the debt was equal to the seven-year term of the 2021 Notes.

Lucitanib

Reimbursements are recorded as a reduction to research and development expense on the Consolidated Statements of Operations. Lucitanib was originally developed by Clovis and Servier with the hypothesis of activity in FGFR driven tumors; however, data in breast and lung cancer were insufficient to move the program forward. We received notice from Servier of termination of their rights to lucitanib, resulting in the return of global rights (excluding China) for lucitanib to us during October 2018.

Net Loss Per Common Share

XML 32 R21.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2018

ASU 2014-09

Revenue Recognition

Schedule of new accounting pronouncements

The cumulative effect of the changes made to our consolidated January 1, 2018 balance sheet for the adoption of ASC 606 was as follows (in thousands):


	Balance at		Adjustments due to		Balance at
	December 31, 2017		Adoption of ASC 606		January 1, 2018
ASSETS
Accounts receivable, net	$	6,181	$	3,336	$	9,517
Inventories	$	27,508		(62)	$	27,446
Total assets	$	735,230	$	3,274	$	738,504

LIABILITIES AND STOCKHOLDERS' EQUITY
Other accrued expenses	$	25,883	$	918	$	26,801
Accumulated deficit	$	(1,477,440)		2,356	$	(1,475,084)
Total liabilities and stockholders' equity	$	735,230	$	3,274	$	738,504

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except for per share amounts)


	Three months ended September 30, 2018
			Balances without		Effect of Change
	As reported		Adoption of ASC 606		Higher/(Lower)
Product revenue	$	22,757	$	25,213	$	(2,456)
Cost of sales - product	$	4,766	$	5,158	$	392
Selling, general and administrative	$	42,495	$	42,689	$	194
Net loss	$	(89,864)	$	(87,994)	$	(1,870)

Loss per basic and diluted common share:
Basic and diluted net loss per common share	$	(1.71)	$	(1.67)	$	(0.04)


	Nine months ended September 30, 2018
			Balances without		Effect of Change
	As reported		Adoption of ASC 606		Higher/(Lower)
Product revenue	$	65,037	$	63,541	$	1,496
Cost of sales - product	$	13,262	$	12,697	$	(565)
Selling, general and administrative	$	126,634	$	126,602	$	(32)
Net loss	$	(268,750)	$	(269,648)	$	898

Loss per basic and diluted common share:
Basic and diluted net loss per common share	$	(5.18)	$	(5.20)	$	0.02

CONSOLIDATED BALANCE SHEET

(In thousands)


	September 30, 2018
			Balances without		Effect of Change
	As reported		Adoption of ASC 606		Higher/(Lower)
ASSETS
Accounts receivable, net	$	14,495	$	12,907	$	1,588
Inventories	$	63,687	$	63,992	$	(305)

LIABILITIES AND STOCKHOLDERS' EQUITY
Other accrued expenses	$	24,732	$	24,347	$	385
Accumulated deficit	$	(1,743,834)	$	(1,744,732)	$	898

XML 33 R22.htm IDEA: XBRL DOCUMENT

Financial Instruments and Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2018

Financial Instruments and Fair Value Measurements

Assets Measured at Fair Value on Recurring Basis

The following table identifies our assets and liabilities that were measured at fair value on a recurring basis (in thousands):


	Balance		Level 1		Level 2		Level 3
September 30, 2018
Assets:
Money market	$	255,143	$	255,143	$	—	$	—
U.S. treasury securities		313,525		—		313,525		—
Total assets at fair value	$	568,668	$	255,143	$	313,525	$	—
December 31, 2017
Assets:
Money market	$	433,136	$	433,136	$	—	$	—
U.S. treasury securities		99,533		—		99,533		—
Total assets at fair value	$	532,669	$	433,136	$	99,533	$	—

XML 34 R23.htm IDEA: XBRL DOCUMENT

Available-for-Sale Securities (Tables)

9 Months Ended

Sep. 30, 2018

Debt Securities, Available-for-sale [Abstract]

Summary of Available-for-Sale Securities

As of September 30, 2018, available-for-sale securities consisted of the following (in thousands):


			Gross		Gross		Aggregate
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
U.S. treasury securities	$	313,570	$	—	$	(45)	$	313,525

As of December 31, 2017, available-for-sale securities consisted of the following (in thousands):


			Gross		Gross		Aggregate
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
U.S. treasury securities	$	99,650	$	—	$	(117)	$	99,533

Schedule of Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity

As of September 30, 2018, the amortized cost and fair value of available-for-sale securities by contractual maturity were (in thousands):


	Amortized		Fair
	Cost		Value
Due in one year or less	$	313,570	$	313,525
Due in one year to two years		—		—
Total	$	313,570	$	313,525

XML 35 R24.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

9 Months Ended

Sep. 30, 2018

Inventories

Schedule of Inventories


	September 30,		December 31,
	2018		2017
Work-in-process	$	51,707	$	24,721
Finished goods		11,980		2,787
Total inventories	$	63,687	$	27,508

XML 36 R25.htm IDEA: XBRL DOCUMENT

Other Current Assets (Tables)

9 Months Ended

Sep. 30, 2018

Other Current Assets

Other Current Assets

Other current assets were comprised of the following (in thousands):


	September 30,		December 31,
	2018		2017
Prepaid insurance	$	752	$	1,926
Prepaid expenses - other		7,031		3,355
Receivable - other		3,741		2,023
Other		256		196
Total	$	11,780	$	7,500

XML 37 R26.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill (Tables)

9 Months Ended

Sep. 30, 2018

Intangible Assets and Goodwill

Intangible assets related to capitalized milestones under license agreements

Intangible assets related to capitalized milestones under license agreements consisted of the following (in thousands):


	September 30,		December 31,
	2018		2017
Intangible asset - milestones	$	56,100	$	21,100
Accumulated amortization		(3,391)		(1,539)
Total intangible asset, net	$	52,709	$	19,561

Estimated future amortization expense for intangible assets

Estimated future amortization expense associated with intangibles is expected to be as follows (in thousands):


2018	$	779
2019		3,116
2020		3,116
2021		3,116
2022		3,116
Thereafter		39,466
	$	52,709

Summary of Goodwill

The change in goodwill established as part of the purchase accounting of EOS in November 2013 consisted of the following (in thousands):


Balance at December 31, 2017	$	65,217
Change in foreign currency gains and losses		(2,143)
Balance at September 30, 2018	$	63,074

XML 38 R27.htm IDEA: XBRL DOCUMENT

Other Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2018

Other Accrued Expenses

Other Accrued Expenses

Other accrued expenses were comprised of the following (in thousands):


	September 30,		December 31,
	2018		2017
Accrued personnel costs	$	14,217	$	13,889
Accrued interest payable		—		2,096
Income tax payable		186		—
Accrued corporate legal fees and professional services		731		415
Accrued royalties		4,187		2,984
Accrued variable considerations		2,407		1,008
Payable to third party logistics provider		14		2,661
Accrued expenses - other		2,990		2,830
Total	$	24,732	$	25,883

XML 39 R28.htm IDEA: XBRL DOCUMENT

Convertible Senior Notes (Tables)

9 Months Ended

Sep. 30, 2018

Convertible Senior Notes

Schedule of Total Interest Expense Recognized Related to Notes


	Three months ended September 30,				Nine months ended September 30,
	2018		2017		2018		2017
Contractual interest expense	$	2,735	$	1,797	$	7,078	$	5,391
Accretion of interest on milestone liability		—		500		978		1,449
Amortization of debt issuance costs		641		321		1,536		956
Total interest expense	$	3,376	$	2,618	$	9,592	$	7,796

XML 40 R29.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2018

Stockholders’ Equity

Component of Other Comprehensive Income (Loss)

The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the three months ended September 30, 2018 and 2017, as follows (in thousands):


	Foreign Currency				Unrealized				Total Accumulated
	Translation Adjustments				(Losses) Gains				Other Comprehensive Loss
	2018		2017		2018		2017		2018		2017
Balance at July 1,	$	(43,870)	$	(44,155)	$	(175)	$	(151)	$	(44,045)	$	(44,306)
Other comprehensive income (loss)		(495)		2,510		(10)		15		(505)		2,525
Total before tax		(44,365)		(41,645)		(185)		(136)		(44,550)		(41,781)
Tax effect		—		(915)		—		(5)		—		(920)
Balance at September 30,	$	(44,365)	$	(42,560)	$	(185)	$	(141)	$	(44,550)	$	(42,701)

The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the nine months ended September 30, 2018 and 2017, as follows (in thousands):


	Foreign Currency				Unrealized				Total Accumulated
	Translation Adjustments				(Losses) Gains				Other Comprehensive Loss
	2018		2017		2018		2017		2018		2017
Balance at January 1,	$	(41,917)	$	(47,434)	$	(256)	$	(146)	$	(42,173)	$	(47,580)
Other comprehensive income (loss)		(2,448)		7,695		71		8		(2,377)		7,703
Total before tax		(44,365)		(39,739)		(185)		(138)		(44,550)		(39,877)
Tax effect		—		(2,821)		—		(3)		—		(2,824)
Balance at September 30,	$	(44,365)	$	(42,560)	$	(185)	$	(141)	$	(44,550)	$	(42,701)

XML 41 R30.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2018

Share-Based Compensation

Share-Based Compensation Expense Recognized in Accompanying Statements of Operations


	Three months ended September 30,				Nine months ended September 30,
	2018		2017		2018		2017
Research and development	$	5,038	$	5,636	$	15,380	$	14,628
Selling, general and administrative		5,909		7,001		22,335		17,573
Total share-based compensation expense	$	10,947	$	12,637	$	37,715	$	32,201

Summary of Stock Options Activity


				Weighted
		Weighted		Average	Aggregate
		Average		Remaining	Intrinsic
	Number of	Exercise		Contractual	Value
	Options	Price		Term (Years)	(Thousands)
Outstanding at December 31, 2017	5,789,735	$	46.77
Granted	639,793		52.33
Exercised	(70,480)		25.82
Forfeited	(217,007)		60.47
Outstanding at September 30, 2018	6,142,041	$	47.11	6.6	$	24,884
Vested and expected to vest at September 30, 2018	5,919,341	$	47.00	6.5	$	24,555
Vested and exercisable at September 30, 2018	4,284,706	$	45.70	5.8	$	21,421

Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award

The following table summarizes information about our stock options as of and for the three and nine months ended September 30, 2018 and 2017 (in thousands, except per share amounts):


	Three months ended September 30,				Nine months ended September 30,
	2018		2017		2018		2017
Weighted-average grant date fair value per share	$	28.97	$	60.81	$	38.52	$	48.39
Intrinsic value of options exercised	$	325	$	3,400	$	1,697	$	17,684
Cash received from stock option exercises	$	604	$	2,149	$	1,820	$	13,262

Summary of activity related to our unvested RSUs



		Weighted
		Average
	Number of	Grant Date
	Units	Fair Value
Unvested at December 31, 2017	589,529	$	41.67
Granted	479,255		55.05
Vested	(199,602)		40.43
Forfeited	(44,686)		46.65
Unvested as of September 30, 2018	824,496	$	49.48
Expected to vest after September 30, 2018	706,795	$	49.25

XML 42 R31.htm IDEA: XBRL DOCUMENT

Net Loss Per Common Share (Tables)

9 Months Ended

Sep. 30, 2018

Net Loss Per Common Share

Shares Outstanding Excluded from Calculation of Diluted Net Loss Per Share


	Three and Nine months ended September 30,
	2018	2017
Common shares under option	3,381	5,696
Convertible senior notes	8,584	4,646
Total potential dilutive shares	11,965	10,342

XML 43 R32.htm IDEA: XBRL DOCUMENT

Nature of Business and Basis of Presentation (Details) $ / shares in Units, $ in Thousands	1 Months Ended	9 Months Ended
	Apr. 30, 2018 USD ($) $ / shares shares	Sep. 30, 2018 USD ($) segment product item	Sep. 30, 2017 USD ($)
Number of operating segments \| segment		1
Number of other product candidates \| product		2
Issuance of common stock, net of issuance costs (in shares) \| shares	1,837,898
Sale of stock, price per share \| $ / shares	$ 54.41
Proceeds from offering	$ 93,900	$ 93,890	$ 545,838
Aggregate principal amount of public offering	$ 300,000
Convertible senior notes, interest rate	1.25%
Net proceeds from convertible senior notes	$ 290,900	$ 290,887	$ 0
Minimum estimated number of months operating plan funded		12 months
Minimum
Number of chemotherapies received by an adult patient \| item		2
Number of prior lines of platinum based chemotherapy received by patient \| item		2

XML 44 R33.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Jan. 01, 2018	Dec. 31, 2017
Revenues:
Product revenue	$ 22,757		$ 65,037
Cost of sales - product	4,766		13,262
Selling, general and administrative	42,495	$ 35,011	126,634	$ 100,384
Net loss	$ (89,864)	$ (60,664)	$ (268,750)	$ (294,514)
Payment terms number of days			30 days
Loss per basic and diluted common share:
Basic and diluted net loss per common share	$ (1.71)	$ (1.24)	$ (5.18)	$ (6.39)
Assets
Accounts receivable, net	$ 14,495		$ 14,495		$ 9,517	$ 6,181
Inventories	43,682		43,682		27,446	27,508
Inventories	63,687		63,687
Total assets	891,464		891,464		738,504	735,230
Liabilities
Other accrued expenses	24,732		24,732		26,801	25,883
Accumulated deficit	(1,743,834)		(1,743,834)		(1,475,084)	(1,477,440)
Equity
Total liabilities and stockholders' equity	891,464		$ 891,464		738,504	$ 735,230
Product Revenue
Amortization period of the asset			true
ASU 2014-09 \| Balances without Adoption of ASC 606
Revenues:
Product revenue	25,213		$ 63,541
Cost of sales - product	5,158		12,697
Selling, general and administrative	42,689		126,602
Net loss	$ (87,994)		$ (269,648)
Loss per basic and diluted common share:
Basic and diluted net loss per common share	$ (1.67)		$ (5.20)
Assets
Accounts receivable, net	$ 12,907		$ 12,907
Inventories	63,992		63,992
Liabilities
Other accrued expenses	24,347		24,347
Accumulated deficit	(1,744,732)		(1,744,732)
ASU 2014-09 \| Effect of Change Higher/(Lower)
Revenues:
Product revenue	(2,456)		1,496
Cost of sales - product	392		(565)
Selling, general and administrative	194		(32)
Net loss	$ (1,870)		$ 898
Loss per basic and diluted common share:
Basic and diluted net loss per common share	$ (0.04)		$ 0.02
Assets
Accounts receivable, net	$ 1,588		$ 1,588		3,336
Inventories					(62)
Inventories	(305)		(305)
Total assets					3,274
Liabilities
Other accrued expenses	385		385		918
Accumulated deficit	$ 898		$ 898		2,356
Equity
Total liabilities and stockholders' equity					$ 3,274

XML 45 R34.htm IDEA: XBRL DOCUMENT

Financial Instruments and Fair Value Measurements (Details) - Recurring - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Fair Value Measurements
Assets at fair value	$ 568,668	$ 532,669
Money market
Fair Value Measurements
Assets at fair value	255,143	433,136
U.S. treasury securities
Fair Value Measurements
Assets at fair value	313,525	99,533
Fair Value, Inputs, Level 1
Fair Value Measurements
Assets at fair value	255,143	433,136
Fair Value, Inputs, Level 1 \| Money market
Fair Value Measurements
Assets at fair value	255,143	433,136
Fair Value, Inputs, Level 1 \| U.S. treasury securities
Fair Value Measurements
Assets at fair value	0	0
Fair Value, Inputs, Level 2
Fair Value Measurements
Assets at fair value	313,525	99,533
Fair Value, Inputs, Level 2 \| Money market
Fair Value Measurements
Assets at fair value	0	0
Fair Value, Inputs, Level 2 \| U.S. treasury securities
Fair Value Measurements
Assets at fair value	313,525	99,533
Fair Value, Inputs, Level 3
Fair Value Measurements
Assets at fair value	0	0
Fair Value, Inputs, Level 3 \| Money market
Fair Value Measurements
Assets at fair value	0	0
Fair Value, Inputs, Level 3 \| U.S. treasury securities
Fair Value Measurements
Assets at fair value	$ 0	$ 0

XML 46 R35.htm IDEA: XBRL DOCUMENT

Financial Instruments and Fair Value Measurements - More Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Fair Value Measurements
Transfers between level 1 and level 2, assets	$ 0
Transfers between level 2 and level 1, assets	0
Transfers between level 1 and level 2, liabilities	0
Transfers between level 2 and level 1, liabilities	0
Transfer of assets into level 3	0
Transfer of assets out of level 3	0
Transfer of liabilities into level 3	0
Transfer of liabilities out of level 3	0
Convertible senior notes	574,828	$ 282,406
Convertible Senior Unsecured Notes 2021 Notes
Fair Value Measurements
Convertible senior notes	283,400
Convertible Senior Unsecured Notes 2021 Notes \| Fair Value, Inputs, Level 2
Fair Value Measurements
Convertible senior notes, fair value	268,200
Convertible Senior Unsecured Notes 2025 Notes
Fair Value Measurements
Convertible senior notes	291,400
Convertible senior notes, fair value	$ 232,800

XML 47 R36.htm IDEA: XBRL DOCUMENT

Available-for-Sale Securities (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Available-for-Sale Securities
Amortized Cost	$ 313,570
Aggregate Fair Value	313,525
U.S. treasury securities
Available-for-Sale Securities
Amortized Cost	313,570	$ 99,650
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(45)	(117)
Aggregate Fair Value	$ 313,525	$ 99,533

XML 48 R37.htm IDEA: XBRL DOCUMENT

Available-for-Sale Securities - Additional Information (Details) $ in Thousands	Sep. 30, 2018 USD ($)
Debt Securities, Available-for-sale [Abstract]
Amortized Cost, Due in one year or less	$ 313,570
Amortized Cost, Due in one year to two years	0
Amortized Cost	313,570
Fair Value, Due in one year or less	313,525
Fair Value, Due in one year to two years	0
Aggregate Fair Value	$ 313,525

XML 49 R38.htm IDEA: XBRL DOCUMENT

Inventories (Details) - USD ($) $ in Thousands	9 Months Ended
Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Jan. 01, 2018	Dec. 31, 2017
Inventories
Work-in-process	$ 51,707		$ 24,721
Finished goods	11,980		2,787
Total inventories	63,687
Total inventories	43,682	$ 27,446	$ 27,508
Cash deposit on inventory made to a manufacturer	$ 44,600
Maximum number of months purchased inventory converted to finished goods	12 months

XML 50 R39.htm IDEA: XBRL DOCUMENT

Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Other Current Assets
Prepaid Insurance	$ 752	$ 1,926
Prepaid expenses - other	7,031	3,355
Receivable - other	3,741	2,023
Other	256	196
Total	$ 11,780	$ 7,500

XML 51 R40.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill (Details) - Licensing Agreements - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Finite Lived Intangible Assets [Line Items]
Intangible asset - milestones	$ 56,100	$ 21,100
Accumulated amortization	(3,391)	(1,539)
Total intangible asset, net	$ 52,709	$ 19,561

XML 52 R41.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill - Additional Information (Details) - USD ($) $ in Millions	1 Months Ended		3 Months Ended		9 Months Ended
	Jun. 30, 2018	Apr. 30, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Licensing Agreements
Finite Lived Intangible Assets [Line Items]
Amortization of Intangible Assets			$ 0.8	$ 0.4	$ 1.9	$ 1.2
Rucaparib
Finite Lived Intangible Assets [Line Items]
Milestone payments	$ 20.0
Rucaparib \| First approval of NDA by FDA
Finite Lived Intangible Assets [Line Items]
Milestone payments		$ 15.0

XML 53 R42.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill - Estimated Future Amortization (Details) - Licensing Agreements - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Finite Lived Intangible Assets
2018	$ 779
2019	3,116
2020	3,116
2021	3,116
2022	3,116
Thereafter	39,466
Total intangible asset, net	$ 52,709	$ 19,561

XML 54 R43.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill - Summary of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2018 USD ($)
Goodwill:
Balance at beginning of period	$ 65,217
Balance at end of period	63,074
Ethical Oncology Science, S.p.A.
Goodwill:
Balance at beginning of period	65,217
Change in foreign currency gains and losses	(2,143)
Balance at end of period	$ 63,074

XML 55 R44.htm IDEA: XBRL DOCUMENT

Other Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Jan. 01, 2018	Dec. 31, 2017
Other Accrued Expenses
Accrued personnel costs	$ 14,217		$ 13,889
Accrued interest payable			2,096
Income tax payable	186		0
Accrued corporate legal fees and professional services	731		415
Accrued royalties	4,187		2,984
Accrued variable considerations	2,407		1,008
Payable to third party logistics provider	14		2,661
Accrued expenses - other	2,990		2,830
Total	$ 24,732	$ 26,801	$ 25,883

XML 56 R45.htm IDEA: XBRL DOCUMENT

Convertible Senior Notes (Details) $ / shares in Units, $ in Thousands			1 Months Ended	9 Months Ended
	Apr. 19, 2018 USD ($) D $ / shares	Sep. 09, 2014 USD ($) D item $ / shares	Apr. 30, 2018 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Dec. 31, 2017 USD ($)
Debt Instrument
Aggregate principal amount of public offering			$ 300,000
Convertible senior notes, interest rate			1.25%
Net proceeds from convertible senior notes			$ 290,900	$ 290,887	$ 0
Convertible Senior Unsecured Notes
Debt Instrument
Aggregate principal amount of public offering	$ 300,000	$ 287,500
Convertible senior notes, interest rate	1.25%	2.50%
Net proceeds from convertible senior notes	$ 290,900	$ 278,300
Convertible senior notes, maturity date		Sep. 15, 2021
Common stock initial conversion rate per $1,000 in principal amount	13.1278	16.1616
Convertible senior notes, initial conversion price per share \| $ / shares	$ 76.17	$ 61.88
Debt instrument, redemption period start date		Sep. 15, 2018
Last reported sale price of common stock as a percent of conversion price	150.00%	150.00%
Debt instrument, conversion in effect for number of trading days \| D	20	20
Debt instrument conversion, consecutive trading day period \| D	30	30
Debt instrument, trading days preceding redemption notice, maximum	2	2
Debt instrument redemption price percentage to principal amount	100.00%	100.00%
Debt instrument repurchase percentage	100.00%	100.00%
Debt issuance costs	$ 9,100	$ 9,200
Debt instrument term	7 years	7 years
Unamortized debt issuance costs				$ 12,700		$ 5,100
Convertible Senior Unsecured Notes \| Semi Annual Payment, First payment date
Debt Instrument
Interest payment date on senior notes	--05-01	--03-15
Convertible Senior Unsecured Notes \| Semi Annual Payment, Second payment date
Debt Instrument
Interest payment date on senior notes	--11-01	--09-15

XML 57 R46.htm IDEA: XBRL DOCUMENT

Convertible Senior Notes - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Convertible Senior Notes
Contractual interest expense	$ 2,735	$ 1,797	$ 7,078	$ 5,391
Accretion of interest on milestone liability		500	978	1,449
Amortization of debt issuance costs	641	321	1,536	956
Total interest expense	$ 3,376	$ 2,618	$ 9,592	$ 7,796

XML 58 R47.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details) $ / shares in Units, $ in Thousands	1 Months Ended	9 Months Ended
	Apr. 30, 2018 USD ($) $ / shares shares	Sep. 30, 2018 USD ($) Vote	Sep. 30, 2017 USD ($)
Stockholders’ Equity
Common stock, shares issued \| shares	1,837,898
Sale of stock, price per share \| $ / shares	$ 54.41
Proceeds from the sale of common stock, net of issuance costs \| $	$ 93,900	$ 93,890	$ 545,838
Number Of Vote Per Common Stock \| Vote		1

XML 59 R48.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Accumulated Other Comprehensive Loss
Beginning balance	$ (44,045)	$ (44,306)	$ (42,173)	$ (47,580)
Other comprehensive income (loss)	(505)	2,525	(2,377)	7,703
Total before tax	(44,550)	(41,781)	(44,550)	(39,877)
Tax effect	0	(920)	0	(2,824)
Ending balance	(44,550)	(42,701)	(44,550)	(42,701)
Reclassifications out of accumulated other comprehensive loss	0	0	0	0
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Loss
Beginning balance	(43,870)	(44,155)	(41,917)	(47,434)
Other comprehensive income (loss)	(495)	2,510	(2,448)	7,695
Total before tax	(44,365)	(41,645)	(44,365)	(39,739)
Tax effect	0	(915)	0	(2,821)
Ending balance	(44,365)	(42,560)	(44,365)	(42,560)
Unrealized (Losses) Gains
Accumulated Other Comprehensive Loss
Beginning balance	(175)	(151)	(256)	(146)
Other comprehensive income (loss)	(10)	15	71	8
Total before tax	(185)	(136)	(185)	(138)
Tax effect	0	(5)	0	(3)
Ending balance	$ (185)	$ (141)	$ (185)	$ (141)

XML 60 R49.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Jun. 29, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total Share-based compensation expense	$ 10,947	$ 12,637	$ 37,715	$ 32,201
Employee Service Share Based Compensation Tax Benefit From Compensation Expense	0	0	0	0
Closing Stock Price					$ 29.37
Research and development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total Share-based compensation expense	5,038	5,636	15,380	14,628
Selling, general and administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total Share-based compensation expense	5,909	$ 7,001	22,335	$ 17,573
Common shares under option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to unvested RSUs	60,400		$ 60,400
Unrecognized stock-based compensation expense related to non-vested options and RSUs, weighted-average remaining vesting period			2 years 5 months 16 days
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to unvested RSUs	$ 31,200		$ 31,200
Unrecognized stock-based compensation expense related to non-vested options and RSUs, weighted-average remaining vesting period			3 years

XML 61 R50.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Summary of Stock Options Activity (Details) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2018 USD ($) $ / shares shares
Share-Based Compensation
Beginning Balance, Number of Options Outstanding \| shares	5,789,735
Number of Options, Granted \| shares	639,793
Number of Options, Exercised \| shares	(70,480)
Number of Options, Forfeited \| shares	(217,007)
Ending Balance, Number of Options Outstanding \| shares	6,142,041
Number of Options, Vested and expected to vest at June 30,2018 \| shares	5,919,341
Number of Options, Vested and exercisable at June 30,2018 \| shares	4,284,706
Beginning Balance, Weighted Average Exercise Price \| $ / shares	$ 46.77
Granted, Weighted Average Exercise Price \| $ / shares	52.33
Exercised, Weighted Average Exercise Price \| $ / shares	25.82
Forfeited, Weighted Average Exercise Price \| $ / shares	60.47
Ending Balance, Weighted Average Exercise Price \| $ / shares	47.11
Vested and expected to vest, Weighted Average Exercise Price \| $ / shares	47.00
Vested and exercisable, Weighted Average Exercise Price \| $ / shares	$ 45.70
Outstanding, Weighted Average Remaining Contractual Term (Years)	6 years 7 months 6 days
Vested and expected to vest, Weighted Average Remaining Contractual Term (Years)	6 years 6 months
Exercisable, Weighted Average Remaining Contractual Term (Years)	5 years 9 months 18 days
Outstanding at June 30, 2018, Aggregate Intrinsic Value \| $	$ 24,884
Vested and expected to vest at June 30, 2018, Aggregate Intrinsic Value \| $	24,555
Vested and exercisable at June 30, 2018, Aggregate Intrinsic Value \| $	$ 21,421

XML 62 R51.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Share-Based Compensation
Weighted-average grant date fair value per share	$ 28.97	$ 60.81	$ 38.52	$ 48.39
Intrinsic value of options exercised	$ 325	$ 3,400	$ 1,697	$ 17,684
Cash received from stock option exercises	$ 604	$ 2,149	$ 1,820	$ 13,262

XML 63 R52.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Additional Information (Details) - Restricted Stock Units (RSUs)	9 Months Ended
	Sep. 30, 2018 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested as of Beginning Balance \| shares	589,529
Number of Units, Granted \| shares	479,255
Number of Units, Vested \| shares	(199,602)
Number of Units, Forfeited \| shares	(44,686)
Unvested as of Ending Balance \| shares	824,496
Number of Units, Expected to vest after March 31, 2018 \| shares	706,795
Weighted Average Grant Date Fair Value, Beginning Balance \| $ / shares	$ 41.67
Weighted Average Grant Date Fair Value, Granted \| $ / shares	55.05
Weighted Average Grant Date Fair Value, Vested \| $ / shares	40.43
Weighted Average Grant Date Fair Value, Forfeited \| $ / shares	46.65
Weighted Average Grant Date Fair Value, Ending Balance \| $ / shares	49.48
Weighted Average Grant Date Fair Value, Expected to vest after March 31, 2018 \| $ / shares	$ 49.25

XML 64 R53.htm IDEA: XBRL DOCUMENT

License Agreements (Details) $ in Thousands		1 Months Ended				3 Months Ended	9 Months Ended
License Agreements (Details) $ in Thousands	Dec. 19, 2016 USD ($) item	Jun. 30, 2018 USD ($)	Apr. 30, 2018 USD ($)	Jun. 30, 2011 USD ($)	Oct. 31, 2008	Mar. 31, 2017 USD ($)	Sep. 30, 2018 USD ($)
License Agreements
Minimum number of chemotherapies \| item	2
Rucaparib
License Agreements
Milestone payments		$ 20,000
Rucaparib \| First approval of NDA by FDA
License Agreements
Milestone payments			$ 15,000
License Agreements Licensor Pfizer \| Rucaparib
License Agreements
Milestone payments		$ 23,000				$ 750
Milestone payment due prior to deferment of milestone payment	$ 20,000
Deferred milestone payment	$ 23,000
Maximum number of months after FDA approval	18 months
License Agreements Licensor Pfizer \| Rucaparib \| Minimum
License Agreements
Annual sales target for sales milestone payments							$ 250,000
License Agreements Licensor Pfizer \| Rucaparib \| Maximum
License Agreements
Maximum potential future development, regulatory milestone payments							31,750
Additional maximum payments payable on attaining the sales target							$ 170,000
License Agreement Terms \| License Agreements Licensor Pfizer \| Rucaparib
License Agreements
Upfront payment				$ 7,000
Milestones paid to Pfizer prior to FDA approval				$ 1,400
License Agreement Terms \| Advenchen Laboratories LLC \| License Agreements Lucitanib
License Agreements
Percentage of Non-Royalty Consideration Payable on Sublicense Agreements					25.00%

XML 65 R54.htm IDEA: XBRL DOCUMENT

Net Loss Per Common Share (Details) - shares shares in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Antidilutive Securities Excluded From Computation Of Earnings Per Share
Total potential dilutive shares	11,965	10,342
Common shares under option
Antidilutive Securities Excluded From Computation Of Earnings Per Share
Total potential dilutive shares	3,381	5,696
Convertible senior notes
Antidilutive Securities Excluded From Computation Of Earnings Per Share
Total potential dilutive shares	8,584	4,646

XML 66 R55.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details) $ in Thousands		1 Months Ended	9 Months Ended
Commitments and Contingencies (Details) $ in Thousands	Jun. 20, 2017 item	Mar. 31, 2017 shareholder	Sep. 30, 2018 USD ($)	Sep. 18, 2018 USD ($)	Dec. 31, 2017 USD ($)
Commitments and Contingencies
Deferred Long-term Liability Charges			$ 0		$ 22,022
Purchase commitment			165,100
Number of putative shareholders \| shareholder		2
Loss contingency due to civil penalty				$ 20,000
Litigation Settlement, Expense			$ 20,000
Number of oppositions filed regarding salt and polymorph patents \| item	2

EXCEL 67 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 69 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 71 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 131 278 1 false 35 0 false 10 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.clovisoncology.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://www.clovisoncology.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 2 false false R3.htm 00200 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.clovisoncology.com/role/StatementConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 3 false false R4.htm 00205 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.clovisoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 4 false false R5.htm 00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.clovisoncology.com/role/StatementConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 10101 - Disclosure - Nature of Business and Basis of Presentation Sheet http://www.clovisoncology.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation Nature of Business and Basis of Presentation Notes 6 false false R7.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.clovisoncology.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 7 false false R8.htm 10301 - Disclosure - Financial Instruments and Fair Value Measurements Sheet http://www.clovisoncology.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements Financial Instruments and Fair Value Measurements Notes 8 false false R9.htm 10401 - Disclosure - Available-for-Sale Securities Sheet http://www.clovisoncology.com/role/DisclosureAvailableForSaleSecurities Available-for-Sale Securities Notes 9 false false R10.htm 10501 - Disclosure - Inventories Sheet http://www.clovisoncology.com/role/DisclosureInventories Inventories Notes 10 false false R11.htm 10601 - Disclosure - Other Current Assets Sheet http://www.clovisoncology.com/role/DisclosureOtherCurrentAssets Other Current Assets Notes 11 false false R12.htm 10701 - Disclosure - Intangible Assets and Goodwill Sheet http://www.clovisoncology.com/role/DisclosureIntangibleAssetsAndGoodwill Intangible Assets and Goodwill Notes 12 false false R13.htm 10801 - Disclosure - Other Accrued Expenses Sheet http://www.clovisoncology.com/role/DisclosureOtherAccruedExpenses Other Accrued Expenses Notes 13 false false R14.htm 10901 - Disclosure - Convertible Senior Notes Notes http://www.clovisoncology.com/role/DisclosureConvertibleSeniorNotes Convertible Senior Notes Notes 14 false false R15.htm 11001 - Disclosure - Stockholders' Equity Sheet http://www.clovisoncology.com/role/DisclosureStockholdersEquity Stockholders' Equity Notes 15 false false R16.htm 11101 - Disclosure - Share-Based Compensation Sheet http://www.clovisoncology.com/role/DisclosureShareBasedCompensation Share-Based Compensation Notes 16 false false R17.htm 11201 - Disclosure - License Agreements Sheet http://www.clovisoncology.com/role/DisclosureLicenseAgreements License Agreements Notes 17 false false R18.htm 11301 - Disclosure - Net Loss Per Common Share Sheet http://www.clovisoncology.com/role/DisclosureNetLossPerCommonShare Net Loss Per Common Share Notes 18 false false R19.htm 11401 - Disclosure - Commitments and Contingencies Sheet http://www.clovisoncology.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 19 false false R20.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.clovisoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.clovisoncology.com/role/DisclosureSummaryOfSignificantAccountingPolicies 20 false false R21.htm 30203 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.clovisoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.clovisoncology.com/role/DisclosureSummaryOfSignificantAccountingPolicies 21 false false R22.htm 30303 - Disclosure - Financial Instruments and Fair Value Measurements (Tables) Sheet http://www.clovisoncology.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables Financial Instruments and Fair Value Measurements (Tables) Tables http://www.clovisoncology.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements 22 false false R23.htm 30403 - Disclosure - Available-for-Sale Securities (Tables) Sheet http://www.clovisoncology.com/role/DisclosureAvailableForSaleSecuritiesTables Available-for-Sale Securities (Tables) Tables http://www.clovisoncology.com/role/DisclosureAvailableForSaleSecurities 23 false false R24.htm 30503 - Disclosure - Inventories (Tables) Sheet http://www.clovisoncology.com/role/DisclosureInventoriesTables Inventories (Tables) Tables http://www.clovisoncology.com/role/DisclosureInventories 24 false false R25.htm 30603 - Disclosure - Other Current Assets (Tables) Sheet http://www.clovisoncology.com/role/DisclosureOtherCurrentAssetsTables Other Current Assets (Tables) Tables http://www.clovisoncology.com/role/DisclosureOtherCurrentAssets 25 false false R26.htm 30703 - Disclosure - Intangible Assets and Goodwill (Tables) Sheet http://www.clovisoncology.com/role/DisclosureIntangibleAssetsAndGoodwillTables Intangible Assets and Goodwill (Tables) Tables http://www.clovisoncology.com/role/DisclosureIntangibleAssetsAndGoodwill 26 false false R27.htm 30803 - Disclosure - Other Accrued Expenses (Tables) Sheet http://www.clovisoncology.com/role/DisclosureOtherAccruedExpensesTables Other Accrued Expenses (Tables) Tables http://www.clovisoncology.com/role/DisclosureOtherAccruedExpenses 27 false false R28.htm 30903 - Disclosure - Convertible Senior Notes (Tables) Notes http://www.clovisoncology.com/role/DisclosureConvertibleSeniorNotesTables Convertible Senior Notes (Tables) Tables http://www.clovisoncology.com/role/DisclosureConvertibleSeniorNotes 28 false false R29.htm 31003 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.clovisoncology.com/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.clovisoncology.com/role/DisclosureStockholdersEquity 29 false false R30.htm 31103 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.clovisoncology.com/role/DisclosureShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.clovisoncology.com/role/DisclosureShareBasedCompensation 30 false false R31.htm 31303 - Disclosure - Net Loss Per Common Share (Tables) Sheet http://www.clovisoncology.com/role/DisclosureNetLossPerCommonShareTables Net Loss Per Common Share (Tables) Tables http://www.clovisoncology.com/role/DisclosureNetLossPerCommonShare 31 false false R32.htm 40101 - Disclosure - Nature of Business and Basis of Presentation (Details) Sheet http://www.clovisoncology.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails Nature of Business and Basis of Presentation (Details) Details http://www.clovisoncology.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation 32 false false R33.htm 40201 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.clovisoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.clovisoncology.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables 33 false false R34.htm 40301 - Disclosure - Financial Instruments and Fair Value Measurements (Details) Sheet http://www.clovisoncology.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsDetails Financial Instruments and Fair Value Measurements (Details) Details http://www.clovisoncology.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables 34 false false R35.htm 40302 - Disclosure - Financial Instruments and Fair Value Measurements - More Information (Details) Sheet http://www.clovisoncology.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsMoreInformationDetails Financial Instruments and Fair Value Measurements - More Information (Details) Details 35 false false R36.htm 40401 - Disclosure - Available-for-Sale Securities (Details) Sheet http://www.clovisoncology.com/role/DisclosureAvailableForSaleSecuritiesDetails Available-for-Sale Securities (Details) Details http://www.clovisoncology.com/role/DisclosureAvailableForSaleSecuritiesTables 36 false false R37.htm 40402 - Disclosure - Available-for-Sale Securities - Additional Information (Details) Sheet http://www.clovisoncology.com/role/DisclosureAvailableForSaleSecuritiesAdditionalInformationDetails Available-for-Sale Securities - Additional Information (Details) Details 37 false false R38.htm 40501 - Disclosure - Inventories (Details) Sheet http://www.clovisoncology.com/role/DisclosureInventoriesDetails Inventories (Details) Details http://www.clovisoncology.com/role/DisclosureInventoriesTables 38 false false R39.htm 40601 - Disclosure - Other Current Assets (Details) Sheet http://www.clovisoncology.com/role/DisclosureOtherCurrentAssetsDetails Other Current Assets (Details) Details http://www.clovisoncology.com/role/DisclosureOtherCurrentAssetsTables 39 false false R40.htm 40701 - Disclosure - Intangible Assets and Goodwill (Details) Sheet http://www.clovisoncology.com/role/DisclosureIntangibleAssetsAndGoodwillDetails Intangible Assets and Goodwill (Details) Details http://www.clovisoncology.com/role/DisclosureIntangibleAssetsAndGoodwillTables 40 false false R41.htm 40702 - Disclosure - Intangible Assets and Goodwill - Additional Information (Details) Sheet http://www.clovisoncology.com/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails Intangible Assets and Goodwill - Additional Information (Details) Details 41 false false R42.htm 40703 - Disclosure - Intangible Assets and Goodwill - Estimated Future Amortization (Details) Sheet http://www.clovisoncology.com/role/DisclosureIntangibleAssetsAndGoodwillEstimatedFutureAmortizationDetails Intangible Assets and Goodwill - Estimated Future Amortization (Details) Details 42 false false R43.htm 40704 - Disclosure - Intangible Assets and Goodwill - Summary of Goodwill (Details) Sheet http://www.clovisoncology.com/role/DisclosureIntangibleAssetsAndGoodwillSummaryOfGoodwillDetails Intangible Assets and Goodwill - Summary of Goodwill (Details) Details 43 false false R44.htm 40801 - Disclosure - Other Accrued Expenses (Details) Sheet http://www.clovisoncology.com/role/DisclosureOtherAccruedExpensesDetails Other Accrued Expenses (Details) Details http://www.clovisoncology.com/role/DisclosureOtherAccruedExpensesTables 44 false false R45.htm 40901 - Disclosure - Convertible Senior Notes (Details) Notes http://www.clovisoncology.com/role/DisclosureConvertibleSeniorNotesDetails Convertible Senior Notes (Details) Details http://www.clovisoncology.com/role/DisclosureConvertibleSeniorNotesTables 45 false false R46.htm 40902 - Disclosure - Convertible Senior Notes - Additional Information (Details) Notes http://www.clovisoncology.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails Convertible Senior Notes - Additional Information (Details) Details 46 false false R47.htm 41001 - Disclosure - Stockholders' Equity (Details) Sheet http://www.clovisoncology.com/role/DisclosureStockholdersEquityDetails Stockholders' Equity (Details) Details http://www.clovisoncology.com/role/DisclosureStockholdersEquityTables 47 false false R48.htm 41002 - Disclosure - Stockholders' Equity - Additional Information (Details) Sheet http://www.clovisoncology.com/role/DisclosureStockholdersEquityAdditionalInformationDetails Stockholders' Equity - Additional Information (Details) Details 48 false false R49.htm 41101 - Disclosure - Share-Based Compensation (Details) Sheet http://www.clovisoncology.com/role/DisclosureShareBasedCompensationDetails Share-Based Compensation (Details) Details http://www.clovisoncology.com/role/DisclosureShareBasedCompensationTables 49 false false R50.htm 41102 - Disclosure - Share-Based Compensation - Summary of Stock Options Activity (Details) Sheet http://www.clovisoncology.com/role/DisclosureShareBasedCompensationSummaryOfStockOptionsActivityDetails Share-Based Compensation - Summary of Stock Options Activity (Details) Details 50 false false R51.htm 41103 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Details) Sheet http://www.clovisoncology.com/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails Share-Based Compensation - Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Details) Details 51 false false R52.htm 41104 - Disclosure - Share-Based Compensation - Additional Information (Details) Sheet http://www.clovisoncology.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails Share-Based Compensation - Additional Information (Details) Details 52 false false R53.htm 41201 - Disclosure - License Agreements (Details) Sheet http://www.clovisoncology.com/role/DisclosureLicenseAgreementsDetails License Agreements (Details) Details http://www.clovisoncology.com/role/DisclosureLicenseAgreements 53 false false R54.htm 41301 - Disclosure - Net Loss Per Common Share (Details) Sheet http://www.clovisoncology.com/role/DisclosureNetLossPerCommonShareDetails Net Loss Per Common Share (Details) Details http://www.clovisoncology.com/role/DisclosureNetLossPerCommonShareTables 54 false false R55.htm 41401 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.clovisoncology.com/role/DisclosureCommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.clovisoncology.com/role/DisclosureCommitmentsAndContingencies 55 false false All Reports Book All Reports clvs-20180930.xml clvs-20180930.xsd clvs-20180930_cal.xml clvs-20180930_def.xml clvs-20180930_lab.xml clvs-20180930_pre.xml http://fasb.org/us-gaap/2018-01-31 http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true ZIP 73 0001558370-18-008187-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-18-008187-xbrl.zip M4$L#!!0 ( .J27TVL^J=&6&P! .6U( 1 8VQVN1A6/K,^6ZI=/B("'?<^2K32J]>274]V0 M[QU;]=JG9OU3HU;O6NWC>N.XU;-N/JLG?PRX:\%X/?'KP3@,@^-/GQX?'ZOX M==7G(WBIUOS$/!$2SZ8'ZLECEWG?GW@6 MY,YQ. WHKP>"30(7!R._&W,Z_/4 N7 8D[GZ0S@'UB?5$,J@[X7T1VC=43L$ M79 2![_8^FOF_'K0%]^NA]]ZWYJU;]C*-TW7;U>^-PHIGYS107@/O?=_,)'\ M".V">H5LX%+\_3.=#"A7XX?F08U8.-6?X#-S\)LAH]R2\Z(S1(E)>'KYMX/? M:D":5J?3K-5_^92^EC8EZ BU-/D"OE)">4Q_!"ZSF1Z+Y3!X3NF_'O3QLAD= M_!;_NG1*OWQ:VGHZGD^S _KET\S8;/VRZ?XN[B% MS#N_?-*<6L6V>N-;LXY\.S)\>R>^'1W6&Z#B6^=;_Y%P9X%AMU2$G-E@1^Y" MW_[^U6.AN+W[6@S&S4PIY=B3<\HOY\XB3A!$O]6_U154WOM+<+/O_#,2(8Y0 M7/C\"WWLV[8?P1B]T0WW/?C3IO+7&3ZG#]W!T!R@F_@:.. _0-NM6J\@_-YD MZJD\K#7W;I)Z3>4Q!=OS="P6HE1&@5BQ ;\[< M32G26H\BK5=0)/8]@!2Y(,&\>:YWWQ@L3B+!/"I$W_Y7Q 3#-R0LH%/W[3P< M,YNXU]J?OK,9!#'T+N@7 PU6S.W@-YS<\3.3*X&ZKW*L#<_?B>?OX&P;7KX_ M+[?B@"^JY04#/Y1>L0?J7'K0[@@CBKX0-!0GT\_DGSX_=8F8]=JNF(U4\T;] M$:?*M2D&;S>8;.JGK9QM 177<#N/W'XCU5X>6I]/ M>?4BJ#T.L \:T8[%P1 M5J^<3W[5<]V0VJ1&2N(3OXKA1F&+P^B57A9A_$_B1O1DFOSY!Q":<'L\O:(/ MU)UA>?+,I1=$H9 /-!0UGDYX2P<\DQJ^HQ[S^5!YQZGSQ0RH:M49=_E$, M*5J/=*EX/4&[YP1LDV$MS\[+&&$S^N?73"EASD^F;G9FK2W,K-XSBW_OO/C7 M.JSW7NOH2JZU#-?>B6LMA)':B[F6.#]'NUI 2IZ^!,>2$;3"YP=Z/AQ2.[SGQ,NDM>+7SQC\RC'ATQ\"%^_]@-F=6J<8HK?+Q:Q-QODR5J8#W@8OW]IA/7K'R*3PRGE* M7!N?H\Y7SZ'\278:E*JSYR)D$^CO9+K@TLXGL_L3'[S!_\UH7+ZE M(-'W-2:=2L:ZLRZ3T.RLY,IXS,8\%]%CSE$N/__*:3SFHJMD?CWFW2NB\9A+ MR5;C,1?.8WY/H=%AUE%6:(X,%FR=K4?K!4)';\I6@P7%PH)W%IJZP8+WPH)U M(/YMV6JPH'!8\ Y"L]$N[S6+I]H%*IYZ5952NT!52MME<9'JX_:F$&WIWA7B MV8RXE] LE^>8S,#[U[M[3HF(^/0.I\U"5A2FKIA9BN&KIY9W-B[?E6+X^(Y\ M?*NM9&FEKG0L%K<2K9[M-BNEFZN;_"Q[E[G?"T[_%5'/GBYO+_.DN,7!7+K=?--AK9*')6-Z0B#R#KGY5=7Y30U&50NLJF^PR\*H M:FY4M6Y4M3RJ6C>JNA-5_>Q[=/J9\.\TO(@\QSB_NU#3Y4S(FXH:Q[>L*FJ< MWI*HJ'%XRZJBQMDMB8H:1[<(,:G1J1T%D$: 7V]CC/#NP" 8P349@AT>*&2" M\YP*MXFM35A;6N$V4:D)"',OW/LFB?O!\F55>SE9F#;^;/[R"L:QWF%E9HYU MU;CG)=+5/8\3RJZK)MHHD:[N>=BS.UTU%5\YT--BK%4;W[>T.FK\WI+HJ/%Y M2ZNCQM\MB8X:7[<0<:E1*E/TE3<)-E5?N38)1G)-FL"4?1GI-@&VB6WW2;I- M:&JBPOQ+][Z)8MEYONY-%S 01K#G/VPWP?VVQ%G/V[4SI$0SMV[6K2S"-]%%)^A40D% M2/+CDUQZMC^!* $ZP/E<^>HFSAFAN*.N"T3ZG7J4$Q?OMG4F0&X1 M)":>"L=&,R^2;O%Y8;JF@N#(!1#O#E0<_P$VM0)#\HDJNPUZ!([E$D M/VM$!D5RA2([O!0W(<[YOR(8,:Y[^1YFA&9DH6_;T21RX5'GGA-/N(J.SC\C M$>++Q1"')^>:"L1ZD\W[X5U;8/47&G[U."4N^U],+SY0-?_?"?.N?%$0,[$Y MT]>:=M[9WS&:7@Q-[^2!U4;3=Z7I6V3_F_/GO6>VI/+<@%C^0.RM=AD8%"L& MBFWU9G&CZOE6]2U&)D;3BZ?IVV1_GOR5K'S+_01N.E' M,"AO=,-]#_ZT52GTO*3KAT!&/(=P1WP-') :+M5Z\T=T7'IL9 1MQ\@NR4D MW,@QGRJQP07GX9#:H<0,MK#B>L;@5TYA("7= MSL3 %G=R.+5Z[;#1>6VZI='+X;+) M5U!T<7OWM2#PF9W23.'EZCGEUU0G);:=S':?M ;'=A^$WD],T_VUZ@N?BR]D MHCC[]',W0_:_E&M+O?S11$:6_WP;V20@G WR+2,X^./GR77PV],/9NFU#8NZ MO+=4AI?_/D?SM]["U%EO"U-G&_7DFPA[F25SCT6@E1&!UE9%(&/F1NBH^GS: M'R4GBJW%NW6>J+= MVO9NF692B&9,N3'E[X'CZ^\ :LJ%D=<*>TU*>TT".7QHZD\;B7O?>0#8&%/O MB@Q\CD#"J+BZ.GV-G%]%0%CB+;$*RW9H]3DGWDB^>0K3Y,0.[_T;RH<^GUSX M_#H<4RY.I@NAU'RW]Y1/&IOO"(V8/TM(DGS('4DZAXW:&B11C[W)H2:" MA]]N4;DDM.*GS\QCDVB2;R"%@1XGPS[X#3_.C+M,AX[4&]_J/57=@W8^^90O M:9;5'O7>36/4\^KH&P?(A!;K#:13YH2Q[+B?3*A2TCO,^3Q^)TG*VNX70[MGJ^8 M-_DBDR\J<;[H#78LK%H2SJLJ&57)GZJ\RE"\\VK_T]=ZF7-M0)8_(DJL[\PRR M% 59'>$J7=4=M),;AH?HZPN^02OACO5Y+R#&A1$2< MJH4'#=Z_?(J_51W@R\N:Z26M..P!")+. 9_[$DVHW-J>-6!QPTSXK4;]Z/CK MW=EL;VI^R]^7S9Y1SY\P;U7#:)_8L1@33L6JEA>;^.539@:K)]Q=(-OJ[E:W MKZ7V\I8"[CN1O;8DM%80)H _UVVCN7PD M9^N^WUC^/@,_:-TF%EI8*:;9-D#E[J/ I?,Z!]^?N]()F_]%G0%AVYSBM]?# M2U!@$*#PVOO,7/@77+4K1@;,!3RQM'K?TN&S&&?AH.2#:CJ60VTV(:[X]> 0 MR%MOM7J 88 8&_2_K1$OMU//C+A=J^ULP,M=C6<&W#OJOG; $75.?1[@L2#T MBHZ(>T&IZ'O.#?>'5*";3]P[RA^83<5IQ#G*5W8""V[@,T-NU=NS0W[! -YD M"FL3_:A9?X,9/'GIN'@5R>O=5F>1Z$]WN(4!KDW01KW1[KUZ?'\2#B+NTE,? M@E.'*K5Z)>%JM>["N);W\XKQK$^G5NWH1<.)@VZYKQN#BH#^KST'#5[.2+- MBWR*PU;]J%O/^RQVKP.=\I+H-3K0JG=:[1R1YD5NZF&KU6[7\CZ+G>M -_>, MWI$.M)J=/)%F>:E7T71@)W6.Q=*!=ZP6?D\=@.%RY!'$IQ"1BN6!5I(XN"', MV696J#Z;9-E\,&\YE\UT6BGTUB;C./(&GF1#Z%E$[_TS.J0=(?*F5,I2> 2#&('2Z)_N_1/ZF3CTVNN'(0 5WLM$X.U[ MPD?TR1Q17HGY[%:S9XA=/YJC]D84RY+Z@3 7\Q(7/L8B6Y-07KTK6)1/9XGBV-\T+POB?Q(UH M#J:8C"4SO5,BQFPYCS6&_WZ2<-UQOW6HUU;=IKU>KVW'JV?'O/L,0>9#[;MG=QS%&ED27+YY0(,CB;&-J;T M+A3:_MD&.KU+9/GE@81Q&Q$T!O*P=L.R8CN MQ#*ULJC; -^\FMCIYT>\A>F]N5G9W@0A^(.X>T_CX^9,Q+:*&#/TDAY>7P@J MKR^^T<3=CO_;J+4Z]>QXGNGLE0-;V]6M-]OUULO&=1&A$XRE!W@W:2:5D[DS MS7-D(#Q/=K%)=CVG$OBJI$(+@XRC;.;[-=1?"S#'OS^%$ M>S:ULQ'],G2_]&Q.05'.J/KWTM.JM,4D<;/>K6>*(E9V^>IA;9;O;;3J1\W7 M#@O"H8 P!^]*W[BPZI6I]TZCVWIJ^!L.[=VFN>%*6UU6C;S--)660C [__]O_^3_X,;!$.'7IKP<3PD?,.ZX%X<\N\^CAF++1.#P&[^@_ M?AY"?X=#,F'N]/B>34 #OM!'Z]:?$*\B/U<$Y6RHGA/ VV.KC@T=Q#W)KO#7 MN#>'B< ETV/F86?JQ4?5X\!W'?5FO5&U-!6LE S8U"=\(3N-3\%SDT*"'3(/ M]Z8<-UK5]D[F*1_\3S()?O8&(OCYA5/) 7]42_CL,0N)RVS55J*6A9G9=CB2 M'^&Z]*R_1AZU$*TKUB.UJ,PL.!:#0,$BUJ//7>>1.=1RM6:16+.L1Q:.+87- M%0M,4=6"5_P!KIU9](?M1KA@;XU]@7]*+_!34XP MP ^2/7_Y 5,Z_?FF?WN3?C[[^6/%B@1,#Z#< ABW0K";LE8!FQ74E0ZC)7R7 M.5883"Z=CYX(X=DO84J>1>3T%$'D[)@'OP/IL"/Y&OX^ CP'ED0# M35#H .(S$>&W\+,<%-H-'!!^6*"[9-.$0+O$^NFH6K- 1%Q ="L*AF@:K$#; MZ=G!X( Y5:OX^-.$?(<6DA7G^*WL'&(B$7O,8(8QF6S*)8^=U&+*'GCB9\N/ M J,<')P*@+(EHQK,%T^9Z 19S@:1:"+L[Y%])W=.**, MX("0VY% %@]@<(\IL9*!I#.%-W^J5ULQ >'9,;/'\(8DE>V//%P6Q0$27?X M+#T,5 $$/*%\!SFO+"VH'NJ0-P@#)^8!\7](IXUA?X"G&@/B,";T/R]"-*2N@'QXB -4>PW$)QXQVA^(S:ZIB6>B\&XUEO "#Y-AI O$[>3I 7@I@5K'E# M4GQ(_)V/5H@('DHO"I3%Q]0$":;+_=L %$X"O[0^#GB[(9Y^ $;CY/:T;TVB M4&GDAQ%8$QPEXMHG:$G L$)F?X1>A _>.OK(Q'D@G@U_ -1Q!CAGXT<.QLRW MQ@1\X@$%GUCV#P_)'L-'B \XC!/\*SP@0H\6O,&*\AAC_UN/7LYD0-"9@U%! M%\#IPX33$#L$Q,/Q.HR,/!_LI"W?U"*@'/<9DP8N6^2&TG"C\URK'K43[WG! M/F;]YS5AN[HIT8STPWR M#\;T%"3/.^95Z^\X**9ZGFUND=@L#42[A?:<"X7>KYX9.L@!9Z[5D8C<78+( M?@0 $KN16C" M+P2A,!K0"H(,# KH-T7'F*&@P>,9@,)@6&( @@C"H'P%5)0IE "'&'0;-0'] M)2^:'"H8RJ#6%'48O)2EX+)2=^OMIW4WT5NI."RFKM&*0LWL$KQ^X'>J$.<1 M]P,*\GGJ3R9,GIN@$D%H2#$_GZ1A8'K?J8SX2!2.?<[^5XG0O/)D;/VSRA,+ M,1A8#P.!!U 1C 0":5E15WP ?R'D#ZDK #^N] 0JUAAH? AS $OW6I6LK.LT M!#()A..1R9MD7HO*J1R*6-4C3\:Y&)?[+IXC &8YXOCH4VV\2,&?,\X+"EY> MJP1"_(QE Y)[ >6C:XEPLT7!D#@6*)::P4$&8A@,GRY7XZZ"8*166IP MIQ:NEOL*%.@0H'7ME0DEEE1GTZ6?((46X1G7*U)AG,^.9QM4H&'C>JY\,VE> M^LQ+,_69Y/H2C4I#%9#[*)#)%"^;W?^I6<\&.^C[Q-N?+#:T1$!M/((/A@G, M83:$<+(F0*)_XD';CW$Z?MT%$,&3XXP)YSJP;+IC@S7B)+$(FD^U.%E^P([ ;B/; MU3K)-'V/@!1!>\YAB!8R2.M;I36#4:*;[=%0S::B;"<>$.H0[J"%?V!"'M(C M::-;]X=#B;4Z80VP('/3%!I2+-&K><2;QNM>0^Y/X&&&C:*_3.7;*[3%0&]^ M9_9"Z+W,A"2-98LA*]8Z^B+DY/^C'@7_]>O?K"LV85KM]=K:DB76--FD8L!$ MHQ7<$TO-0:>VE)IXCOX;<^K-KEDFN+I*U8CC&),TD:#RSZ@P%<=N1 M!.69]514TP0"9OHPBKC[TI%UBV*N(AL^>B\NBBDOS_(SLY>#)\3ZGCK"5&$- MFFV)@&J%#K7V_/H.(><+>!QRM0.0MBF1=@0(A+[!&J4T;BQ$Z%5 _$SY+F9RIZJ=1<-!/C-(![N MM+(9F9#@*O4"P!F%>-R@G.'7ZEU5OO=7 %)/1:YI[8Z$::0*=")/P43O5!8_ MC;%H4R)[7)63^H)#B@[:DDH8X/W,@' V<[ SF+F1!)%>>,K*E"&8""1!SA9 M)E-#8#_V5>E2V+$, @$"7=NAKV"EUE4Z/>O!98OW5CESB:*NJ5WHG,25@ ,B MV")2))'O3$B(2;5,9]G82"I!.!$B5AO,%3"^FF(S1TV8J%4LQGG* .1R1HC MOOG@N]%$%1FH^#!]:T4PJ];"1NP!9T.'0T#9.*32I4%R<1/3O&F54!)U+2_P MFT\"("7@GY08C?9_J#'*G6/I^:A9RB:4JL0>(WC'F6)#?#D%F'0$*DK,$$A5 M,LK5P?&"-&CD6\+!-"VSW70,\-V%5T)+AM;J@'7,)3M,+D9BO;O.PLS8P21S M$Z^U;BE]DW1B0-: K$I\/X^<,K>MY$WZ# HV(B^$V%HE8P+&DV@1A1-=Q21S MDZP]B!E8J(#@8OFP=!0EZFKU.!Q,#V--4?(,7?$I?JW_C($Y\EPL;\7(WHV1 M3+:H:K.R4P+OPY6:?SG$YX<$Q^Y#A V(B:/-CG(9%L1UR>GZC!U)!PM\&FP, M/^C*@S3C%P+U+75M!XPV):B-:TW+!UK1:S>HV'+9U_6%M &2I(F?6"8]-K'7 M' 7.(H[LQ^H;:6#CE7\5R2A/.91*M'U&E06:XAH.&0VTR[$Q']0.B[7KLD$[? CX8YT0A).>/(LGADBR[2? M1@F-K= ,6PH#<[ AMW'0,.+RK=E]+1_FW-F/LXZ!\GHL1\E@ZH&_?-77P$H^ M8$7[O+@6,E4US+&57?0 4"2D653I%1Z-,DXK]VWF8N4'2,L'0:E\$M'*NO#Y M!&9T^#?EIJ:+>F#JP4B*C\4V5^L+$O[EL ?K4_SA4W:G:OQ![Z%=O1]V9M,L M1%A S^D- *0]W:$Q/ MH#\+?0N&Q93X'U7GBZ94O@A."U,!@;Q&_"+&VFH0^(:'R^*80+*) %?>]1_U,K&'Q58T M6?+"(YP!ZZ3W/Y2'=L@,]"--'X77Y+1U\Q4KQ*.F65)VQ?TAR*^>$7@>#@7G M!WFFMC6IE(VLI[-<=&3DNACNUXRH=K^2LCH')JI+ T04!#Y740QZ:A:>UV2K M ?X==Q3B2AO6(NF4T.PX5+)!!U*8 Y91'ZS:-*M]>UU(6&<0" 80:F^T.T,3(2#63Z#2LQ MJ/0-26C]U&Y56W4,<=7;:J$9U5QN/:5.4H5!T_>DE_Q3KUGMI=M955[243$# MUL=A"/Z()^5B>,.$#/Q%DMY2=:GJ<]*NCB5 Y2&,T#78N+JR$$'-3P0+79JU MF3J:I.((* 9 $N"N!U4Q P_7JYC1M-/#U;!:%D]$?&[*E??Y6(5"= 1J5HG<38^ M*?G7M9Y"BMT ;=F#WB:(\TCVR")85I3)09/U $2,&4KB Z0/@0F'2%Y,R.M3 MHQ4>8\'RH]Y!.V\6L43$Q?R2-HU) EHQ_4=HU1MZ9\Q3:+VA [O<-\VZKV 2 MKSUY+]\=#4-]1>8V+S28/9=F:7^9\21GF@D\_U]NV;_W+QS2CTNHS=%!VS\Z M2)[\E[#H.1;,<$L>L?8EPEZNAZ#DN:8"S_"^5?DW M=;CAN4P<7RA<0_K&ZGJ#VKI)$'=3;WQ>/L27=)V9R$;D77IHWX:'XZVF_;-$ MGYVR/$P?+\N^'CZKPX4[>108WOT\1Y>GIKV22OHX6.J FJ&Q'%/G=Q_K"U\H M?>NUOF0XUT&\S5]< C@*9-X>\ -GHP#SL;X1I=(KL#@1BVQ#\F'S45KS4$L M&SX*Y(UR&$Y3?^'E9^>UGQ_LTBZ7C$W"Z!4Z+?"WWC DO92,)FUR]_'V57JM M$2Z;F=SS_4#OTOO.D7$ 8WCMDHM;-)?/JYGQ)YJKSL_M/#_NY_M?,FJ\X/U& MW@P%/M==N&'";FZ01PN#K,\-FYUKNTK 9$C=K9[.#66@OVV52 M?016-5N%?& 6PL:6ZLVXEL67L:2#$]OJ2US''W'#]#;LV5> &^#TKMIA%DLL)?F M]6+*69IT5DH[*R&>6>_,3>92[U%OZ4,;5'H?//QE;+-.?-Q(-E.'?=&_.YDI MP;:8$!'R_>ZK;/BPUJM8V3=N5>)=I>QB>-"[;DXCB%LG [9)BMZ#4-@G6)2 MW!WW(S %CSOXHB!0R0B5N,*=ZK8+WOYPBI. X0CK@^V[NOX=\Y1WIU:G MUIFK)M??6@'7=?!8@*%+2G4>5Z\CI/OL9$Z*4R V[H:2_]_LW MR6MZ"[3,HHTB\#X]FZ;],J$3C+H %+?PR4,?U?DY"&TB5$>G0, "H]2G]^@] MF/'>IS@-J7.NLO@U"EU9(!;7F,?#)S;'PJ@A>.YJV],$JQ\">?RF ^Q)*L]U M499\&>Q/]F=Y+(\N6HT3> &R&2!7Q'LPQ5CNEV03>4:(?DB]#6I[%Z8/_TJ\",\;J*NC263ZU4YD3K(*E^X] M/\RDLDF2MY5#D,<+0510Z#68LD'75UE*J/5$;G"!,>'R7W*F@$AT[!%+ Z6S MJN%%[VE53ACWY7H@2.%$GI$TDI$[GG.!U4*V2LK+K=1Z9Z_2[R$"B="%8QD7 M0TNW+-]4(U*+I$*5:\FJI(4-(B"N@B[V7+7N_;28J# M^*C0G"0$_UF=C#CSN.Y"GOV3+1+5PXM;DZ_"NRD9U)EFQ!-$E<$!JMD4'WOX M*!/X=ES[N?!07&Z_=M?R3$=H-A&J69GZ@,2'V68()Z I,908N:*;%-UE"3K@ MG\2B>'>I*@PB6 =7456P1.@3>!.+K%!,*)G2^[/AJV'D#N4J1C(#M5*68KNJ M>9=1E9#+7:XOL,!6PYV'EVC2BI;T"I;9RO5(N9"M!RBWC"=DD MEZ?H^F%N) MS=*VV[.V/9:%@F]#*F>INSJ14U9T$%TXCF712P GD(%/7(MM*U2+72"0VHF8 MY_X(#VR1&RKBM4"UM#E;>!&7J>#=WKI.1.Y 0KW41:Q*51)A7>X2M \1GZSX MA.;$>%NBQW@B9Z+FDMM^X,$\=PRSU-R2_!F #8@6QH-Y5OY0S6O"AZX:?2%[*,(CW'A*IC\)_WH[&D M%1WA!;73IV--*(F/5\#Z)B:+KK%N.E2%'J!H?B32D"T59I%4HE5Q;J2'"(!;XXIJ,78EJ7!L494]'DK M"$;Q+H(1!ER'H7^(E2/IH+6&JSIA,-BVWB^0A:;,-LCDM'TL_?-4X1U$--03 MRNLHO/R62!71*;.C2>3JFAJU[TO;-146Z -D8Z',;M^8CVD'Q)4NIACCGJOD MPH8X=$T]?+FI@PCMSPOPF-&N@FJ"\(B/QX4GZT82@C4XNJU'YH1C-="#N"I' MGJD,3KGK!EC,Y(U^/:@=R,\"C'7\F8!3[_UZ8,O=TP=Q>P,$,'XH?89 T./X MCY]51U:O5DWZ2B87\N2C^NQ8#[KY"7,[8?]R MUL/_M>(?73H,5_\Z\$, O-6_<\7&A9]C_L(P@%.:2L>S7'N#7.YLM^A:8NAQ M/ 8:42\C0/,#V2#5^TRF=U:6M&R%SDKV*0+/L:]6KW8[AGT;L&^6&5N@?[UK MZ+\[^O>JG9:A_R[EW^"/P9^]I7^]46T;^AO\V6/Z&_PQ_D\9Z:\^\YG/3T37 M2]FS\^AZ0.SO(^Y'GH-Y!)\?6W\A4>AOS"CU\E_4%IZM)&:Z&P;6LR-(&TK: M*768O9]\?/JOEW 9>A8V&4W"BY,>&E4O+4A&_$=A.& M%5;W#8:_'Q_K6\@T[11996&*I4EBH'4C:$UN,V^J8IXCHWJE5;TWB%R,ZKTF M=%FHCS/*5UKE,W8O5\HW5\+ZEG%%/HLGEXC#Z>GY^<5%/C7S5?Q7<'MW=WY_ MMQ\(FV=.EJR*8+^IO^L:@OVFOD$>@SQ[2OV=5T_N-?4-\ACDV5OJ&Y_G;:A? MBK ZERS89%U.Q$.U$K>*U ":/G7#*L9/8BES3>6"E^>@/IW[4M MV9 S5A/^OZ;^/YL(ELWGE&U6IU+OU@UR&>0J"XWS@%P[C[_W ;F:E6:SC&O" MN=0J@UPY5 'C _74=0XE-$L%XU[)#%;! MJ&],V39Y5D@CUSBJM&N;E8X9(-Q+('QUI>;^D/\M$@N[(G]1@.Q#I_'1P%BY M],CX<\:?,_[?.4OOZK)_7]Y?F?UOYQ9=_?7IW_[ MX_KJ[/SV[K^L\__^>GG_CQ*&UKGD9LF,R3[0>-$[[Z#FU*[5N:S//J12!>]E3;!L>3^^"R04_V71 M?T4LG);0L!5,"DIF\@I&?6,,]S[-7=ZC\ JFBP8)]QT)3=F#.5@OSUPU.%A^ MZN=EA#]E?5V:9F.=0+SQNM*IM^.H-B/(,19XZWBZ9 M6E"H5JU&K=^5L!W1$O&3.H+C)I&4/?L0M.Q* $92+RNI! MZP32ZF'CR^0[# N8P7W7\H>R[7@&,.>E,V*>)F@RG?LQ_/;(7-<:DP?%!#8) M"+8QM"*Q="HD@'9_L D)J0N4?_2134/L_Y'2[\*BA+L,V!)")T"1H0^$HX? MA-@(]N"!V(D0IDBX(V %$E0!H1N9)FV)Z:+ QG M>\K\YM#]?BBE+)(-DZ-\!S.1+V8/2Y%OGEY_N;N^NCSKWY_CV2CPS^?S+_=W MUO6%=7US?MN_OX0'Y,$II]>?;V[/_SC_\D%!^+/M>-1!A+"*SW?H/E _!(!R/@4;4RPC0ILYK^F8]?K/4YQ(7CGTE"^7WG?Z[ M#LOWG?X&?W9-?X,_.Z3_SI=']IS^!G]V3G^#/\;_*2/]RUI_2:+0?TVQK4[. MY&"A:)O1]5+V[=RZ%)Q]&V,=C$H$!-C1/7@:]YJ]:GW;N+?91ILBL:;[DB36 MZL/"TY:3AN_E\L@SJR*O6;U]#GX+^1,Q:4D*Q[D:%-V%L M[LJ=\LO8DL4'^TQ[ VC;]3_>%-T2K[3QC%=:;U:/2L'Q*W:;92!X^70<55KB55UIV/BC:B),?.# ";&+#:S7IZ^ MVP6(FO3=RU&TCU7<@<]#ZABE*ZW2O4%T8I3N%4JGMP"@\]*_.[4ZM3(>:F64 MSUB\'"K?'_ LY9\^7/F/E'_<2._*6AA0JBW -WI;F]Z0MA_ FF<.EJSNK MWUA_S!;Z)WA6R"WTC4;EJ'UD@'#7JFB <-^!<.>;!O8<"-N51MWYCP*(<2GOI"+G:K0Y$.X]-[2FC,J4<<4KEUIED"N'*E#&W,(^(%>[4F^7\3KJ7&J50:XXRU#_$42)I"*5,'L3O>?:&AY?I"E-"*Y9)!);-5N:2QL4@OX$Q1;,V' M;J_2[;0V*[PS@&4 *\@:P#&"5A\9Y "SC8;T58-4K MW:/:'NYL*%7B;2^/@,LSNTIFE_:;^KNV/?M-?8,\!GGVE/H[#]/WFOH&>0SR M["WUC<_S-M0O1>R<2Q9LG/NX\H6P LJM 1',EN7_#G.CD.(!I9.)[UEB3#@] M+F$TG4L&ELQ^[ .-=VTE]H'&!BL,5I2 QCN/9?> Q@8K#%:4@L;&K]C[&+-@ M"8"-H\^3A:#3T]79,B;-1J E#$ +QMV2F9""4=\4(&V59\4I3:H>U+ MR&RW_@/E0]=_/!X#C:B7$:!-]3Y]LQZ_6>H-#(5C7\D\GWVG_ZZ]F'VGO\&? M7=/?X,\.Z;_S%-*>T]_@S\[I;_#'^#]EI']9RTU(%/JO2;&I+$4>Q)0L/]IGV!M"VY8\\ZWZ\*;HE M3FGC&:>TWJP>E8+CY?!)3XA+/!O&\LC"L1^%EG%:C(Z_6L=KU6ZC#!POAXZ? M#X?4#BU_:)V.B3?:;$^1B3'S%;:8&#-7S'IY]FX7(&JR=R]'T;ZP. U\'E+' M*%UIE>X-HA.C=*]0.L M;]MI5VK-(P.$NU9% X3[#H0[WS.PYT#8K+1;=0.$NU9% X3[#H3&(]PI$-8K MK=YF*<=2I#[*H8ZGOI#+WH*XT.6A%:B$1PG-6B[Y53+CE4L:&Q.U.6>*:8B: ME4:G8:#+0%=9:)P'Z-IYFF$OH*M1Z?3*F%7-I5H9Z,JA#ABOJSAP]:'=:;]I MM4-A:J1+E9N[HR[\-*I8(^I13EQY_P9Q)LQC(N0D9 ^F F+G7"V9\2H8]8U9 M,_GN1J?2:;8,$NY:%PT2[CL2[CPW89"P4RMCQK5@NFB0<-^1L#P^86'0[T.S ML8<[/LJA@5_T9:(E-%VY9%#)#%0N:6S,4)DS[HU.MW+4KFUF<0QB&<3*,8WS M@%@[3R&4&+%ZE4ZK:Q#+(%9I:)P'Q"J:CU7(U&:W]Z;GC.]98DPX/2YA-)U+!I;,?NP#C7=M M)?:!Q@8K#%:4@,8[CV7W@,8&*PQ6E(+&QJ_8^QBS8 F C://DX6@T]-UVC(F MS4:@)0Q "\;=DIF0@E'?%")ME6=%*4OZT 8U*6-%9<'4SX#?OH/?SF/WO02_ M1BDWP!1,_0SX[3OXEJVZX:$;<]D/]9$,7)J\[+"'[*\KS03S'.J% MQXU6M0U?O0%%GB''4U7=R=2"?9O*S#V:[S\3^6+VWDSYYNGUE[OKJ\NS_OWY MF772O^I_.3VW[OXX/[\O\%3E@Q\N/2L<^Y$@GB,^KC$;T*XY[Q$'>Q!KGU1% MRZ:NJ]'KUX/:@?PL F+'GS4@JZDG@*R!$F#")8&@Q_$?/ZN.K&ZMFO15W,QG MS&,8!G!K4[O\8C&9[=9_H'SH^H_'8Z 1]3)"M"FHIV_6XS=+O5.E<.PKF8N[ M[_3?M;NZ[_0W^+-K^AO\V2']=YXKW'/Z&_S9.?T-_AC_IXST+VM=$8E"_S4+ M23I!DX,$ZC:CZZ7LV[EU*3C[-L8Z&)4("+"C>_ T[C5[U?JV<4_X+G,L39)2 ML:;[DB16-NL[.Z2TY:3A.QJ$=#*@W&K6*E:C5G_3,W8*E0*CI?# STA+O%L&,LCPP7\T#).B]'Q5^MXK=IME('CY=#Q\^&0VJ'E#ZW3 M,?%&FVT5,S%FOL(6$V/FBEDOS]7M D1-KN[E*-H7%J>!ST/J&*4KK=*]071B ME.X52N?X0*B@$W9 QY84,'3.4L8/>>2826S M%[FD\<9*4<:3E?;A_*1ZJ]+JM0UT&>@J"XWS %T[#\#W KH:E5[MR$"7@:ZR MT#@/T&6\KO> KDJ[^Z8;/O,9_QETR^B?%TP5#1#N.Q#N/!VQ]T#8ZVUV2KT!0@.$):-^'H"P M/!YA8<#O0[/6WL,=! 54P?+O+\XE4TIFE?:!QKNV(OM 8X,5!BM*0..=A]Y[ M0&.#%08K2D%CXU?L?8E\J9(ZZ^P\O[KLGUQ>7=Y?GM]9_2]GUMW]]>G?_KB^ M.CN_O?LOZ_R_OU[>_Z.$H6C!^%PR8[+?U-^UF=EOZAOD,3"\U]0W MR&.09V^I;WR>7 3=^3PD.I*&4A>B[953)K MD4L:FQ*BS3E3R(K)1JMRU"QCQ60NU]Y%*M#'3E M4 >,UU5,Z&IV-SL(R"RX%T 9^[8=32*7A-2Q'#ID-BOC074%XV+)S%;!J&\, MVE9Y5A3S]J%>.6HU*]UF:[/]2 8!#0*6C/IY0,"=9R/V% %E:M4@X,YUT"#@ MOB-@>7S 0J8[NKU7'<&G/N+I[\G+#GO(_KK25##/H5YXW&A5V_#5&Q#D&6H\ MM=,[F5I@IK*#J>BK3BV'.:"LH34F#]0BGD5&(TY')*06FP0$[W3W+#_B>.^ M91,QM@+N/S"'.M9@:OD!Y20$_;7@2?; 0@:C'42AQ:F(7,P$,;Q7=2AH*)^R MY>7P K^U*0\)_$L$_"B@9\=R&1DP5S420 MXK:5C/;)P#,\E_4="-[NL;Z8& M:_N>O)53)J-$"/],H#&\X54V,73]1U&!KF&<0Y?:>J#A&"@P\($.4MM$M?!, M7DM>\2\ %.O3/+Q8V0^_?++=!W%\2_&V47 MGMX##4YG 6(6=][UL=_K=1 MJW>_W?O?>M^:-?GAX#<]XF2,:\#A^S-@W0YD@S.D 6W@%"_]0*/JH)@2^.1$ MMKRF./11NRCA]EAJC4,?J.L'4L!U+1;J+ KS:58-[F(U$*@'UTI[X(&J=179 M#+C'!M8C].6#+64><=UIW+32]5,7]%XIZAWE#XQRJ9JRH_$T\.%?P63;6A^G MJ%,7OU_<6@YG#Q2&%$U\+GZVQOXC-,PK%@R,X$,#3HD(%09$"!/$L[%Y"F1@ MGHB&F$W&^<'<)U(_H4_ H1$G$VOH\T>0NZKU=ZHO2J$2T9A-K2'W)\EH860A MY1.86WS=,S3#N"5]!X%MNS$A*AK $%TT,' :1ER^-7+] 7'CUS[0'[8;H0]C MG0).D8\XH+0E;#82EA-Q?.+:#OT!# 7%^"ETV5 E5ZM51OON"$#:9P;_"<$W MNR%3*0M? :;XI7<%U/($#+$/Z*^EY"F-/$*-;'YKZ@_8P3?5!DU;4%\ R[^0 M">W_8.*9YVZ&H&;\,YT B58\>C\-GFKI-K))0#@;J$8.K,AC:@)?X8_Z 4BT MS2;$%;\>'+8.?CMJHY>FR;@I?;9.VE8&[%HQV&V%#M\B<3@B)/AV2T>X0N/S M:7]$/7N:-G'!N C[ 1IWXEX/ :K.>#2"+T":%I)T/3 MSE9I^APE&K7B4B+?BHO$;6Z-N&.PM2<$?,I3?X+&4U*KSSDZJOCPR31]1+?< M1WMS_J\(3-RE)T(>R49E5?0].+C7@;2KYV"+T;.\]_^$<7V)<%XSK.F+;]?# MU*U)E%0VG] K55WHB6&#=R$ .Y)%W-Y]74ZO;I9@EU\N .IJG:->.Z;7NTYZ M!]3^NW3TP#T%-X.,Z._0?G@&[L\%8?Q/XD;TO1C1RS*B#U<1K]%GBQU.&(6'3V)#\V#WWJM5B\##SN<5!%H.Q=>/4/;>JW> MK!6$N/);90CDJZKE&Y=XX@8<>O+CTH.6P3K8LCT(<80,9>'1&XX!Q"),=+XU M>DOI-*_JC5ZU>?0DD5X[NLST[\>, W5Y.+WR1PSH9@L9]M@4C+3*JDQ/(\XQ MB%J<4[T1>_+/,;_1Z=13WF_0Z];&NKZRXSY(I8.2>>&2T4;YB2$, M@O[R::&1M&W=V043-G'_ <'\N><@)F_4S>%AO7'8K*N.5K68]GGFVU+1U",W ME#/?N8#OGH[TYCO][Z;J;V5KJSK$,6W>'?YW68=):XO=J;&\A*#XW\-:[[!9 MF^URIL7%#M%%V*B?>NWPOV=[P";2AL^]$ 42ON?$O01\^/$W.MVH!Q#]>JO3 M:=:T="QM<:%#?S(!5$)\4=!T'84"TWHR=;N(&M!99ZDJ+KJ?[<91O=YM',V, MYHGN%H:FI/N6!C[7V<9P0TGZ!Q4SO2]M<;[?\PG%%.+H=^X_AF,$;^)MQHD, M%CS1Y'R_%Q#,\%.0MA'$ZAOU=T7XB%I]VZ8N9OBH8\FVLB.8:7R^YUN* (D^ M(@9_&W6M,X37'BZ"C:85Z]*SJ]F.9]N>[_D.Y,4]B<#&4;$9:Q=H/--4VL\] M)RA<=]/)P'J@YDV5-,Z,CB.[VL&+P?7#_H>IL=QC^Q5NK!Q!N@% M=CSBM.RI[^QQ7/+-;M52.X%YX,&W$4,_6S%6O%QR(;&(S';K/U"."\/'8^: !&8$Z$6G$7O5/*/VO&;6 MWU8S=^U[EM-$&K_3^)V&1[%R481O<=]&#HUS MGCE9LF7<@E%_8SUZBX.5=KWTN]\'*]5;E<:;N#(&" T0%H;Z!@@-$#8KW6YO M/V*Z/*OB?BUPY)(%+PZO&&9PJ BM0&W?*J%;D4N&EV[6O ML \>P5Q>_R\_&K5ZJXQKM;G4-X-I.=0)@VD%Q[1&I=;KE##(R:5Z[5?ZS^Q9^@<$S@V?[2GV#9WN1 MO=EUZ%-6)2M%4)1+%KQX?>#CB8B62T?$M8:4JMM, NX/J1#,]^!;H8^% M+:$[D4MVELQIV <:[]HUV <'X*A9-PA42.TP"&00J P(U*JW2QAO%%L[2A%5 M%"SD>W&\P?TI:;_QGI3 M@%L;=LFU8KH1K^__?N_6=8O M*QHYC3BG,#,;1@@OW-+AKP=]\>UZ^*W>^-:L?\.;?0^LR&/JIZ_P1_W GK=F+[5UR)0KUU?SJ%I<^!ST M3S<(6'7#?0_^M*G\M?^#B?2MY*&[D'@.X8[X&C@DI'AZ9:WWF4X&E"=/7\*< M&7'[0> R6VX8NP&]]IW3:!*Y\/F!G@^'U [O.?$$P]]G.CMC\"O,QZ8G-'RD MU+NE#]2+Z.\1^FIUT_HT.=2^X8AY?=^P.Q.K:/&\JR(-IN=]^' VEI3 M;[5Z[7<>4Y'$XI2X-CY'G:\>V.0GA6(S8:@W>K5WTL="4OX]%++>[G9?S@). MY: G/@_9_\H)7@_1 LL68$ WG$Y8-!&7W@/5Q)YASEFD-K;&>'GT[=Y/>/6L M@3E<@)(7C.?-Y]3-SNE9-#JLUXYZ;S*M63]I&P:^ ;+37!CKTGY>,9PU;7NC MTUUT?MYJ, 9%YARK^@*(;)OT:VM0HW74;+S;:(HD"6]GR1NMYF($9&C^7DYU M=\%_W8#VM_&I>ELQ";UN:]E8YCMYZ4C61H%6O;M4()\=B&(K=:ZQ,O34GP2< MCBEP]H&J&Y^N?"' ([H>WI,?3Y&J\ZRE;QVU$35GQ[A)]V\W]D1\04-"J4+G M_XI8.,4V?6^91L5=0_-?/4Z)R_Z7.JD_\CMA'O:^GD ?UEL+KEW1"2/QP94 MDL+6FN1H'0&^YHD@G;5=]%:K6)>*-=B>?]GX=&:\?+83Z^1C[KH5<<;54A'F5 ME-=[BXLL>3!LSZ?>6JU:*UX*R(_*1I=7B7A3QI;YH562WI9 M.1SZSD5\,8E2<+J\SAUO=K9)#\>1J3'BWA &/#HE 0N)"VU,?.\N].WOKRO MZ':/ZKVY%/2S76YAB.LGI6N->J]W]+H1NJYO(_WOQH33$R*H@TP #D@>GZM= MS5M<7VLV&O.!S5I#>.-A9U*S*'6)7ESY*C\[HP^W5%#"[7'?<\[H W7]0*J0 MZG3-)=)6I]$M.!GNJ.LR;_0[]2@G+J:9G0GSF BY2F'K'?%K$N2H/1\,O#-! MCEXBSO5&IWF4OV&_MSBW._,E.(6CPE:E&40B%R"W69U \^BHWL[?L-\=F]O- M^364PI%AJ]+<:#2;NY6+HY>(<[W6FU] SL.PWQV;:\W=>AJOI\)6I;G=J_5> M3X^9NJD+YA'/AA&>^F*KU6B]^3S@$]V^=H O\G^:C?J[#?!%-@W _-U)N-D( M._,+&B\Z/^B%-5&K.&(K;1=Z[5GICY_ !>/_>GG<1WG7OKG:?^M$?QOFSO[8;M M>9A[]S53]T+F,#="BW='[8C+*JSS'[8;.=2YX/X$K584ZL;."?=@A.*&Z @ ,#Q,SH( MTZ>62],"!UJ=^9HFPX"-&' ^"5Q_2JG,C%X'V-*:I&]W>B4@_=.>RJ+&UWOS M&?SBS[I0&M]MS]?"&@:\D\8WF_-;3]^ ](MNS*;K5D?-=J,YYV4L\R96]K3F MWI@CK!!OO;X?4W@_'U$?O8*J:T>=W5X=O(453R(D0.E.![*+ 7G/XK J&9SLA2\FSF M2=P@"<,"85XSE=5L=#J])9-;,H.WFFCRYQ^,X*&0#]3G M5/.]:==J-NOSJ:&BT*ZQ8]KU>NUFLYBD:^Z8=+NDF6QI,9OQV??H]#/AWVEX M$7F.,(JYBE)?[^ZYG-ATWG'?9U5\M5@9$U) XN_:!NTET8WU>B4F%Q5J]I;P MNX:9_-K7]Z%_N1%GR7+@>X?PG6ZGTWUK 7MRGD7%Q$:[76^]N6Z^">EVC6K@ MM[8;[4*2;H\!J1CQ>P[4LCCA>PX4<6_#]_P*JHG>RTAS8[E,[+Y/=-\UQN37 MMIK0?07='PAS\7C@"Y_?D?D2JLC)M<]OT37U1/WTA,A MCW!^:[)HDVEO8S[O0Z*EA=%[12$\:2 W0E2?/^]F&Y-Z'SJ]IR3-'ZWS[E12 M]?NX84R$)T2PIVOWWH$B/56ANSY1%F:P]?FOO_\8#/;$3BY&?P[\.[-YY^^ MB>U$J'^]'<6CIEW[=%_4,)G&GUC=FX^H"U,,'%#7CNY>>?R58/99&+II]W# MS<+RV)HCW]I\WXYE;SG8=X*3=YWO-LJ$7RY0RPMZ7SWT]Q"OI4.7>'X]S%3! M^RZSI^J_R45DFVSO^4U?CI9%[_5-K[Y[5'U./!=1[>$SQ[C65;,5FTI MB^T/K1M.!5!/SOR)F^&>FJ6\?)%Y#C1SW&A5VSN9^/J7W!5C*GW7M88QNEG, M _]Z(IED!8ICU(%OY6X9885C:A%]31 R%3_C]AGB32WBP8/P]>/8=]WIH?_H MP9LB&@CF,,)!?ZH6]B78R&-#9A,8%H/6N:W?'Q 7=V<(V5"(6SN(C>,0UI@\ M4&M J6=1ETU@K&I,J%0"],R1PZT6GA,E$JI[D(O((Y'#D%6I>(GX !$I/:>N M_P#@<.WA59RC:24EP*5G5V.IG0I79H$9 BDFY# B$D807E :71 M#YB'P@O-PY3(2/96L0BGED=!N@3A4ROTK2%X=.Y4#)9%1&S7NJG6)8LXF27,3,K4\/P21 MAE$[(B.L#Y+=?_D!1N_TYZ_5NZKU>[]_DWYY M]O/'C.:#KCMXP(MC 0G\"0NQI2#B(D(@ 89*VD4P@%2*D RL5"KW"6(O(;;-+"EF;YALT2 M:\!]XE N)3!2-$5-@J$-(@%8(3362[7%0:+K%G.$,_%=P%1PFM)4@"V!B<9O M/@7WF]XNNYX/-^?WZ7&<46%S)G>H]CU'MY3U=?;)!Y1OUJO6%XRB):*=9!F] M35_0V.C73F7>^EK2Z'X(_1%%;%'HQ-3^U125L@Y=1:IN%A.T+Y@%@\KL [+3 MU;\_TM6_ 7"L_C$2LP@$,P, 8GXP)F#R;!J%8&==*W8VASX@$AH3M&K_BABN MEU4@5)2'MZ%!DT8>; 'XIPS3S_@=\SS_01EK,#KLT$93"$ WDM"\S,A5K/.( M@^L@FR/)J;_*\?6(_C21]0S@'_^=6B&("@TE2#KI47)@7_T1)Y/4VPC!H$C_ M!_5)@'N /K7D#E4.BQYQ_:O(40@V ?^">-2/!-AHW4E%L1M,?0C6&QX% M%H\\7P#5P+CZKI!#EO8!;([#N'3$)#GQ+G:@V@B4=444>4 0I$9EAHZ<&OI;V!&)*RW;EK-63"Z)!\3%Y MK)[N#8A),VZ0\MZP!>#B W/D\WH&OM8S2 5Q,=R"V<0RMW)(1(AH0F//,P Q8?+JN*FN _ ^9@@\.LFC+O4(N"DZ4_?2!N1*1GZ@%T MV=" 46144Y]Z@? MCL0T149-&VB$@R>"(\;H\R'U1X0<,*!+!TFIQ-,5OE9>Z%X^!%8P[@TH47@; M42)S=PWRE? J%HC;:,")3;3IZ)]G)OR!1S8!/&0#94P"5-Y5LH,-GC+^?#B8NS_J+''#[Z24 H\9IZTEX)/,1,_@K@CD*]P@QPJO7.H@& M"G4Q> "+Q1E0$B)>%Y6&P/BC@41.I513&;DBL*#X2ZM1M3" 9^H8CDP?Z>"P M+\HT/>*(06F'#63B8G%TQ &[ ]@%&H78)6'/H2[%V!ALD75R>]JW/HPC8+O4 M1H'8Y .^()V34 G#4<8E"I )@#G0^DO_HS71![A8'T:43Y#KR(=/,$GA8U!L M?UR#)I4GB8*)K4Q *N>6C QX ^].?"P^&M.)CQX4":2/)'&!NC,!//R&":_8 M X'0[*Q_F(B8!NDCQKG+#H 4%2$DS^NE$5B9$VE(9 MOS_+F4UD:0VZJ?A4>PS(<_D*>!O8K#8\TK 'Z"]XT>1042=#S*F22IPGN$(R MP:*">ZZG#"UEB*04%3174,P=5))H%/D!T:[+*#^4@I*1:F0&SL3G: $Y?6" M1"%@D'PP89C*$($D@/T@RG>1[LX8'K":5O_V\ORJF;H8(1#-K5IG&9<*++DT M7T(F@K"XBW$M'@D?I'LDTTD080XR#(UGMIRAZ71,2G395- WY,=_D6<\UG8U M,5#@SV2:45\5)X!"91)0L9@3F?UB,]&"C%&B< R2JKVOK.P3=+2]6'&>U_98 MZT!9/"7:F/QT2: 3;C+\@#!>_B"!6@(N_+@2;RO6&(AZ"', A_>U&%)9%WRE M[EHX'NGE)_-:1!,%S#$V11XN ,JXQ7>5QSJ,N(R#GVACSL-[AO&S@C<@]O<1 M1W_U4/U@_>5"_H]>EA%*QV4N^ M$K7]BO8Z=>EZ/XOTM\\4)B9%LC_"&MY95_#\\YPK2"RI(BIL]K7I7JWS93#M M%3D3E:@,2S@5FBTR*GV:N6UBZ6*. \H5,?V0X0&$=2+AE0 MA8PQTE729(+%_4$DDIAT:88JS@."O0)7]I%,E>:A[M)0YD9DIA94=X*J,@UD M ()100KQT(1:]400'+@ I:#(2I]UM)+1J",Y0%S.5&N F#%2GG0Z/A :>YS!=\!0$>FTRBU(&YOCF[ M_/-Z:9CNL0??!]W ,OM1HG 37#L5"DZ6>,=G,-T9WM_ZI<1A[ MO!,:$E0@".-LDF1WP-"!R!.EHDJ_M(W\,#F]O3G]F'JPB74##\L%#R64F5'E MN8+Z@893E5\)P%>R/O1O/QZJA#MUDNG)=5/R@P!'EKBEQBCD6)ACWQ5Q4$ME M:@5D+*/"#IVB3//4)I^(8DRFG#LL6V("A^FI?,)P" M*F"4_!TLG4@6%Z3)?B#"EFDL\!+]V!^'T/ 1P&<(#T(K,1H(JV[%2->T/OQY M_OO%;?VP"<$V.M>83#T$:R[!954#Q W&1-E^ #+KP\T9M!$OI39/ZC]_2OYN M8#""I40,+#YX"H!4:PWK0H^J:J5$>@3@A;AEA&YUNNR(Z#V-Z\"PJSO*'UB\ M^(R$&T\#I(DN'$C(!M8=>[$+G*9\LF"%Y.N M2;HQ)>*J,K5ZI7/:8<3E6R/7'V#4I%[[0'_$3MOI&-I6JP1)2]AL)"Q'!>Q9 M&RD'#*XFH_&,+,S+$NCD[K&>T8.:%>!4TCOUQ/%D?%^B0#H9Y,_YAVOR' MJX^9'G0VAV:6BY73C7ZNR@C$JIAI3H6+RCU^ZK6GAY. >)(?QG6;B),1\D62 M'-I 796#O.G?WJ0#%W--5JUS D&P&JM0R0Q<@@3Y3ZH LZ/4(C1D',3\7Q&$ MW4H<99B(TY.I 2P0M'6AX//KN!F'.)EYU3JA-HD$72[KB2;$"_,DOG,GM6U: MN-?N'\4?X$6.8YG\&R\]1U.Y]6WF8HIJQB#*-#$V*]>_,%4X8QEI #@@H,L-_?Z'4SXW/"'D>"AO-YI9B M3L5L;LD+)THD5&9SB]G<8C:WF,TMN]G% MMV4E,\L*T)/$Q%*443B%]@03B1*F$H".RTU$QK[*U"#Y#H8JYKK:S8&%\X'" M7FG.B+Q4+BY2!87'%9Y)XDT2>;A:Q7(9D07VLC:4JEOK-2BH:^KTW_($I*Q] MJX(O(>-J'<\.,/A0R[/Q:BJB3S+*F;*>9.AQPS"IN#_ Q84@M*USQLL1X+0J<7IB68H.>HDI)8NI[9I"(W&-<*^:R M87P8O&DTPMBH6@E1Q2^'R287M)'R!Y@+3!T#ZGE>/&;2G[ZV4,)7-5YRZ5QE M AFWHPFNVMG2@;?#2)6L)(Z,(Z\2C.M$,/[/C)QG^RT.9)<=HZ\8J#"X'-/" M(UJ)P#G.A@$D8>V9,Q,I>X S '*(@V)V6Y!$ ;UH#NHLD^N('T3O4<)8)])% M-ID@)EZ+A=4/I%@$D]".F'TI&*7#+!4'8/6A*L M^!@148DL:K<4 (F83RK*:>OF*RK^3]: ^X/07[UC"!D=&A )<^L*)#[$\< M9++VSW(QBZBV>DCL%@J:DN(&!R8JRVK2RDHD#6[,LO#<(EL-4"X+0)B&:V6Z M?3H[#K6>$GDN^K$P58R$7)R5XTN3(PM/LS/TJ#8JA&'V/ZW/1/H5.GU1$APJPJS8)HX*()1K,H13*T M?FJWJJTZ9@C4VVJ;!NHT2)0-8B'2.LOD/;D ^U.O6>WAOD97)B0(7L,;>R/P MC*IQPS@6E]' $5*^5)P]5X&L^IRT&SM458AUO607HD[RJ_)4%9/-3P1F_%.S M5JO6XO%89#3B" (TCO_1Y5&W9L/#]6JC_1^H ?%%X5@.C14\*H!U(JP:;K17 M$T,FCF>HT>C5WHX(R7C@_+IU B-]5N9_%;9%!!'^)6?=2[C>5/:>% MRJEK.[>+:V87RWS>1*8K9!UL12*[9LVJ[="59(!J@W6ZX>Z!)B.HS.S[].,U M2MUTMI1\H>0&GXZ#1L:+L"]HG<.*3+ B)CR0[!"8<(GEQ&U.30C/%]!^A56]@$5PXWNXY&AN?B3%[IL8ID )>P'_.4X+TPU/"^10FM>HX MR/7/K6MU6O7>[#U.:W6ZG7&N?4@=($&WW=S&,.>>OP79A$@+%$ZW-_M%YLFG MR-QY=OSU3KW;61C_BP?SMO.*V?+\Y>CU>NNH491IO5HKX0 MIF?H>%@_:C;GCC;?*2'3'7UH*&1LAMO-T&/X(=BQQ]Q?#R &I <;@L6G+?;S M!'77[R:]F&+_#M=J5:T,9:2S.$.;8L6C!8RCUTU#WLIS>53ER)4NBKR@-,N] M(F=%RIJ@G-GJ%I?,+A2U8DPI+(;C9D.F5J6_8#U"O5'9:$_XRARVZK"?=+A) MH[*)2KP"S[BCMN-2$9=VRZ5TE0911TEE3E5**A1U<0%NUTZ.GE+S?J08?PI] M]-0TSE9'Z,#21*4? 4WR2 M,4-KHWCW5;*JILR7K']0M0+N% RGEDN5I%6% M*S MG>?R/71918S909M)G\&+?[4:&2_X7(;!8PVS>2?9JM"3G1G=]B9P+3%'=;8 MR+.%FC59I]%5YRNM+..0=4V!*C9V=1I;28=UWS_)EX$5:;H\HE&X]L>42# M1HP9/ZO(]NU-.)N?F:W1@3H +MU'W%3*N6QO>RH7\2F@2R3CP_RYI\E/LY5B M>K>2YWN'JS9P$]C6I M9L!-.0EL]V>VW\B$VFL MZ8] UG-EC;/R%1KM2KS K8X"4G(ZB605$,Y:.Z_*3Y8.M%S;AZ\6W9**]5.] MTZ[6$V<'O=Z(V_)(N,QA2TJ2,D5(R8@S7NXVS$V]46V4R-[DUY.XHB-U4A N MH^+"Z59FN-S$%I-WQ?,5_JZF6"%)];K# $]B*XM MC0^=<C%ZS5G9YZ1* 2N.< U;QIKQ%V#4AF@;*^DV#%7S".B&-A*/ M;TT'H);I!O4I5JUQ'>TGTFE6Q=E9_=H)*<=5?HHJ$] M5)Q%>%P&)IE]PH>W.FMS!?P>F;V3^9G*1EAYX6,EBCRD8NYRA][/L[D]S\?4 M5;PO^XO_D)P:W5:5. H^,FDX$?O?<='[; GZDMW* :GDF=*;I)\5QFBS S*23&9I)"X/&%NFH4;Y.WU![/ M^-6XXNF,J05 N4L0SU!NRJ9EIS_T8GW M,ZUH\4Z^LQ"L9L\4S.[^0M#VK'BW:GJP?Z /SR0CH#%0(B8\I_&6J-3:%5D7 M]E6MKS,:6J_%"9,^A-F![^ IE6?@'*GU"EG,O&AK5X=!0OKZCX.'$)'YBOK%P\0$'MF1V;F8STA:5/2N1* MC^2?H[VL;67"I405O*:LP!IAN?R2I=CL0<#QZ=EQ'D8>U:_7E)Z0*D'I=Y%N MI@(;6I$GH\A"7\+UXD8@]Y7*L^CQ/@2U32Q=AVC'FCM'WAO9!QL.1:R1,.F) MRH*LIYI]_?0J%94,D\2*!O)D1'5\M&0%GB85DUVK" 7F2J0_6LDY"ELGPGH9)*87A_, M,VE_T/"']*"^&;=+'9/'&1W*=4$O(YLS7N[$U_N.\&HL@:7XE6S64/VKCJ16 MB6D\,$:=]@&.\:GO#7%MU\:U6[T_ Q,1'8(V,]?B1?AR!IJB;;WU)S2L[M%?-D-(A/N6W#DH?S^S%#V M1@NL;')X_T#@6E^749$Z+4[BII Q[8R.?Q]8HH6#-. MCG0M=2&.=EN>$JZEL@ET1WQIUC_;?Z,>6.4% M%_\,#Q!6S:5!PHQO7]$@F>G-X3=WTF%D_64^8.6]-:H0 >DV1C M>6IOXN;=J7.MA@#;$+_)+:?:0+3B(C#IRBV=;YS)D@F_V3.)\$0'+)30.QR5 MIX8E86YV]2-[@ 11N]0OL0)QX<0O=:%NAIQIGAM<4EP7_N*K\1[6&HW&(B=F M:N,R[2S)"59GD+C JK"O6JT%&)V;5(*7JF*209L1CS^Q*:Q[N;]T]4Q M_2HQ6Q[8Q_[_,^]D3TI3N92EV3$\GQL#"'U>]I!!(,(P6' B553ZF-;,Q/ P MF&;2,W@FL0S.N-H1*W-?3' :9/:;SB/,;'HF.:]K[AB\)+&%ER(Q5V<@Y U9 M&?-Z?_G[^>WA_\P?CH/9^0%5-VUY&%VM.&5.W4:$-;?R?+?*S)EN>A2A#XBB MHS'JC=2YTO)4/,$D%'&9E5J7,SJC$A\"A'5=7A(,"AT-IJ6M&52>NW[W^/#SQ"8F"@QQ]4VFV.S50?A;T3_I+S_Z1S];C49M7;((W"J-IRE.?)0G&?6&8[72CN& 3-WAR8N^1Z=IMNW_ M9^]MFQNWD;7A[UNU_P'ES:E*JF1%I-X]R51Y[)G<\(M2*MC2CX!;Z /%$ZLNL M;F&6 &;V? >KZ[E-Z/*2)P)#)?KJ)''$$^T-M0 MA(JD'S=M]$*ZK195UJ)XIQ9U8.:.7KT"WA; 0"178RC%/6BY+L[@,N?KY!>K MFROC%$-W+6B?^LZ_Q<&N/>K5QG2RVN4@OEH(;U_[KF?%R4Z,R"5QNJ.[[2") M]';6R*K6%:=NDHO1_HN?I>;>9%*^YR[DIP]]>N>Y=S*EH]CS3+SU):\A(@/\ M9?OKVW@@-Y&3X2=;CZ+FJ,5D+&&5X4AFZDQ."_!,W+R@A&O/94W8#[*"D?03 M-OO(<3=W'H$_R7-AWP-+12F(IX<#KA+'V1C\:/VTY61 EL+YG%]*6%L!I0SF MAW)X-!PXVLF613+[I0R2)_O%V5Y4K@(1?T!@IL@L+D\.>(_/['CS*Q@\(U@: M9W+]YV7U)0R^/THU3MV)JV3*)Y?O/\!XSY.$K#[=R!LMCBHD:9[_H#*I%#]Z MG^NZ0^;4<[+PNR']I.$V^:-WW](Y06K&-._=I]NR*>S_&7 -6?FRR3:S5*'D M#%]ZW U0*O#B_"+WX(7!YZRZ=)XX6T!\6MMRO0-.6,G71% E&^H>K\%;&:YP MDR705F4Z%S4L[MU$<61>'#[3YYTTOMC.JA>Z/D]PGM4AH'_'E$5I_&Y59$,D MJ;SCIRQ\/F_SB$"28":?]U%XJF44G,@"&Z*U2Y[$/:O)FQSUZ3PYK;C5X<@= M.)>73W><.\\L@Q_*2]C!)X5< MLTL"LK^?GK)R5%[G-Y,G+]T"1NKBHRE$(& M]=X*Q35@D9^5UPU9-R41?@Z[L-"<6[/9HXS&R\C^J@X(6_FPH.=\TI[-9*@= M/ )Y 9QGEX_ S19.P"H(E^S^3'+%@M)64BWF9V[!HKGIRM4:=UZSB^E9Q[E: MZ_*.0+Y7KL2K95E60%I<::FL'6>+BV7.V$_F/GD(38LECSN=/$$,YVU8V+R+;Y:%+L&XMZ%N.>697>Q MQ8Z&*[,'KKRP]50F,L6)<,!6=WB%-4?N,L[2R8A#;;!:"[F0L^(VZ=R*H" K+P6BK5MI@\Y M.:TK(L_DG-1[?2+]=>FDA7?F/%NL7-\+08L:2US,8AZ0JTDAO#5QR32YJ8,A M>_2XK7 _FSK=-=J?)!(78N72>1;B+^8NG<$6 EJ M=RX]7YKE1M#I6?9?_%$?P#%U'-*_<8#RY:'&B"[!25J[Y9!6PA0.6\RO1E.198DGB MIUM7!@[38IBKP"&@^VT,4\HZ5-^[]$%U?Z_DFV'I8DC.!9%U8: M(=RBW%/9QL3MG^E-Q(7ET'1NXF+S^=0E?W<]L?V4QBC$6FD]@U=2 MPD1T*$YP;NWS:5/R].FJM4':VBV_+)AQX*66T]KCG.;82Y)OY%)=).8"JRKP M17Q^.32)R_&28JX-C\E#5"+CQUJA"%";./5?93WTM9B+)1,R4<_+E GL,:VA MNN0V'LKBK[#9S& ;X2F-BUWBOAJ4@ZU+?$. M_JE(48QB>:R?YL .?+'C]<4*/X?"871$J8S@%=*H/B5G<>P/@]!19Q"K)L\H0P44_[?5NHV.WL-5<^R MJV*B/LIY\W5L&O:&HZ%A3%\@2/9S*#$%N#,TQ[W)>#1^+2V?XTA$A9+CO=5R M)]?9J\@JET_[4/7Z>CU#XSE5WE;O9G?/>Q=WV*P;LJMCF,CG/'WP/:_7 &[8 M)QI]GEU;WTNLVW%J3J:C_G"3KN=Z?B6)XX-('$Y[\/_'H?"PHAWFV#! NX_* MQ((D3GO]T<%,S.K17=+;Z%-6 ^]55FA.S$%OHV+,3,S)T.2GG]WV8WMW;.;7+M7H@K@-U\$^:G#BP(PLV<:XL,? M8@GYXOB&G-W]P9,Y7/'Q#8N,;VH25S->3)[XP,<<>[EZIHHDSQU^K%O$9#X$ MX2?ZL!(IC&=U7(BM#77UT%5R)(!]$T>,H.U!;RI9D%, D9K^7%[P7(G](EZ( M^YWW21&WZZP8^%IG%Y9GRU,((L/_5UGO^[?8%9='/_KRY7>4Y[>_#I:N/>J- M]A2".9IN.L HA*U"N'1G22*C=S1ZH-1_40S DW->L[F8.$Z'H^,X! X,J;P0V8T\SX;^H[\-% MQ(2(^!:RRT2R#S")T)6UG;*4H%3G#YZ'BI$I=9\ MRFS>9%;_[H^G[?$S!PD)23)O8$IH<6Z?.Z,KG57ZL&0YQR)=8>#!\0_BA)L?'BY2+G\R*\8? F!;<;6(/^4^QN# MEV/\F>N['H7?[D>M'=$P3]Z.C.YDLAK5WM26-\C!C3'=8R?C5:,WNP8-=8*F5)Y:JA M"%-@\6SS6[AW%"8,@T84LG@/U@V/9>%'X_B!SX]M3(>;ISJ>([ @X=1A7@V MQ]%_>H*V@G'LL_U2)C%NN/-(Y/'/ ?7%*:Z7!I>07=[8LJ??/68?_Y]+0YXX M[O%W7GAP38.R9S[ZRSABX@%S(]9]M&-AHXGY>G9]%$5C6 0.*Y6'YUXU#[A\7CR-'C);]>=!1?Y"VW ML]/>]-1X=C!YHEXB_BMUZ&*YVLZ"@8?144=B3%X>R;,4[CDL[F0^HS[U+2V> MA[QG*2]QN#4L%4H>\#60=R0-_3+^[W.D"3#.'W6WG:NE7,/KWPFD;H9<90TR#"HR))]M-Y6HR>7S3. M6EO0:!XX7?(?/EBN.3PMS?/-"H;P>@[T;YZ+-,N&=$_]4Y%+@S?QE(:7$LH4 MW2O8HH&;*CJC(3B6/#LM<)7O+;#?PC0KTM$7@].GGNHS]!T^C&,L!J?&Z\;! M*>)X\KMKW;H>>!@7,LO6ZZ[C@(Z96ZEZKKM7$[?W><%7$_651T'XK?BR+B_U M1QO'^%[JZ54T[ *?'X#:V(\MZ[ M_Y(I+G9@U1QL'&X^@.+L6O[GV45:?9GO\<@L)L+FQ278=SQUVI=DVUECU^#) M@1#QIF%T9;&I4\$'DF=52W)!-&,H4DA)EL>\D%*O*BU\!_X-S^$BGQ1%RZW% M6NX1D?:=!,LD3R!WIGB&,EY=0?S"39-EN5QAH>(%CY0F/R[CT)[SJG= H-_) MTIS)G&0B+PD_F[& P Z MT5P2>I)ZJ)$H4F93SUORY+C^W:\GO1/QG2TM._UN>>Z=_^L)7Y1R[RII[U;4 MYCVU@G06/?^K;/WYWT,IQR<_IP*&L8"H$C:= MK8NM EQ?[Y8OD6:@S6=SUP$5S&G0)B%[P;Y,"I>^^8Q"K2M3HER14TQ\/;/; M&Z'X"HAO71BOYK_1G4Z0_[7QWS"[@Q[ROS[][W<-Y'^]^(/X7RO^F(C_->H_ M^C^UXX^)_*\/?Q#_Z_9_>JC_M>+/!/6_5OR98/BH1OWO=8>(/_7R']>_E?!? M?@_7OCRL[(Y.# =O:FUH%M M=25GE !J0!5;6L#\XE!OU>!XVS!<;9ZX[*]C[0. \WSD_/'\8XGFW6O2+0VS;5 M7@VHR_OJC>] H\)EAE)RKTK,Z->H*\>7/QTBY"Z+QCJ+KP?RI=9 M[9<22Y,9Z<._/?EOWL,5'2LJ4#+L]/HM"2FK;(F:771L&/<5P<%Z+T>V'0=' M_1&ZDXVSQ*K=2=7B,EH)KPH8U6;J:R2,&L-.?])KQ^Z'RJ:HV<71AG%?$2"L M][)IRX%PT!F952RL%=PKTLH4V[9!I++PVG7]54D1%+:?*^K!3W<= MS+OO+%S?Y35R>9Y\#9?9>LBN:7LSQ0ZOH(SJV(NI5$:-= V'G6EOJN&6BY+V MI?[&"H*8^ALI"&*;(#;N]'H&.G**BJ=INR*(@>KO@B &;F*@:7;Z_:&&FQU* M&ICZ6QJ(8NIO82"*/=FI&'>&X[Z&.Q5H8,KO1R@IHG;M.C1L2ZBP_5P'D>41 MMJ-"G88K6=T%VZ3-"A-^=X*8U[=[Q55;K<37@*LD=4JMF:YDKS,=5'%!NNZM MC889H]J;'@B&3;Q/@F!8% S-SJC?DI1.6AECDS9/$$N;>*D$L;0@EO;'G;&A MXTY+PXQ1[3T8!,,F7BQ!,"P*AF;'K.3L3=T;-KH;H]9;.0T3WJ&;//*K!6B5 MB)Y7\2#/"MF!_MB2VOQ^B_?8(18C#_"VY?H1_$M\&I%@2?G] M%^C'"Q@CMA6&C[,@?+!"AXEVYM8])91Q[7+9'/JSN,W'DE3+\X('R[>!MCMH MD46"6A",&U+1O$-G- SY@($)%F/P)R BF&VANMMD=2A'LVM2XWQ*0]D2?_;, MC0#;[>0"5138?Y'/2RYUAH)29RC78&^S@)NAP H^!Q 6+X!6:)$)<[2X_;O1 MHP0?\5A @C@$VQ?BY%^7<6C/ 8HX$@&Z0(]L,3I?7 5@,MU8 M;G!"3]+)5G+=IIZ7>!6_GO1.Q'>VM.ST>^(HR=3"F:.4.##@7GC6DM&S],,; MV1&9]+I97P>?YQB,:TY!^(H:M]W>,%D*':PIAY>ZW=L'2-_4NK914Z58>L'T MTNNIHAC0&AHJ!J/F#($H!B&&<==$4*I?# A**HBA]GQ[* :T!G7$8'3[M4;A M40Q"#-/N&#VE^L50]X:B]F+8V)QJ9L2JE*I%*WG57[RHWB)4=7L"VHGSR<9- MO>4"U8Z8E2S]IX4"U3H=@":))JEZV$YYZ5=O@'6'[! 5$141%96*&S;0)*O7 MA_^(AZF#RQ*T]I)]H'KCHLI+O_KIMNZ8: ,!MWJAU!TA5=XNM"X%E2;6=W<7TCLKJL+^,)!2NW@QD**;^#&0HHX M,9"BX)R)@10M[ (#*CZS+4QDM*0I31&4EHM?HRDJ"- C*2T$WC3.X"_A1:=A1;'EI=,ZT.(S:-ML!_6UZ,YUZ:LES' M:$VKQ8_1&G4$V,AH#0L\UWE-.3.<,+<50$&3:XS)U1JC0?-[M?E]"5T;(S0- M-;ZC1VC0X%YM<--_J16RG] FVF M09KT!A?;8P_7L^#F%F^4XD) M8LRF=@%CS.;5E7J/C,$O:\ Z"7(!&4+SG<*'VN6"WSM^B>Q4$OD6^9-@93Z:=<7^(1JN(T6I6 M[*Z90BAL2#]48#\*9MMN'3X.1MTQ.C2--*>TR6FOCK57%U-D- MD*'^R;,1,BLQ-P6#LPTPMV-!IA8!V,,$F9JL82HKU-]"RX^H0S3T9)IK?*T/ ME[9FAB2C_K0SGO;1_)KL:M8=^&P1J^L.5+8'F89FMX^XI));T+:@8VMLK26A M1;2\_1V*>@.(*DM*LS A@IQ>P4"530=#?C5&=1L0#$S3O+2DOE'C@_2MCQ.6 M+M2&S*7DQW&O,YCT6G+;J &&JEE$$86@0*P13Q"\(>:P.S$1Y10Q,*6B)+7' M)]$^VQ*Y1&MM?DRSF3+4+-J)D-F6.&@SS0TCI'@H,GKS(0AGU-6SSGMSK4_' M:&>QQ"^Z!S5-8]SI]<8Z1C55-CO-8I MAY@]8Z*A(Z*C:'6+%9KPNQ/$MQY]39;HMFVUD5''&)B=WL! LU7$;#6+-393 M"(4-"5-.ZHF/X%8:B(V--4NMXYUHG^"_=$=HG8I89^F>"QZ';*CG4G>0%)'Q M#3$'G98JE:"_#=E/'^DY3N$?E]2FW^) G(/?UZ+H.:*^/36 MB_CH&%-MKH@Q1 /GKM=# M-%/;Q+2.6[;'UD9='4OYJ6QIFL4@56:U$GY#W9'&]F"9.>@,AU7 6=WQ1*UL MK,U1PY8$AM?BB2(=I<5C-^T-)>HH=PPRXB8>7ZQWS,F@,^[A(0=5S%:SP&0S MA:#$TJ/ND"7B(^#CL#O6,9C9$K/4.LR)]OF&#+NXX%#%.C4+C393"$IX+G4' M31$9WQ#3Z S,*DZ5U!U.;8E=EA-HE5]Y_"Y[V7'O\[\^8DI N0\J <"9^@B^1]7WSQ0ZYM1AU2."3( Z) M[06,7Z)G46#_!:^X-B7!C/Q@3KO],;$8_[*Z76].Y.WZ#GF8N_:=(CE>9M_?G"C.9!Y"F^<+L"* M'Y,'6!I9YD=5@?]A]G=)5S2W(N( <[J-E[5F:CL+/"]XX'HE]9/%"Z 56F0@ MYUD0+BRA *"V<2344*K?NGCYU@(\*]5\'E(J_N)#1P2T))J#>L!XG2W)'\2# M\&%,?A1F$L0,_L(ZH$\V/$R6\"R;6R&TN( I(F(_G36>[84T"-!]8YG*"3U) MT5\*S::>ETR6OY[T3L1WMK3L]'LR_]LP=AIF\W\R+\-Y>L/NKU:G<=4P# 6$%4AG^(U.K+>+8!^. -#.YN[#JA@3H,.VNB1 M4^F.F;2L9=MP@.(K(+[2E\WU;I*WG/^&V>TC_VO4_W[7J#5LU';^UQT5;SG_ M.?[4&IYI.?_1_ZF=_U/4_QKQ!_&_;O^GA_I?*_Y,4/]KQ9\)SK\UZG^O.\3U M5R7\W]C::V9T=S*ZX[+E4*PB75F"R)UKD?L^"IC8CDLJ6VSN6NPF;M]$?.;2$AJGML;9 MZX[*]D70. \WSD_/;_ ?SS;K]D_UM$WT3=$WQ>E/*3F6"MVE%S9BN*[K-7_<&O3[H4)(9'\^@2[^*C 9=T*"K**",TSU.]Z]' MAWYW@NB@Y71?[WZT/NC0L.F^WQWK&GQKAO0KFNXQ@*:$01<1K*[1N4/N_1XK M=%K$TQ-O_D>00)U3ZYZ&UATE=Z'ERUN09&:Y87([-+OAU@Y/7AD13TORY:>O MM.5FW )JE20K2*%1^S6BT@0H\V$US=NK=-M%07CINCK3.<>F;511FK'L#1$-KTWJ;0T-Y MZ;B9T3YT[ PJJ7B/WF/C\+%)AM<$>>FX_= Z?#0ZHXH.T-2[R:"AO6F]E:"A MO'3<,&@?/HX[H\E PWV!^@T.H_^XL_.2;"\L-E_5MIJ%P8+D"Q9EFP-,P^6= MRK)MFF.#MRT:[?+4O:& 9R1RYW^K\(3JWFIHE85JO0G1*DGJN#V!6+NZV=8Q M!E6<1T//5B.TU<-8FR!)'3<[$&USVR 3LXIMXKJW05IEHUIOD+1*DCING2#: MKM"VWS%'55QMJWM3164C56>[17[EU>ZSEQWW/O]KJ>6?GN?!#@:\-.1L',M= M= L+=7V'^M&9.>@.ZQO*.>-W*[*Z#J3?ZQ">6;)#HCDEL1]2.[CSH75'9K$Z MO;48Y6D%%TOJ,RO9=.&?*0FI9T7P8Q3 B_>4\<_)K8T.L9P_8_&761"*-^SD MRXRZ41S"<,B#Q<@/HUYW0�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end